PMID,Multiple Answer,time_usage
18715920,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper focuses on in vitro experiments and does not mention sequencing of viral samples directly obtained from patients.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: To delineate the effect of resistance mutations on viral susceptibility to integrase inhibitors, in vitro resistance selections with raltegravir and with MK-2048, an integrase inhibitor with a second-generation-like resistance profile, were performed.

Rationale: The paper mentions to delineate the effect of resistations mutations on viral susceptibility to integrase inhibitors.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro experiments, which doesn't report new sequences, and does not mention depositing sequences in GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro experiments, which doesn't report new sequences, and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information about the number of individuals from whom samples were obtained for sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information about the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information about the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: Site-directed mutants (SDMs) of IN coding sequences were constructed in the pUC19-5′HXB2D vector (XbaI–SalI fragment of pHXB2D), containing the HIV-1 clone HXB2D IN coding sequence, by using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and high-performance liquid chromatography-purified primers (Genset Oligos, La Jolla, CA). Plasmid sequences were confirmed by dideoxyribose sequencing.

Rationale: The paper focuses on the integrase gene (IN) of HIV-1, and mentioned that SDM of IN were confiredm by sequencing.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: Plasmid sequences were confirmed by dideoxyribose sequencing. PCR products were genotyped by automated population-based full-sequence analysis (ABI PRISM BigDye Terminator cycle sequencing; Applied Biosystems, Foster City, CA).

Rationale: The paper mentions the use of dideoxyribose sequencing, and ABI PRISM BigDye Terminator cycle sequencing which means the study was using sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether sequences were obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",68
19104010,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The in vitro antiviral profile and mechanism of action of GSK1265744 were established through integrase enzyme assays, resistance passage experiments, and cellular assays with site-directed molecular (SDM) HIV clones resistant to other classes of anti-HIV-1 agents and earlier INSTIs.

Rationale: The paper provides in vitro drug susceptibility data, through integrase enzyme assays, resistance passage experiments, and cellular assays with site-directed molecular (SDM) HIV clone.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention GenBank accession numbers. It focuses on in vitro studies and laboratory strains.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not mention GenBank accession numbers. It focuses on in vitro studies and laboratory strains.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the number of individuals from whom samples were obtained for sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information about the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The IN coding sequences have been analyzed in selected HIV-1 variants isolated at various stages of the resistance selection process.

Rationale: The evidence indicates that the integrase (IN) gene was sequenced and analyzed for resistance mutations.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether sequences were obtained from individuals with virological failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: Not mentioned.

Rationale: The paper does not provide any information regarding whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",56
21115794,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention the sequencing of clinical specimens. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper provides in vitro drug susceptibility data, through integrase enzyme assays, resistance passage experiments, and cellular assays with site-directed molecular (SDM) HIV clone.

Rationale: The paper provides in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using short-term resistance assays with TZM-bl cells.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the sequencing of clinical specimens. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Rationale: The paper does not mention the use of sequenced samples from any specific individuals. It focuses on in vitro studies and laboratory strains.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the use of sequenced samples from any specific countries. It focuses on in vitro studies and laboratory strains.

Rationale: The paper does not mention specific countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide any information about the years from which sequenced samples were obtained. It focuses on in vitro studies and laboratory strains.

Rationale: The paper does not provide any information on the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention the use of sample cloning. It focuses on the in vitro phenotypic susceptibility test.

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase gene of HIV-1, as it discusses the construction of integrase region-recombinant HIV-1 molecular clones and the sequencing of the integrase region of HIV proviral DNA.

Rationale: The paper focuses on the integrase (IN) gene of HIV-1, particularly examining mutations and their effects on drug resistance and enzyme activity.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of sequencing services provided by Operon Biotechnologies, but does not mention the sequencing method.

Rationale: The paper does not specify the sequencing method used, only mentioning the strains and their accession numbers.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the sequencing of clinical specimens. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Rationale: The paper does not mention the sequencing of clinical specimens. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not provide any information regarding whether sequences were obtained from individuals with virological failure.

Rationale: The paper does not provide any information regarding whether sequences were obtained from individuals with virological failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide any information regarding whether the patients were part of a clinical trial.

Rationale: The paper does not provide any information regarding whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not provide any information regarding whether the sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper does not provide any information regarding whether the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information regarding the drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide any information regarding the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information regarding the specific drugs received by individuals before sample sequencing.

Rationale: The paper does not provide any information regarding the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",78
23749954,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Cell culture drug selections were performed with various drugs in MT2 cells.""

Rationale: The paper does not explicitly mention that HIV sequences were obtained from patient samples. It mentions cell culture drug selections, which suggests that the study involved laboratory experiments rather than direct sequencing of patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""In vitro phenotypic susceptibility of the constructs to TAF and TDF was evaluated in an MT-2 cell HIV assay and in viral breakthrough assays modeling physiological concentrations of TAF and TDF.""

Rationale: The paper reports in vitro drug susceptibility data by evaluating the phenotypic susceptibility of patient-derived HIV-1 isolates to TAF and TDF.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. There is no mention of accession numbers in the provided content.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. There is no mention of accession numbers in the provided content.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information about the specific countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information about the specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""Clinical isolates containing K65R were cloned into the pXXLAI construct (n = 42).""

Rationale: The paper mentions that clinical isolates were cloned into the pXXLAI construct, indicating that some samples were cloned prior to sequencing.

Answer: Yes
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information about the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide information about the treatment history of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide information about whether the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information about the treatment history of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",54
24227862,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""The Connection Domain Mutation N348I in HIV-1 Reverse Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication Capacity""

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""Phenotypic susceptibility analyses of RT inhibitors were performed with recombinant HIV-1 NL4.3 clones in a TZM-bl cell-based in vitro assay, as described previously (37, 38, 61).""

Rationale: The paper includes in vitro drug susceptibility data by detailing the effectiveness of RT inhibitors against various HIV-1 clones.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not mention making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention the number of individuals.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The Connection Domain Mutation N348I in HIV-1 Reverse Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication Capacity""

Rationale: The paper focuses on the reverse transcriptase (RT) gene of HIV-1.

Answer: RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""No evidence""

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""No evidence""

Rationale: The paper does not mention virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""No evidence""

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",59
25637519,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention obtaining HIV sequences from patient samples. It focuses on laboratory-based studies, including site-directed mutagenesis, virus production, and phenotypic drug susceptibility assays.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The susceptibility of the mutant viruses to NNRTIs (nevirapine, efavirenz, etravirine and rilpivirine) and NRTIs (zidovudine, abacavir sulphate, lamivudine, emtricitabine and tenofovir disoproxil fumarate) was measured in a single-cycle cell-culture-based phenotypic assay.

Rationale: The paper mentions the use of a single-cycle cell-culture-based phenotypic assay to measure the susceptibility of mutant viruses to various RT inhibitors.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention the submission of sequences to a public database such as GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals from whom samples were obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The RT gene was sequenced.

Rationale: The paper mentions the sequencing of the RT gene.

Answer: RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention the treatment status of individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention the treatment history of individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",53
26246578,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention any patient samples or sequences derived from patients. It primarily discusses laboratory-generated viruses and their resistance profiles.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""We conducted an in vitro resistance selection study using wild-type HIV-1 and mutants with the E92Q, Y143C, Y143R, Q148H, Q148K, Q148R, and N155H substitutions to assess the DTG in vitro barrier to resistance.""

Rationale: The paper mentions the in vitro resistance selection study, which means it reports in vitro drug susceptibility data.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the number of individuals from whom samples were obtained.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any specific countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing, as it primarily discusses laboratory-generated viruses.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The integrase region of HIV-O viruses was amplified and sequenced as previously described.""

Rationale: The paper specifically mentions the sequencing of the integrase region of HIV-O viruses to study resistance to integrase strand transfer inhibitors (INSTIs).

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the sequencing method used, focusing instead on the experimental procedures related to drug susceptibility and resistance.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of samples that were sequenced, as it focuses on laboratory-generated viruses.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any sequences obtained from individuals with virological failure, focusing instead on laboratory studies.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention any clinical trials or patients, as it primarily discusses laboratory experiments.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention any sequences from individuals who had previously received ARV drugs, focusing instead on laboratory-generated viruses.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding drug classes received by individuals, as it focuses on laboratory studies.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any specific drugs received by individuals, as it primarily discusses laboratory-generated viruses.

Answer: Not reported
""""""",54
26311878,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Rationale: The paper does not provide any information regarding the use of patient samples for obtaining HIV sequences. It primarily discusses laboratory-generated viruses and their resistance profiles.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using short-term resistance assays with TZM-bl cells.

Rationale: The paper includes detailed phenotypic analyses of viral isolates and drug-resistant molecular clones, with the mention of calculating EC50 values (effective concentration at 50% inhibition) and fold change (FC) values compared to the wild-type virus.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the number of individuals from whom samples were obtained.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any specific countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information on the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing, as it primarily discusses laboratory-generated viruses.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1, particularly examining mutations and their effects on drug resistance and enzyme activity.

Rationale: The paper discusses mutations in the integrase gene and their impact on resistance to integrase strand transfer inhibitors (INSTIs).

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the sequencing method used, focusing instead on the experimental procedures related to drug susceptibility and resistance.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of samples that were sequenced, as it focuses on laboratory-generated viruses.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any sequences obtained from individuals with virological failure, focusing instead on laboratory studies.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention any clinical trials or patients, as it primarily discusses laboratory experiments.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention any sequences from individuals who had previously received ARV drugs, focusing instead on laboratory-generated viruses.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding drug classes received by individuals, as it focuses on laboratory studies.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any specific drugs received by individuals, as it primarily discusses laboratory-generated viruses.

Answer: Not reported
""""""",59
26559830,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention the collection of HIV sequences from patient samples. It discusses the construction of HIV-2 molecular clones and the testing of their susceptibility to protease inhibitors.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The susceptibilities of each wild-type or mutant HIV-2 molecular clone were determined using a single-cycle assay.

Rationale: The paper reports in vitro drug susceptibility data for various protease inhibitors, including amprenavir and darunavir, using a single-cycle assay.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention the deposition of sequences in a public database such as GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the collection of samples from individuals for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the country of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the year of sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the protease gene of HIV-2.

Rationale: The paper discusses the construction of HIV-2 molecular clones and the testing of their susceptibility to protease inhibitors, indicating that the protease gene was sequenced.

Answer: PR
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention the collection of sequences from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention the collection of sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",50
27009474,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: A 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014. His CD4 count at the time of diagnosis was 405 cells/mm3 and his plasma HIV-1 RNA level was 3,980 copies/ml. A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper mentions that the patient underwent HIV-1 seroconversion and that a baseline genotypic resistance test was performed, which revealed various resistance mutations. This indicates that the study involved HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: Q148N ± G140S was associated with 2.4- to 4.5-fold reduced susceptibility to elvitegravir but not to raltegravir or dolutegravir (Table 1). This level of INSTI resistance was lower than that observed with Q148H alone (19-fold reduced raltegravir susceptibility and 5.5-fold reduced elvitegravir susceptibility) or Q148H+G140S (>150-fold reduced susceptibility to raltegravir and elvitegravir and 3.4-fold reduced dolutegravir susceptibility).

Rationale: The paper mentions that the study assessed the effect of the novel mutation Q148N on INSTI susceptibility using the PhenoSense assay, which is an in vitro drug susceptibility test.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper explicitly states that the sequence of the clinical clone has been submitted to GenBank under the accession number KU761565.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper explicitly states that the sequence of the clinical clone has been submitted to GenBank under the accession number KU761565.

Answer: KU761565
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014.

Rationale: The paper describes a single patient case, indicating that samples were obtained from one individual.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: A 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014.

Rationale: The paper mentions that the patient underwent HIV-1 seroconversion in August 2014, indicating that the samples were obtained in that year.

Answer: 2014
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper mentions that the study sequenced the reverse transcriptase, protease, and integrase genes.

Answer: RT, PR, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the specific sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper mentions that the study sequenced plasma samples.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: A 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014. His CD4 count at the time of diagnosis was 405 cells/mm3 and his plasma HIV-1 RNA level was 3,980 copies/ml.

Rationale: The paper describes a patient who underwent HIV-1 seroconversion and had a high plasma HIV-1 RNA level, indicating virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patient was part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: A 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014. His CD4 count at the time of diagnosis was 405 cells/mm3 and his plasma HIV-1 RNA level was 3,980 copies/ml. A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper mentions that the patient had previously received ARV drugs, as indicated by the presence of resistance mutations.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper mentions that the patient had previously received NRTIs, NNRTIs, and PIs, as indicated by the presence of resistance mutations.

Answer: NRTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper mentions that the patient had previously received zidovudine, tenofovir, and various PIs, as indicated by the presence of resistance mutations.

Answer: Zidovudine (AZT), Tenofovir (TDF), various PIs
""""""",115
27124362,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention any patient samples or sequences derived from patients. It primarily discusses laboratory-generated viruses and their resistance profiles.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""Using a single round HIV-1 infection assay, we tested RPV and DOR against a broad panel of NNRTI resistant mutants to determine their respective activities.""

Rationale: The paper reports in vitro drug susceptibility data using a single round HIV-1 infection assay. They measured the susceptibility of RPV and DOR against a broad panel of NNRTI-resistant mutants.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. There is no mention of accession numbers in the provided content.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. There is no mention of accession numbers in the provided content.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the number of individuals from whom samples were obtained.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention any countries from which samples were obtained, as it primarily focuses on laboratory experiments.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific years during which the sequenced samples were obtained. There is no mention of the time period for sample collection in the provided content.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not specify which HIV genes were sequenced, as it primarily discusses laboratory-generated viruses.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the sequencing method used, focusing instead on the experimental procedures related to drug susceptibility and resistance.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not specify the type of samples that were sequenced, as it focuses on laboratory-generated viruses.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure, focusing instead on laboratory studies.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention any clinical trials or patients, as it primarily discusses laboratory experiments.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention any sequences from individuals who had previously received ARV drugs, focusing instead on laboratory-generated viruses.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding drug classes received by individuals, as it primarily discusses laboratory-generated viruses.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any specific drugs received by individuals, as it primarily discusses laboratory-generated viruses.

Answer: Not reported
""""""",54
28559249,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention that HIV sequences were obtained from patient samples. It discusses the antiviral activity of MK-8591 against HIV-2 isolates and drug-resistant HIV-2 mutants in culture, but it does not provide information about the source of the HIV sequences.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""We initially compared the ability of MK-8591 to inhibit two prototypic isolates derived from full-length plasmid molecular clones: HIV-1 NL4-3 and HIV-2 ROD9.""

Rationale: The paper reports in vitro drug susceptibility data for MK-8591 against HIV-1 and HIV-2 isolates.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention that the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention that the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",50
29373677,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the evolution of resistance to dolutegravir in a patient who experienced treatment failure with raltegravir and dolutegravir.

Rationale: The paper mentions that the patient had been under HIV treatment for 20 years and had received drugs against all available ARV targets, including raltegravir and dolutegravir, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using cell-free reactions and HeLa-P4 cells.

Rationale: The paper discusses the results of in vitro experiments that tested the susceptibility of HIV-1 to dolutegravir and raltegravir, including the determination of IC50 values and the analysis of resistance mutations.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, nor does it mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper focuses on a single patient who was heavily treatment-experienced and had developed resistance to multiple drugs, including dolutegravir.

Rationale: The paper mentions that the patient had been under HIV treatment for 20 years and had received drugs against all available ARV targets, indicating that only one patient's sample was obtained for HIV sequencing.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide any information regarding the countries from which samples were obtained.

Rationale: The paper does not mention any countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper provides a timeline of the patient's treatment and the acquisition of resistance mutations, indicating that the sequenced samples were obtained between 2008 and 2015.

Rationale: The paper mentions that the patient received an antiretroviral treatment including INSTIs from 2008 to 2015, during which time CD4 counts had increased from 350 to 940 cells/mm^3.

Answer: 2008-2015
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention whether samples were cloned prior to sequencing, as it primarily discusses laboratory experiments.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the sequencing of the HIV-1 integrase (IN) gene, as indicated by multiple references to the amplification and sequencing of this specific gene.

Rationale: The paper discusses the results of experiments that tested the susceptibility of HIV-1 to dolutegravir and raltegravir, including the analysis of resistance mutations in the IN gene.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper describes the sequencing procedures involving Beckmann CEQ 2000 XL Sequencer, which is a Sanger sequencing method.

Rationale: The paper mentions the use of the Beckmann CEQ 2000 XL Sequencer, which is a Sanger sequencing method.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that plasma samples were used for the amplification and sequencing of the HIV-1 integrase gene.

Rationale: The paper mentions that plasma samples were used for the amplification and sequencing of the HIV-1 integrase gene.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper focuses on a patient who experienced treatment failure with raltegravir and dolutegravir.

Rationale: The paper discusses the evolution of resistance to dolutegravir in a patient who experienced treatment failure with raltegravir and dolutegravir.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the patient was not in a clinical trial, but rather a case report of a single patient with a detailed history of treatment and resistance development.

Rationale: The paper discusses the patient's treatment history and resistance development, indicating that the study is not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses a patient who had been under HIV treatment for 20 years and had received drugs against all available ARV targets, including raltegravir and dolutegravir.

Rationale: The paper mentions that the patient had received drugs against all available ARV targets, indicating that the individual had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient had received drugs against all available ARV targets, including INSTIs (integrase inhibitors), and all available ARV targets, which include NRTI, NNRTI, PI, INSTI.

Rationale: The paper discusses the patient's treatment history, including the use of INSTIs and other ARV targets.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient had received drugs against all available ARV targets, including raltegravir and dolutegravir.

Rationale: The paper discusses the patient's treatment history, including the use of raltegravir and dolutegravir.

Answer: Raltegravir (RAL), Dolutegravir (DTG)
""""""",80
30053052,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper mentions that plasma samples were obtained from patients and used for sequencing.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""DSA was performed by determining the extent to which EFdA, nevirapine, efavirenz, etravirine, rilpivirine and tenofovir alafenamide inhibited the replication of the reference virus (NL43) and the 24 treatment-naive patient-derived chimeric viruses (HIV-1B, 6; HIV-1C, 14; HIV-1A-like, 4).""

Rationale: The paper reports in vitro drug susceptibility data for various antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not mention making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper mentions that samples were obtained from 42 therapy-naive patients and 9 patients with virological treatment failure.

Answer: 51
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper mentions that the samples were obtained from patients in Sweden.

Answer: Sweden
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not specify the years during which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any process of cloning samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The gag-pol fragment (HXB2: 0702-5798) was cloned into pNL43 plasmid following digestion with BssHII and SalI (New England Biolabs, USA) and ligation using T4 DNA ligase (New England Biolabs), as described by us previously.""

Rationale: The paper mentions that the gag-pol fragment was cloned and sequenced.

Answer: gag-pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""The DSA experiments were performed with three technical replicates for each virus with the specified dynamic concentration range of the drug, and at least two independent analyses (biological replicates) were performed.""

Rationale: The paper does not explicitly mention the sequencing method used, but it mentions the use of a drug susceptibility assay (DSA) which involves sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper mentions that samples were obtained from patients with virological treatment failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper mentions that samples were obtained from patients who had previously received ARV drugs (those with virological treatment failure).

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""In Zambia, first-line ART regimens comprise two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)—among them tenofovir (TDF), zidovudine (ZDV), stavudine (d4T), abacavir (ABC), lamivudine (3TC), and emtricitabine (FTC) during the period of this analysis—along with a non-nucleoside reverse transcriptase inhibitor (NNRTI), either efavirenz (EFV) or nevirapine (NVP).""

Rationale: The paper mentions that patients received NRTIs and NNRTIs as part of their first-line ART regimens.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""In Zambia, first-line ART regimens comprise two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)—among them tenofovir (TDF), zidovudine (ZDV), stavudine (d4T), abacavir (ABC), lamivudine (3TC), and emtricitabine (FTC) during the period of this analysis—along with a non-nucleoside reverse transcriptase inhibitor (NNRTI), either efavirenz (EFV) or nevirapine (NVP).""

Rationale: The paper mentions that patients received specific NRTIs and NNRTIs as part of their first-line ART regimens.

Answer: Tenofovir (TDF), Zidovudine (ZDV), Stavudine (d4T), Abacavir (ABC), Lamivudine (3TC), Emtricitabine (FTC), Efavirenz (EFV), Nevirapine (NVP)
""""""",96
30803972,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention that the samples were from patient samples. The study is about in vitro activity of bictegravir, and the HIV isolates were obtained from NIH ARP.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""We compared the activity of the integrase inhibitor bictegravir against HIV-1 and HIV-2 using a culture-based, single-cycle assay. Values of 50% effective concentrations ranged from 1.2 to 2.5 nM for 9 HIV-1 isolates and 1.4 to 5.6 nM for 15 HIV-2 isolates.""

Rationale: The paper reports in vitro drug susceptibility data for bictegravir in both HIV-1 and HIV-2 strains. The study employs single-cycle assays to compare the sensitivity of wild-type and INSTI-resistant strains of HIV-1 and HIV-2 to bictegravir.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not specify the number of individuals who had samples obtained for HIV sequencing. The study focuses on the in vitro activity of bictegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about clinical trials involving the patients.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not specify the countries from which the sequenced samples were obtained. It mentions the use of sequences from NIH ARP but does not provide specific country information.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the sequenced samples were obtained. It mentions the use of sequences from NIH ARP but does not provide a timeline.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""HIV-2 integrase mutants G140S/Q148R and G140S/Q148H were 34- and 110-fold resistant to bictegravir, respectively; other resistance-associated mutations conferred ≤5-fold changes in bictegravir susceptibility.""

Rationale: The paper focuses on the integrase gene of HIV-1 and HIV-2, examining the effects of various integrase mutations on the susceptibility to bictegravir.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the exact sequencing method used for the sequences.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention what clinical specimens were sequences, although PBMC was mentioned it's in the introduction part.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention that the patients from whom the HIV isolates were obtained were part of a clinical trial.  the study focuses on the in vitro activity of bictegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about clinical trials involving the patients.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial. The study is about in vitro activity of bictegravir.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention that the patients from whom the HIV isolates were obtained had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention that the patients from whom the HIV isolates were obtained had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention that the patients from whom the HIV isolates were obtained had previously received ARV drugs.

Answer: Not reported
""""""",66
31988104,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions the study is about selection of in vitro resistance to both TAF and the parent compound, which means the samples were not from HIV infected individuals.

Rationale: The paper focuses on in vitro experiments and does not mention specific patient-derived sequences or samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper describes the resistance selection experiments conducted with tenofovir alafenamide (TAF) and tenofovir (TFV). The study used a dose escalation method and analyzed genotypic and phenotypic changes in the virus over time.

Rationale: The paper provides detailed information on the in vitro experiments, including the methods used to assess drug susceptibility and the results obtained.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention whether the sequences were made publicly available or provide any GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any specific GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the specific countries from which the sequenced samples were obtained.

Rationale: The paper does not provide geographical information about the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information on the years from which the sequenced samples were obtained.

Rationale: The paper does not mention specific years for sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention whether samples were cloned prior to sequencing.

Rationale: The paper does not provide information on the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions sequencing the entire RT portion of the pol gene, spanning nucleotide 200 of protease to nucleotide 105 of integrase.

Rationale: The paper specifically mentions the RT, integrase, and protease genes as being sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of dideoxyribose sequencing, and ABI PRISM BigDye Terminator cycle sequencing.

Rationale: The paper specifically mentions the use of Sanger sequencing methods.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify the type of samples that were sequenced.

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not provide information on the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients from whom the sequences were obtained were part of a clinical trial.

Rationale: The paper does not provide information on whether the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not report if the clincal isolates were from treatment naïve or treatment experienced individuals.

Rationale: The paper does not provide information on the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not report if the clincal isolates were from treatment naïve or treatment experienced individuals.

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not report if the clincal isolates were from treatment naïve or treatment experienced individuals.

Rationale: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",66
32601157,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Rationale: The evidence indicates that the study does not involve patient-derived HIV sequences.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper includes detailed phenotypic analyses of viral isolates and drug-resistant molecular clones, with the mention of calculating EC50.

Rationale: The evidence clearly states that the paper reports on the in vitro antiretroviral activity and susceptibility data of various HIV-1 isolates.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention whether the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any specific GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not specify the number of individuals from whom samples were obtained for sequencing.

Rationale: The paper does not provide any information regarding the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention specific countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information regarding the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not specify the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide any information regarding whether the samples were cloned prior to sequencing.

Rationale: The paper does not mention whether the samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1, as it discusses mutations and resistance related to integrase strand transfer inhibitors (INSTIs).

Rationale: The evidence indicates that the integrase (IN) gene was sequenced and analyzed for resistance mutations.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not provide any information regarding the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not provide any information regarding the type of samples sequenced.

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not provide any information regarding whether sequences were obtained from individuals with virological failure.

Rationale: The paper does not mention whether any sequences were obtained from individuals with virological failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide any information regarding whether the patients were part of a clinical trial.

Rationale: The paper does not mention whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not provide any information regarding whether the sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper does not mention whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information regarding the drug classes received by individuals before sample sequencing.

Rationale: The paper does not specify which drug classes were received by individuals prior to sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide any information regarding specific drugs received by individuals before sample sequencing.

Rationale: The paper does not provide any information regarding specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",70
33855437,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Clinical samples were obtained through the Fonds de Recherche du Québec Santé-Réseau SIDA, obtained with ethics approval (Veritas) and informed consent. Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively).30 Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).""

Rationale: The paper mentions that clinical samples were obtained from treatment-naive persons and patients bearing common NRTI and NNRTI RAMs, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""Phenotypic cell-based assays were performed to deduce the impact of NNRTI-associated mutations acquired by doravirine or rilpivirine at designated weeks of serial passage in escalating drug pressure on cross-resistance profiles to doravirine, rilpivirine, etravirine and efavirenz (Table 3 ).""

Rationale: The paper reports in vitro drug susceptibility data using a cell-based assay to assess the impact of NNRTI-associated mutations on cross-resistance profiles to doravirine, rilpivirine, etravirine, and efavirenz.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively).30 Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).""

Rationale: The paper lists several GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively).30 Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).""

Rationale: The paper lists several GenBank accession numbers for the sequenced HIV isolates.

Answer: MW484893, MW484894, MW484895, DQ380549, AF492618, OQ336290, OQ336291, OQ336292, OQ336293, OQ336294
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively).30 Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).""

Rationale: The paper lists 5 clinical samples from treatment-naïve persons and 5 clinical samples from patients bearing NRTI and NNRTI RAMS. Two samples 96USSN20 and pNL4.3 recombinant clone (GenBank AF324493) were not clinical samples. So the number of individuals is 10

Answer: 10
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Clinical samples were obtained through the Fonds de Recherche du Québec Santé-Réseau SIDA, obtained with ethics approval (Veritas) and informed consent.""

Rationale: The paper does not specify the countries from which the sequenced samples were obtained. It mentions that clinical samples were obtained through the Fonds de Recherche du Québec Santé-Réseau SIDA, but no specific countries are listed.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide specific years for when the sequenced samples were obtained. It mentions the study's timeline and publication dates but does not specify the years of sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""Genotypic analyses were performed by the Sanger method on viral extracts isolated at Weeks 8, 16 and 24 to evaluate the acquisition and accumulation of mutations associated with reduced susceptibility to antiretroviral drugs.""

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Genotypic analysis ascertained the appearance and accumulation of NNRTI RAMs. The M184V substitution in HIV-1 RT develops frequently in individuals failing treatment and confers high-level phenotypic resistance to these drugs, both in vitro and in vivo.""

Rationale: The paper focuses on the sequencing of the reverse transcriptase (RT) gene, as it discusses mutations and resistance associated with NNRTIs and NRTIs, which target the RT gene.

Answer: RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Genotypic analyses were performed by the Sanger method on viral extracts isolated at Weeks 8, 16 and 24 to evaluate the acquisition and accumulation of mutations associated with reduced susceptibility to antiretroviral drugs.""

Rationale: The paper mentions that genotypic analyses were performed by the Sanger method on viral extracts, indicating that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Clinical samples were obtained through the Fonds de Recherche du Québec Santé-Réseau SIDA, obtained with ethics approval (Veritas) and informed consent.""

Rationale: The paper mentioned that  the study is about cell culture selection, the samples wer from naïve and experienced individuals, but the clinical specimens were not reported.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).""

Rationale: The paper mentions that viruses were amplified from patients bearing common NRTI and NNRTI RAMs, which suggests that some sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""Clinical samples were obtained through the Fonds de Recherche du Québec Santé-Réseau SIDA, obtained with ethics approval (Veritas) and informed consent.""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Clinical samples were obtained through the Fonds de Recherche du Québec Santé-Réseau SIDA, obtained with ethics approval (Veritas) and informed consent. Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively).30 Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).""

Rationale: The paper mentions that viruses were amplified from treatment-naïve patients, drug-treated persons, and lab isolates, which means some sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Clinical samples were obtained through the Fonds de Recherche du Québec Santé-Réseau SIDA, obtained with ethics approval (Veritas) and informed consent. Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively).30 Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).""

Rationale: The paper mentions that viruses were amplified from treatment-naïve patients, drug-treated persons, and lab isolates, which means some sequences were from individuals who had previously received ARV drugs, the received drugs were not reported.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Clinical samples were obtained through the Fonds de Recherche du Québec Santé-Réseau SIDA, obtained with ethics approval (Veritas) and informed consent. Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively).30 Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).""

Rationale: The paper mentions that viruses were amplified from treatment-naïve patients, drug-treated persons, and lab isolates, which means some sequences were from individuals who had previously received ARV drugs, the received drugs were not reported.

Answer: Not reported
""""""",143
34516245,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient-derived sequences or samples. It focuses on in vitro experiments and the generation of site-directed mutants.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: To delineate the effect of resistance mutations on viral susceptibility to integrase inhibitors, in vitro resistance selections with raltegravir and with MK-2048, an integrase inhibitor with a second-generation-like resistance profile, were performed.

Rationale: The paper mentions the use of in vitro resistance selections to study the effect of resistance mutations on viral susceptibility to integrase inhibitors.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro experiments, which doesn't report new sequences, and does not mention depositing sequences in GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro experiments, which doesn't report new sequences, and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the number of individuals from whom samples were obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: Site-directed mutants (SDMs) of IN coding sequences were constructed in the pUC19-5′HXB2D vector (XbaI–SalI fragment of pHXB2D), containing the HIV-1 clone HXB2D IN coding sequence, by using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and high-performance liquid chromatography-purified primers (Genset Oligos, La Jolla, CA). Plasmid sequences were confirmed by dideoxyribose sequencing.

Rationale: The paper focuses on the integrase gene (IN) of HIV-1, and mentioned that SDM of IN were confiredm by sequencing.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: Plasmid sequences were confirmed by dideoxyribose sequencing. PCR products were genotyped by automated population-based full-sequence analysis (ABI PRISM BigDye Terminator cycle sequencing; Applied Biosystems, Foster City, CA).

Rationale: The paper mentions the use of dideoxyribose sequencing, and ABI PRISM BigDye Terminator cycle sequencing which means the study was using sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention whether the individuals from whom sequences were obtained had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",67
35730213,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data or related experiments.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether any sequences were made publicly available, nor does it provide any relevant information to determine this.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention the number of individuals from whom samples were obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention the years during which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",45
35913500,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the use of genotypic drug resistance testing by Sanger sequencing and ultra-deep sequencing by Illumina MiSeq on plasma viral load specimens collected from patients.

Rationale: The paper focuses on clinical cases of treatment-emergent resistance to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in HIV patients treated with bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC). The methods involve genotypic drug resistance testing using Sanger sequencing and ultra-deep sequencing to identify resistance mutations in clinical samples collected after therapy initiation.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Between June 2021 and April 2022, 51 patients initiated LAI-ART, with 39 receiving at least 2 follow-up injections by database closure.

Rationale: The paper mentions that 51 patients initiated LAI-ART, and 39 of them received at least 2 follow-up injections.

Answer: 39
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information about the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Between June 2021 and April 2022.

Rationale: The paper mentions that the samples were obtained between June 2021 and April 2022.

Answer: 2021-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not specify which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma viral load specimens.

Rationale: The paper mentions that plasma viral load specimens were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: Yes, the paper discusses cases of individuals who experienced virological failure on a treatment regimen.

Rationale: The paper describes cases of individuals who developed treatment-emergent resistance mutations, which means sequences were from individuals who had previously received ARV drugs and experienced virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: Yes, the paper discusses cases of individuals who had previously received ARV drugs.

Rationale: The paper describes cases of individuals who had treatment-emergent resistance, which means sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: NRTI, NNRTI, PI, INSTI, CCR5 antagonist.

Rationale: The paper lists various antiretroviral drugs from different classes that were received by the individuals before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI, CCR5 antagonist
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Answer: DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.
""""""",67
35945163,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Seven people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response (Table 2 ). Of these, three had a body mass index >30 kg/m^2, which may have contributed to incomplete virological response by potentially interfering with the ability to reach the target muscle during injection. Individuals approved for the programme may have had incomplete ART histories and unknown pre-existing resistance-associated mutations, which may also have affected virological response to LA therapy. Six people living with HIV-1 had NNRTI resistance-associated mutations at discontinuation that were not observed at programme initiation, two of whom also had INSTI resistance-associated mutations [ 14 ].""

Rationale: The paper discusses the presence of resistance-associated mutations in HIV-1 sequences from patient samples, indicating that HIV sequences were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Efficacy and safety data were available for 35 people living with HIV-1 who received cabotegravir LA + rilpivirine LA through the compassionate use programme from February 2016 through July 2020.""

Rationale: The paper mentions that 35 people living with HIV-1 had samples obtained for HIV sequencing.

Answer: 35
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Included individuals were from ten countries, including 12 from the UK; 11 from the USA; two each from Belgium, Canada, Netherlands, and Switzerland; and one each from Portugal, Italy, South Korea, and Spain.""

Rationale: The paper specifies the countries from which the sequenced samples were obtained.

Answer: UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Efficacy and safety data were available for 35 people living with HIV-1 who received cabotegravir LA + rilpivirine LA through the compassionate use programme from February 2016 through July 2020.""

Rationale: The paper mentions the years during which the sequenced samples were obtained.

Answer: 2016-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Six people living with HIV-1 had NNRTI resistance-associated mutations at discontinuation that were not observed at programme initiation, two of whom also had INSTI resistance-associated mutations [ 14 ].""

Rationale: The paper mentions the presence of resistance-associated mutations in the reverse transcriptase (RT) and integrase (IN) genes, indicating that these genes were sequenced.

Answer: RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not specify the exact sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Seven people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response (Table 2 ).""

Rationale: The paper mentions that the samples were from individuals who discontinued cabotegravir LA + rilpivirine LA therapy, indicating that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Seven people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response (Table 2 ).""

Rationale: The paper specifically focuses on sequences obtained from individuals who experienced virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""Physicians could request compassionate use of oral and long-acting (LA) cabotegravir + rilpivirine for people living with HIV-1 under a single-patient request programme supported by ViiV Healthcare and Janssen.""

Rationale: The paper describes the study as a compassionate use programme, not as part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Individuals approved for the programme may have had incomplete ART histories and unknown pre-existing resistance-associated mutations, which may also have affected virological response to LA therapy.""

Rationale: The paper mentions that individuals may have had prior exposure to antiretroviral therapy (ART), indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Individuals approved for the programme may have had incomplete ART histories and unknown pre-existing resistance-associated mutations, which may also have affected virological response to LA therapy.""

Rationale: The paper mentions that individuals may have had prior exposure to antiretroviral therapy (ART), but does not specify the exact drug classes.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Individuals approved for the programme may have had incomplete ART histories and unknown pre-existing resistance-associated mutations, which may also have affected virological response to LA therapy.""

Rationale: The paper mentions that individuals may have had prior exposure to antiretroviral therapy (ART), but does not specify the exact drugs.

Answer: Not reported
""""""",85
36415058,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention whether the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 486 individuals eligible for LA cabotegravir and rilpivirine were interviewed.

Rationale: The paper mentions that 486 individuals were interviewed, but it does not specify how many had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information about the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not specify the exact years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not specify which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The study is not a clinical trial.

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention any sequences obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",44
36454248,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: HIV-1 *pol* sequences were recovered from 67 (88.2%) of 76 children/adolescents (median age 12 years), carrying 65 subtype B, 1 subtype G and 1 unique recombinant URF_A1B.

Rationale: The paper explicitly states that HIV-1 *pol* sequences were recovered from patient samples, indicating that sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.

Rationale: The paper explicitly states that the sequences were deposited in GenBank, indicating that they were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.

Rationale: The paper explicitly states that the GenBank accession numbers for the sequenced HIV isolates are OM201778 -- OM201846.

Answer: OM201778 -- OM201846
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Plasma samples from 76 HIV-infected children/adolescents were collected during 2018--19.

Rationale: The paper states that 76 HIV-infected children/adolescents had samples obtained for HIV sequencing.

Answer: 76
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted amongst people living with HIV-1 residing in Panama.

Rationale: The paper explicitly states that the study was conducted in Panama.

Answer: Panama
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Plasma samples from 76 HIV-infected children/adolescents were collected during 2018--19.

Rationale: The paper states that the samples were collected during 2018--19.

Answer: 2018-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: HIV-1 *pol* sequences (46PR/45RT/67IN) were recovered from 67 (88.2%) of 76 children/adolescents.

Rationale: The paper mentions that the *pol* gene, spanning the protease (PR), reverse transcriptase (RT), and integrase (IN) genes, was sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: HIV-1 RNA was extracted from plasma by automated magnetic silica extraction using the EasyMAG extractor (bioMérieux). The extracted RNA was amplified by RT--PCR and nested PCR to obtain the HIV-1 *pol* region.

Rationale: The paper mentions the use of RT--PCR and nested PCR for amplification, followed by sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma samples from 76 HIV-infected children/adolescents were collected during 2018--19.

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: All 62 children/adolescents treated with *pol* sequence had received NRTIs, 45.2% non-NRTIs, 95.2% PIs and only 11 (17.7%) INSTIs. Despite the use of ART, all treated children/adolescents with *pol* sequence showed virological failure (VL > 50 copies/mL).

Rationale: The paper mentions that all treated children/adolescents with *pol* sequence showed virological failure, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: Among the 71 treated children/adolescents, 14 (19.7%) had failed more than three different ART regimens at sampling.

Rationale: The paper indicates that a significant number of patients had previously received ARV drugs, confirming that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: All 62 children/adolescents treated with *pol* sequence had received NRTIs, 45.2% non-NRTIs, 95.2% PIs and only 11 (17.7%) INSTIs.

Rationale: The paper provides details on the types of ARV drugs received by the individuals, indicating the drug classes involved.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The 71 treated subjects were under their first (33.8%), second (29.6%) or third (16.9%) ART regimen, and 14 (19.7%) had received four to eight different ART regimens at sampling, having failed at least three previous ART regimens. Most treated children (98.6%) had received lamivudine + zidovudine, followed by lopinavir/ritonavir (95.8%) and efavirenz (45.1%).

Rationale: The paper lists specific ARV drugs that were administered to the individuals, indicating which drugs were received prior to sequencing.

Answer: Lamivudine, Zidovudine, Lopinavir/ritonavir, Efavirenz
""""""",85
36519389,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples. It focuses on weight and metabolic changes after switching from different antiretroviral therapy regimens.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any in vitro drug susceptibility testing. It focuses on clinical outcomes and metabolic changes after switching from different antiretroviral therapy regimens.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequencing or the number of individuals who had samples obtained for sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention sequencing of any HIV genes.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention virological failure or sequencing of individuals on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences or previous ARV drug use.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",45
36571282,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""For this study, participating sites were asked to provide a FASTA viral sequence, encoding the HIV integrase and RT obtained at the time of inclusion.""

Rationale: The paper mentions that participating sites were asked to provide a FASTA viral sequence, which indicates that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not provide any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""We included 2705 PWH, 72% men, median age of 37 years (interquartile range, 30--48);""

Rationale: The paper states that 2705 PWH had samples obtained for HIV sequencing.

Answer: 2705
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""MeditRes HIV is a consortium that includes ART-naive PWH in France, Greece, Italy, Portugal, and Spain who have been newly diagnosed during 2018--2021.""

Rationale: The paper mentions that the sequenced samples were obtained from France, Greece, Italy, Portugal, and Spain.

Answer: France, Greece, Italy, Portugal, Spain
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""MeditRes HIV is a consortium that includes ART-naive PWH in France, Greece, Italy, Portugal, and Spain who have been newly diagnosed during 2018--2021.""

Rationale: The paper mentions that the sequenced samples were obtained from 2018 to 2021.

Answer: 2018-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""For this study, participating sites were asked to provide a FASTA viral sequence, encoding the HIV integrase and RT obtained at the time of inclusion.""

Rationale: The paper mentions that the HIV integrase and RT genes were sequenced.

Answer: IN, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""The integrase region from HIV was sequenced using different protocols at testing sites, including the Sanger sequencing--based assay and next-generation sequencing (NGS)--based assay.""

Rationale: The paper mentions that both Sanger sequencing and next-generation sequencing (NGS) were used for sequencing.

Answer: Sanger sequencing, Next-generation sequencing (NGS)
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""No evidence""

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""No evidence""

Rationale: The paper does not provide information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""No evidence""

Rationale: The paper does not provide information on whether the individuals had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide information on which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide information on which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",59
36597160,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention whether any sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not specify the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention which HIV genes were reported to have been sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",44
36645792,"Here are the answers to the questions in the format you requested:


""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""One hundred thirty participants were randomly assigned to receive lead-in supplementary dolutegravir (n = 65) or placebo (n = 65) (Figure 1).""

Rationale: The paper mentions that participants were randomly assigned to receive lead-in supplementary dolutegravir or placebo, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""


""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""None of 6 participants (3 in each arm) eligible for resistance testing by 24 weeks developed dolutegravir resistance.""

Rationale: The paper does not report in vitro drug susceptibility data. Instead, it focuses on clinical outcomes and resistance testing.

Answer: No
""""""


""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""


""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""


""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""One hundred thirty participants were randomly assigned to receive lead-in supplementary dolutegravir (n = 65) or placebo (n = 65) (Figure 1).""

Rationale: The paper mentions that 130 participants were randomly assigned to receive lead-in supplementary dolutegravir or placebo, indicating that 130 individuals had samples obtained for HIV sequencing.

Answer: 130
""""""


""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""We recruited patients from 3 primary care clinics in Khayelitsha, a large, periurban settlement in Cape Town, South Africa.""

Rationale: The paper mentions that patients were recruited from primary care clinics in Khayelitsha, South Africa, indicating that the sequenced samples were obtained from South Africa.

Answer: South Africa
""""""


""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Participants were recruited between 28 August 2020 and 10 November 2021.""

Rationale: The paper mentions that participants were recruited between 2020 and 2021, indicating that the sequenced samples were obtained during this period.

Answer: 2020-2021
""""""


""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""


""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Baseline GART was performed retrospectively for all participants after completion of week 24 visits, on plasma samples stored at enrollment (with results not returned to clinicians).""

Rationale: The paper mentions that genotypic antiretroviral resistance testing (GART) was performed, but it does not specify which HIV genes were sequenced.

Answer: Not reported
""""""


""""""
Question: What method was used for sequencing?

Evidence: ""GART was performed at the National Health Laboratory Service Virology Laboratory at Tygerberg Hospital in Cape Town, South Africa, and drug susceptibility prediction was performed with the Stanford algorithm (version 9.1) [13].""

Rationale: The paper mentions that GART was performed, but it does not specify the sequencing method used.

Answer: Not reported
""""""


""""""
Question: What type of samples were sequenced?

Evidence: ""Plasma HIV-1 RNA was measured at baseline and every visit from week 4 onward.""

Rationale: The paper mentions that plasma HIV-1 RNA was measured, indicating that plasma samples were sequenced.

Answer: Plasma
""""""


""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Eligible patients had virologic failure (2 consecutive human immunodeficiency virus type 1 (HIV-1) RNA ≥1000 copies/mL) on first-line TEE.""

Rationale: The paper mentions that eligible patients had virologic failure on first-line TEE, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""


""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""ARTIST is a noncomparative, randomized, double-blind, placebo-controlled, phase 2, 48-week trial of second-line TLD with or without a lead-in supplementary dolutegravir dose in patients with virologic failure on first-line TEE.""

Rationale: The paper mentions that the study is a clinical trial.

Answer: Yes
""""""


""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Eligible patients had virologic failure (2 consecutive human immunodeficiency virus type 1 (HIV-1) RNA ≥1000 copies/mL) on first-line TEE.""

Rationale: The paper mentions that eligible patients had virologic failure on first-line TEE, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""


""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Eligible patients had virologic failure (2 consecutive human immunodeficiency virus type 1 (HIV-1) RNA ≥1000 copies/mL) on first-line TEE.""

Rationale: The paper mentions that eligible patients had virologic failure on first-line TEE, indicating that individuals received NNRTIs (efavirenz) and NRTIs (tenofovir and emtricitabine) before sample sequencing.

Answer: NNRTI, NRTI
""""""


""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Eligible patients had virologic failure (2 consecutive human immunodeficiency virus type 1 (HIV-1) RNA ≥1000 copies/mL) on first-line TEE.""

Rationale: The paper mentions that eligible patients had virologic failure on first-line TEE, indicating that individuals received efavirenz, tenofovir, and emtricitabine before sample sequencing.

Answer: Efavirenz, Tenofovir, Emtricitabine",85
36659824,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Baseline laboratory results and baseline genotype for HIV-1 drug resistance mutations were available at Week (W) 1 and by W4, respectively.""

Rationale: The paper does not explicitly state that HIV sequences were obtained from patient samples, but it mentions the availability of baseline genotype for HIV-1 drug resistance mutations, which suggests that sequencing was performed.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data.

Rationale: The paper focuses on the clinical outcomes of BIC/FTC/TAF treatment and does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention whether any sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 112 participants were included in the ITT population.

Rationale: The paper does not explicitly state that all 112 participants had samples obtained for HIV sequencing, but it mentions that baseline genotype for HIV-1 drug resistance mutations were available for the participants.

Answer: 112
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in France.

Rationale: The paper does not mention any other countries from which samples were obtained.

Answer: France
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted between November 2019 and September 2020.

Rationale: The paper does not mention any other years from which samples were obtained.

Answer: 2019-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that baseline genotype for HIV-1 drug resistance mutations were available.

Rationale: The paper does not explicitly state which HIV genes were sequenced, but it mentions the availability of baseline genotype for HIV-1 drug resistance mutations, which suggests that the pol gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention any sequencing methods used.

Rationale: The paper does not provide any information about the sequencing methods used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma HIV-1-RNA was quantified.

Rationale: The paper does not explicitly state that plasma samples were sequenced, but it mentions the quantification of plasma HIV-1-RNA, which suggests that plasma samples were used.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that protocol-defined virological failure (PDVF) was observed in 11/112 (9.8%) at W24 and 14/112 (12.5%) at W48.

Rationale: The paper does not explicitly state that sequences were obtained from individuals with virological failure, but it mentions the observation of PDVF, which suggests that sequencing was performed.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a national, prospective, single-arm study.

Rationale: The paper does not explicitly state that the patients were in a clinical trial, but it mentions the study design, which suggests that it was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some participants had previously received ARV drugs.

Rationale: The paper does not explicitly state that HIV sequences were obtained from individuals who had previously received ARV drugs, but it mentions the previous treatment history of some participants.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some participants had previously received ARV drugs, including INSTIs, NRTIs, and PIs.

Rationale: The paper does not explicitly state which drug classes were received by individuals in the study before sample sequencing, but it mentions the previous treatment history of some participants.

Answer: INSTI, NRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some participants had previously received BIC/FTC/TAF.

Rationale: The paper does not explicitly state which drugs were received by individuals in the study before sample sequencing, but it mentions the previous treatment history of some participants.

Answer: BIC, FTC, TAF
""""""",72
36660819,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 sequencing was performed in batch for all subjects at screening and at time of virologic failure (VF).

Rationale: The evidence indicates that the study involved sequencing of HIV samples from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not provide any information regarding in vitro drug susceptibility data.

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention whether the sequences were made publicly available.

Rationale: The evidence does not mention whether the sequences were made publicly available, nor does it provide any relevant information to determine this.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 1045 participants were included in the ITT-E population.

Rationale: The evidence indicates that 1045 participants had samples obtained for HIV sequencing.

Answer: 1045
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information about the countries from which sequenced samples were obtained.

Rationale: The paper does not mention the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2014 to 2022.

Rationale: The evidence indicates that the study was conducted from 2014 to 2022.

Answer: 2014-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention whether samples were cloned prior to sequencing.

Rationale: The evidence does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 sequencing was performed in batch for all subjects at screening and at time of virologic failure (VF).

Rationale: The evidence indicates that the HIV genes reported to have been sequenced are not specified.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that sequencing was performed with an ABI Prism 3100-Avant Genetic Analyzer.

Rationale: The evidence indicates that the sequencing method used was Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma HIV-1 RNA levels were evaluated.

Rationale: The evidence indicates that the type of samples sequenced were plasma samples.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that virological failure was confirmed when available by sequencing the pol protein.

Rationale: The evidence indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a phase 3b randomized, open-label, active-controlled, multicenter, parallel-group noninferiority study.

Rationale: The evidence indicates that the patients in the study were in a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that participants were virologically suppressed and had previously received ARV drugs.

Rationale: The evidence indicates that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants received CAB+RPV LA.

Rationale: The evidence indicates that the drug classes received by individuals in the study before sample sequencing were INSTI and NNRTI.

Answer: INSTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants received CAB+RPV LA.

Rationale: The evidence indicates that the drugs received by individuals in the study before sample sequencing were CAB and RPV.

Answer: CAB, RPV
""""""",67
36694270,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""We amplified the nucleotide sequences of HIV-1 protease, reverse transcriptase and integrase using nested polymerase chain reaction (nest-pcr) method."" and ""Sequences were then spliced and edited using the Seqman pro and Megalign7.0V software, and were submitted to the drug resistance database of Stanford University (https://hivdb.stanford.edu/hivdb/by-sequences/) for HIV-1 subtypes and resistance mutation analysis.""

Rationale: The evidence clearly states that the paper reports HIV sequences from patient samples, as it describes the process of amplifying and analyzing the sequences.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on the sequencing and analysis of HIV-1 genotypes in patient samples and does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information indicating that the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information indicating that the sequences were made publicly available.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""We retrospectively collected matched pairs of 68 HIV-1 patients who were admitted to Chongqing Public Health Medical Center from June 2020 to June 2022 and completed plasma CD4+ T cell counts, HIV RNA viral load, and CSF biochemical tests.""

Rationale: The evidence indicates that 68 individuals had samples obtained for HIV sequencing, although 6 patients had low CSF viral load and could not be tested for drug resistance.

Answer: 62
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in China.

Rationale: The evidence clearly states that the samples were obtained from patients in China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from June 2020 to June 2022.

Rationale: The evidence clearly states that the samples were obtained from patients between June 2020 and June 2022.

Answer: 2020-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information indicating that the samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""We amplified the nucleotide sequences of HIV-1 protease, reverse transcriptase and integrase using nested polymerase chain reaction (nest-pcr) method.""

Rationale: The evidence clearly states that the paper reports sequencing of the protease, reverse transcriptase, and integrase genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that ""Sequences were then spliced and edited using the Seqman pro and Megalign7.0V software, and were submitted to the drug resistance database of Stanford University (https://hivdb.stanford.edu/hivdb/by-sequences/) for HIV-1 subtypes and resistance mutation analysis.""

Rationale: The evidence does not explicitly state the sequencing method, but it mentions the use of software for sequence analysis.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that ""CSF and plasma samples were tested for drug resistance of HIV genotypes.""

Rationale: The evidence clearly states that the paper reports sequencing of CSF and plasma samples.

Answer: CSF, Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that ""Among patients receiving ARV treatment, 8/11 (72.7 %) had HIV-1 resistance mutations in both plasma and CSF.""

Rationale: The evidence clearly states that the paper reports sequencing of individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information indicating that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that ""Among patients receiving ARV treatment, 8/11 (72.7 %) had HIV-1 resistance mutations in both plasma and CSF.""

Rationale: The evidence clearly states that the paper reports sequencing of individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""NRTIs were the main drugs used in ARV-treated patients.""

Rationale: The evidence clearly states that the paper reports sequencing of individuals who had previously received NRTIs.

Answer: NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""The NRTIs 3TC and TDF in multiple ARV treatment regimens are prone to cause 184 V/I and 65 R mutations; NNRTI EFV is prone to generate Y181C, G190A and K101E mutations; PI LPV/r appears to lead to M46I and V82A mutations.""

Rationale: The evidence clearly states that the paper reports sequencing of individuals who had previously received 3TC, TDF, EFV, and LPV/r.

Answer: 3TC, TDF, EFV, LPV/r
""""""",78
36706364,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Plasma samples from all participants with VL ≥ 1000 copies/mL underwent sequencing of the Pol region using a laboratory-validated modification to the ViroSeq HIV-1 Genotyping System v2.0 (Abbott Molecular, Chicago, IL).""

Rationale: The paper mentions that plasma samples from participants with a viral load ≥ 1000 copies/mL underwent sequencing of the Pol region, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing. It focuses on clinical data and outcomes rather than detailed sequencing data submission.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It focuses on clinical data and outcomes rather than detailed sequencing data submission.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Plasma samples from all participants with VL ≥ 1000 copies/mL underwent sequencing of the Pol region using a laboratory-validated modification to the ViroSeq HIV-1 Genotyping System v2.0 (Abbott Molecular, Chicago, IL).""

Rationale: The paper mentions that plasma samples from participants with a viral load ≥ 1000 copies/mL underwent sequencing, but it does not specify the exact number of individuals.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""We conducted a single arm, prospective, interventional study in two primary care clinics in Khayelitsha, South Africa.""

Rationale: The study was conducted in South Africa, and the samples were obtained from participants attending primary care clinics in Khayelitsha.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Participants were enrolled between August 2019 and July 2020.""

Rationale: The paper mentions that participants were enrolled between August 2019 and July 2020, indicating that the samples were obtained during this period.

Answer: 2019-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""Plasma samples from all participants with VL ≥ 1000 copies/mL underwent sequencing of the Pol region using a laboratory-validated modification to the ViroSeq HIV-1 Genotyping System v2.0 (Abbott Molecular, Chicago, IL).""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Plasma samples from all participants with VL ≥ 1000 copies/mL underwent sequencing of the Pol region using a laboratory-validated modification to the ViroSeq HIV-1 Genotyping System v2.0 (Abbott Molecular, Chicago, IL).""

Rationale: The paper mentions that sequencing was done for the Pol region, which includes the protease (PR), reverse transcriptase (RT), and integrase (IN) genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Plasma samples from all participants with VL ≥ 1000 copies/mL underwent sequencing of the Pol region using a laboratory-validated modification to the ViroSeq HIV-1 Genotyping System v2.0 (Abbott Molecular, Chicago, IL).""

Rationale: The paper mentions the use of the ViroSeq HIV-1 Genotyping System v2.0, which is associated with Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Plasma samples from all participants with VL ≥ 1000 copies/mL underwent sequencing of the Pol region using a laboratory-validated modification to the ViroSeq HIV-1 Genotyping System v2.0 (Abbott Molecular, Chicago, IL).""

Rationale: The paper specifies that plasma samples from participants with a viral load ≥ 1000 copies/mL were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Two participants met criteria for virologic failure (two consecutive VL >1000 copies/mL after week 12) during the follow up period.""

Rationale: The paper mentions that two participants met criteria for virologic failure, indicating that sequences were obtained from individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""We conducted a single arm, prospective, interventional study in two primary care clinics in Khayelitsha, South Africa.""

Rationale: The paper describes a single arm, prospective, interventional study, which is a type of clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Participants were enrolled and switched to TLD with additional 50 mg dolutegravir for two weeks to overcome efavirenz induction effects on dolutegravir metabolism and transport.""

Rationale: The paper mentions that participants were switched to TLD, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Participants were enrolled and switched to TLD with additional 50 mg dolutegravir for two weeks to overcome efavirenz induction effects on dolutegravir metabolism and transport.""

Rationale: The paper mentions that participants were switched to TLD, which includes NRTIs (tenofovir and lamivudine) and an INSTI (dolutegravir), and that they had previously received an NNRTI (efavirenz).

Answer: NRTI, NNRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Participants were enrolled and switched to TLD with additional 50 mg dolutegravir for two weeks to overcome efavirenz induction effects on dolutegravir metabolism and transport.""

Rationale: The paper mentions that participants were switched to TLD, which includes tenofovir, lamivudine, and dolutegravir, and that they had previously received efavirenz.

Answer: Tenofovir, Lamivudine, Efavirenz, Dolutegravir",87
36738248,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Overall, 24,394 SS sequences and 5211 NGS (Illumina) sequences were available from 21,297 PLHIV enrolled in the SHCS as of August 2021.""

Rationale: The paper mentions that HIV sequences were obtained from patient samples, specifically from people living with HIV (PLHIV) enrolled in the Swiss HIV Cohort Study (SHCS).

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""We found a good agreement (Cohen's kappa and Light's kappa >0.8) for DRMs conferring resistance to PIs, NRTIs and NNRTIs with variant-calling thresholds above 5%.""

Rationale: The paper does not report in vitro drug susceptibility data. It focuses on the comparison of HIV drug resistance mutations (DRMs) detected by Sanger sequencing (SS) and next-generation sequencing (NGS) in patient samples.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information regarding the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Overall, 24,394 SS sequences and 5211 NGS (Illumina) sequences were available from 21,297 PLHIV enrolled in the SHCS as of August 2021.""

Rationale: The paper mentions that samples were obtained from 21,297 people living with HIV (PLHIV) enrolled in the Swiss HIV Cohort Study (SHCS).

Answer: 21,297
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""The SHCS is a prospective multicentre study that is highly representative of the HIV-1 epidemic in Switzerland...""

Rationale: The paper mentions that the samples were obtained from Switzerland.

Answer: Switzerland
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""As of August 2021, the SHCS has a cumulative total of 21,529 patients.""

Rationale: The paper does not provide specific years during which the sequenced samples were obtained, but it mentions that the data is available up to August 2021.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""SS typically detects HIV-DRMs present in at least 15%--25% of variants of circulating viruses in the plasma...""

Rationale: The paper does not mention that samples were cloned prior to sequencing. It discusses the differences between Sanger sequencing (SS) and next-generation sequencing (NGS) in detecting HIV drug resistance mutations (DRMs).

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""SS was performed by amplification and sequencing of HIV genomic regions targeted by antiretroviral (ARV) drugs, such as the protease (PR), reverse transcriptase (RT) and integrase (IN) regions.""

Rationale: The paper mentions that the protease (PR), reverse transcriptase (RT), and integrase (IN) regions of the HIV genome were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""SS was performed by amplification and sequencing of HIV genomic regions targeted by antiretroviral (ARV) drugs, such as the protease (PR), reverse transcriptase (RT) and integrase (IN) regions.""

Rationale: The paper mentions that Sanger sequencing (SS) was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Genotyping was done on dried blood spot and/or plasma of participants with high HIV VL (≥1000 copies/mL).""

Rationale: The paper does not mention the specific type of samples sequenced, but it mentions that genotyping was done on dried blood spot and/or plasma of participants with high HIV VL (≥1000 copies/mL) in a different context.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""We found a good agreement (Cohen's kappa and Light's kappa >0.8) for DRMs conferring resistance to PIs, NRTIs and NNRTIs with variant-calling thresholds above 5%.""

Rationale: The paper does not specifically mention that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""The SHCS is a prospective multicentre study that is highly representative of the HIV-1 epidemic in Switzerland...""

Rationale: The paper does not mention that the patients were part of a clinical trial. It describes the Swiss HIV Cohort Study (SHCS) as a prospective multicentre study.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""We found a good agreement (Cohen's kappa and Light's kappa >0.8) for DRMs conferring resistance to PIs, NRTIs and NNRTIs with variant-calling thresholds above 5%.""

Rationale: The paper does not specifically mention that sequences were obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""We found a good agreement (Cohen's kappa and Light's kappa >0.8) for DRMs conferring resistance to PIs, NRTIs and NNRTIs with variant-calling thresholds above 5%.""

Rationale: The paper does not specifically mention which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""We found a good agreement (Cohen's kappa and Light's kappa >0.8) for DRMs conferring resistance to PIs, NRTIs and NNRTIs with variant-calling thresholds above 5%.""

Rationale: The paper does not specifically mention which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",86
36751650,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: A total of 1653 samples, including 716 MSM, 827 HES, 50 PWID, and 15 others, were successfully sequenced.

Rationale: The evidence indicates that the paper reports HIV sequences from patient samples, including MSM, HES, PWID, and others.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data is provided in the paper.

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence of publicly available sequences is provided in the paper.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No GenBank accession numbers are provided in the paper.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 1653 samples, including 716 MSM, 827 HES, 50 PWID, and 15 others, were successfully sequenced.

Rationale: The evidence indicates that samples were obtained from 1653 individuals for HIV sequencing.

Answer: 1653
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Guangxi, China.

Rationale: The evidence indicates that the sequenced samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study was conducted from 2016 to 2020.

Rationale: The evidence indicates that the sequenced samples were obtained from 2016 to 2020.

Answer: 2016-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence of cloning is provided in the paper.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The target fragment of 1316 bp in the *pol* gene (HXB2: 2147--3462, encoding the protease and the first 299 residues of reverse transcriptase) was amplified.

Rationale: The evidence indicates that the *pol* gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The PCR products were sent to the company for Sanger sequencing.

Rationale: The evidence indicates that Sanger sequencing was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma was separated within 12 hours of blood collection and stored at −80°C until further use.

Rationale: The evidence indicates that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence of virological failure is provided in the paper.

Rationale: The paper does not mention any sequences from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence of a clinical trial is provided in the paper.

Rationale: The paper does not mention any clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence of previous ARV drug use is provided in the paper.

Rationale: The paper does not mention any previous ARV drug use.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence of previous drug use is provided in the paper.

Rationale: The paper does not mention any previous drug use.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence of previous drug use is provided in the paper.

Rationale: The paper does not mention any previous drug use.

Answer: nan
""""""",55
36779485,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described [7].""

Rationale: The paper mentions that genotypic sequence data from patient samples were included for analysis, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described [7].""

Rationale: The paper mentions that genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis.

Answer: 277 and 1372
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Our retrospective analysis indicates that rilpivirine DRMs are common in a setting wherein NNRTI-based treatment was recently widely implemented, and has significant implications for operational implementation of CAB/RPV LA.""

Rationale: The paper does not specify the countries from which the sequenced samples were obtained, but it mentions that the analysis has implications for operational implementation of CAB/RPV LA in low-and-middle-income countries (LMICs).

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Pol sequences were submitted to Stanford HIVdb v9.0 to identify rilpivirine DRMs.""

Rationale: The paper mentions that pol sequences were submitted to Stanford HIVdb v9.0 to identify rilpivirine DRMs, indicating that the pol gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described [7].""

Rationale: The paper mentions that genotypic sequence data from patient samples were included for analysis, but it does not specify the type of samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described [7].""

Rationale: The paper mentions that genotypic sequence data from patients experiencing NNRTI-treatment failure were included for analysis, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described [7].""

Rationale: The paper mentions that genotypic sequence data from patients experiencing NNRTI-treatment failure were included for analysis, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Our retrospective analysis indicates that rilpivirine DRMs are common in a setting wherein NNRTI-based treatment was recently widely implemented, and has significant implications for operational implementation of CAB/RPV LA.""

Rationale: The paper mentions that the analysis was conducted in a setting where NNRTI-based treatment was recently widely implemented, indicating that individuals in the study had previously received NNRTI-based treatment.

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not specify the exact drugs that were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",67
36795586,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV genotype testing was performed on all patients with detectable (>40 copies/mL) VL. Frozen plasma was shipped to the United States for genotyping. RNA was extracted from 200 µL of plasma via Biomerieux's MiniMAG (Biomerieux, Durham, NC).

Rationale: The paper explicitly states that HIV genotype testing was performed on patient samples, which involves sequencing of HIV genes.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether any sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 9419 CALHIV received DTG across the BIPAI COEs during the study period.

Rationale: The paper mentions that 9419 CALHIV received DTG, which implies that samples were obtained from these individuals for HIV sequencing.

Answer: 9419
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted at sites in Botswana, Eswatini, Lesotho, Malawi, Tanzania-Mbeya, Tanzania-Mwanza and Uganda.

Rationale: The paper explicitly mentions the countries from which the samples were obtained.

Answer: Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study period was from January 2017 to December 2020.

Rationale: The paper mentions the study period, which indicates the years during which the samples were obtained.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV genotype testing was performed, but does not specify which genes were sequenced.

Rationale: The paper does not provide information on which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Frozen plasma was shipped to the United States for genotyping. RNA was extracted from 200 µL of plasma via Biomerieux's MiniMAG (Biomerieux, Durham, NC).

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that 79.8% (426/534) of previously unsuppressed CALHIV achieved VLS using DTG.

Rationale: The paper implies that sequences were obtained from individuals with virological failure, as they were able to achieve VLS after switching to DTG.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The study was a retrospective cohort study.

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that 9419 CALHIV received DTG, which implies that these individuals had previously received ARV drugs.

Rationale: The paper implies that the sequenced individuals had previously received ARV drugs, as they were switched to DTG.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the majority of CALHIV were shifted from NNRTI-based regimens.

Rationale: The paper implies that the individuals received NNRTI-based regimens before switching to DTG.

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the majority of CALHIV were shifted from NNRTI-based regimens, and that DTG was used as part of the treatment regimen.

Rationale: The paper implies that the individuals received NNRTI-based regimens and DTG before sample sequencing.

Answer: NNRTI, DTG
""""""",64
36851704,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Protease, reverse transcriptase, and integrase genes of HIV-1 were sequenced.""

Rationale: The paper explicitly states that HIV-1 genes were sequenced, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 206 participants were enrolled in the survey;""

Rationale: The paper states that 206 participants were enrolled in the survey, indicating how many individuals had samples obtained for sequencing.

Answer: 206
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""The Ministry of Health of Uruguay implemented a cross-sectional nationally representative survey""

Rationale: The paper clearly states that the survey was conducted in Uruguay, indicating the country of origin.

Answer: Uruguay
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""From October 2018 to October 2019""

Rationale: The paper mentions that the survey was conducted from October 2018 to October 2019, indicating the years from which the sequenced samples were obtained.

Answer: 2018-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Protease, reverse transcriptase, and integrase genes of HIV-1 were sequenced.""

Rationale: The paper explicitly states that the protease, reverse transcriptase, and integrase genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Sanger sequencing was performed on a 3730xl Genetic Analyser (ThermoFisher, Waltham, MA, USA).""

Rationale: The paper explicitly states that Sanger sequencing was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Whole blood specimens were collected by venipuncture in EDTA-containing tubes from participants before initiating or reinitiating ART.""

Rationale: The paper describes the collection of whole blood specimens from patients, which were then used for sequencing.

Answer: Whole Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Among those with a CD4 lymphocyte count result available at the time of treatment initiation (65%), 28.9% (IC95% 24--34.2%) had <200 cells/µL""

Rationale: The paper mentions that some individuals had low CD4 lymphocyte counts, which may indicate virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""The Ministry of Health of Uruguay implemented a cross-sectional nationally representative survey""

Rationale: The paper describes a cross-sectional survey, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The proportion of individuals who reported previous exposure to ARV drugs was 35.6% (95% CI: 34.2--37.0%).""

Rationale: The paper mentions that some individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""NNRTI-based ART regimens were the most frequently prescribed (55.1%, 95% CI: 54--56.1%), followed by dolutegravir (DTG)-based regimens (29.4%, 95% CI: 28.4--30.4%), and PI/r-based regimens (11.7%, 95% CI: 11.0--12.6%)""

Rationale: The paper mentions the use of NNRTI, PI/r, and INSTI-based regimens.

Answer: NNRTI, PI/r, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""NNRTI-based ART regimens were the most frequently prescribed (55.1%, 95% CI: 54--56.1%), followed by dolutegravir (DTG)-based regimens (29.4%, 95% CI: 28.4--30.4%), and PI/r-based regimens (11.7%, 95% CI: 11.0--12.6%)""

Rationale: The paper mentions the use of DTG, NNRTI, and PI/r-based regimens.

Answer: Dolutegravir (DTG), NNRTI, PI/r
""""""",70
36851760,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Dried blood spots (DBSs) were obtained from 107 HIV-1-infected children aged less than 15 years old living in two West African countries, Mali and Benin.""

Rationale: The paper mentions that dried blood spots (DBSs) were obtained from HIV-1-infected children, which indicates that HIV sequences were obtained from these patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""All sequences were submitted to GenBank and registered under accession numbers OQ435656-OQ435729.""

Rationale: The paper mentions that all sequences were submitted to GenBank and registered under specific accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""All sequences were submitted to GenBank and registered under accession numbers OQ435656-OQ435729.""

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates.

Answer: OQ435656-OQ435729
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Seventy-five (75) of the 107 samples were successfully sequenced, assembled, and aligned using Sescap and SmartGene HIV Software (Innovation Park, Lausanne, Switzerland).""

Rationale: The paper mentions that 75 samples were successfully sequenced.

Answer: 75
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Dried blood spots (DBSs) were obtained from 107 HIV-1-infected children aged less than 15 years old living in two West African countries, Mali and Benin.""

Rationale: The paper clearly states that the samples were obtained from Mali and Benin.

Answer: Mali, Benin
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""The DBSs were collected from 51 ART-treated children with virological failure, defined as having at least one viral load (VL) >1000 copies/mL, during a study conducted in Benin between 2015 and 2016 [ 14 ] and from 56 ART-naïve children, collected between 2018 and 2020 during early diagnosis testing and follow-up in Mali.""

Rationale: The paper mentions the years during which the samples were collected.

Answer: 2015-2016, 2018-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Genetic sequencing of HIV integrase was successful in 75 samples.""

Rationale: The paper mentions that the HIV integrase gene was sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Seventy-five (75) of the 107 samples were successfully sequenced, assembled, and aligned using Sescap and SmartGene HIV Software (Innovation Park, Lausanne, Switzerland).""

Rationale: The paper mentions that Sanger sequencing was used for processing the PCR products.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Dried blood spots (DBSs) were obtained from 107 HIV-1-infected children aged less than 15 years old living in two West African countries, Mali and Benin.""

Rationale: The paper describes the collection of dried blood spots (DBSs) from patients.

Answer: DBS
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""The DBSs were collected from 51 ART-treated children with virological failure, defined as having at least one viral load (VL) >1000 copies/mL, during a study conducted in Benin between 2015 and 2016 [ 14 ]""

Rationale: The paper mentions that sequences were obtained from individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The DBSs were collected from 51 ART-treated children with virological failure, defined as having at least one viral load (VL) >1000 copies/mL, during a study conducted in Benin between 2015 and 2016 [ 14 ]""

Rationale: The paper mentions that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""At enrollment, 90.3% of the treated children were receiving non-nucleoside-reverse-transcriptase-inhibitor (NNRTI)-based regimens, and only 9.7% received both nucleoside-reverse-transcriptase inhibitor (NRTI)- and PI-based regimens.""

Rationale: The paper mentions that individuals received NNRTI, NRTI, and PI-based regimens.

Answer: NNRTI, NRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide specific information about the drugs received by individuals in the study.

Answer: Not reported
""""""",74
36920025,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""We generated 31 recombinant viruses containing the entire *gag* and protease genes from 31 plasma samples from HIV-1-infected patients with ( *n* = 21) or without ( *n* = 10) prior ARV experience.""

Rationale: The paper mentions that 31 recombinant viruses were generated from 31 plasma samples from HIV-1-infected patients, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""We analyzed in vitro susceptibility test results on 2,725 HIV-1 protease isolates.""

Rationale: The paper mentions the analysis of in vitro susceptibility test results on HIV-1 protease isolates, indicating that in vitro drug susceptibility data is reported.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""Sequence data have been deposited in GenBank. GenBank accession numbers for Sanger protease-RT sequences are OP894533-OP894623 while those for Integrase are OP894444-OP894532.""

Rationale: The paper states that sequence data have been deposited in GenBank, indicating that the sequences are publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""GenBank accession numbers for Sanger protease-RT sequences are OP894533-OP894623 while those for Integrase are OP894444-OP894532.""

Rationale: The paper provides specific GenBank accession numbers for both Sanger protease-RT sequences and Integrase sequences.

Answer: OP894533-OP894623, OP894444-OP894532
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""We generated 31 recombinant viruses containing the entire *gag* and protease genes from 31 plasma samples from HIV-1-infected patients with ( *n* = 21) or without ( *n* = 10) prior ARV experience.""

Rationale: The paper states that 31 plasma samples from HIV-1-infected patients were used to generate the virus isolates, indicating that samples were obtained from 31 individuals.

Answer: 31
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not mention any countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide any information regarding the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""We generated 31 recombinant viruses containing the entire *gag* and protease genes from 31 plasma samples from HIV-1-infected patients with ( *n* = 21) or without ( *n* = 10) prior ARV experience.""

Rationale: The paper mentions that the entire gag and protease genes from the patient samples were sequenced and analyzed.

Answer: Gag, PR
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""We used the Illumina bcl2fastq pipeline for the initial processing and constructed template consensus sequences (TCSs) with TCS pipeline version 1.33 ( https://github.com/SwanstromLab/PID ) ( Zhou, 2019 ).""

Rationale: The paper mentions the use of the Illumina bcl2fastq pipeline and the TCS pipeline for sequencing.

Answer: NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Thirty-one plasma samples from ARV treatment-experienced or -naïve patients were used to generate the virus isolates.""

Rationale: The paper specifies that 31 plasma samples from ARV treatment-experienced or -naïve patients were used to generate the virus isolates.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""No evidence""

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Twenty-one samples from ARV-experienced patients were selected from two different past Gilead studies in order to capture a snapshot of patient susceptibility to bevirimat at two different time periods.""

Rationale: The paper mentions that 21 samples were from ARV-experienced patients, indicating that these individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information regarding drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",80
36931676,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention the reporting of HIV sequences from patient samples.

Rationale: The paper discusses various aspects of HIV care and research, but it does not specifically mention the reporting of HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data.

Rationale: The paper does not discuss any in vitro experiments or drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention whether any sequences were made publicly available.

Rationale: The paper does not provide any information regarding the public availability of sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any specific GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not report any individuals from whom samples were obtained for HIV sequencing.

Rationale: The paper does not involve sequencing and does not report any sample collection.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention any sequenced samples or their countries of origin.

Rationale: The paper does not involve sequencing and does not report any sample collection.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide any information regarding the years of sequenced samples.

Rationale: The paper does not involve sequencing and does not report any sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not involve sequencing and does not report any sample preparation methods.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not report any sequencing of HIV genes.

Rationale: The paper does not involve sequencing and does not report any genetic analysis.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention any sequencing methods.

Rationale: The paper does not involve sequencing and does not report any sequencing methods.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify any type of samples that were sequenced.

Rationale: The paper does not involve sequencing and does not report any sample collection.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences obtained from individuals with virological failure.

Rationale: The paper discusses virological non-suppression but does not mention obtaining sequences from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not discuss any clinical trials or experimental treatments.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention any sequences obtained from individuals who had previously received ARV drugs.

Rationale: The paper does not involve sequencing and does not report any genetic analysis.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drug classes received by individuals prior to sample sequencing.

Rationale: The paper does not involve sequencing and does not report any treatment information.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drugs received by individuals prior to sample sequencing.

Rationale: The paper does not involve sequencing and does not report any treatment information.

Answer: Not reported
""""""",58
36961945,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""We investigated whether deep sequencing of archived HIV DNA of antiretroviral-naïve persons with acute/early HIV infection could identify transmitted drug resistance mutations (DRM), per the IAS drug resistance algorithm, that are not detected by routine bulk (consensus) sequencing.""

Rationale: The paper reports HIV sequences from patient samples, specifically archived HIV DNA from antiretroviral-naïve persons with acute/early HIV infection.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not provide any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Overall, 190 individuals were included, 72 (37.9%) with acute, 20 (10.5%) very early, and 98 (51.6%) with recent HIV infection.""

Rationale: The paper mentions that 190 individuals had samples obtained for HIV sequencing.

Answer: 190
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Samples were collected from January 2005 to February 2020""

Rationale: The paper mentions that the samples were collected from January 2005 to February 2020.

Answer: 2005-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about cloning the samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Genotypic resistance testing on PR, RT, and IN from proviral HIV-1 DNA was performed using a modified version of the ""deepTypeHIV"" assay""

Rationale: The paper mentions that the PR, RT, and IN genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""NGS of HIV partial pol was performed to identify DRMs present in archived proviral DNA""

Rationale: The paper mentions that Next-Generation Sequencing (NGS) was used for sequencing.

Answer: Next-Generation Sequencing (NGS)
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Genotypic resistance testing on PR, RT, and IN from proviral HIV-1 DNA was performed using a modified version of the ""deepTypeHIV"" assay""

Rationale: The paper mentions that proviral HIV-1 DNA was sequenced.

Answer: Proviral HIV-1 DNA
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Despite identifying both high frequency and low frequency DRMs in either archived proviral DNA or blood plasma, there was no evidence of viral rebound from any participants during the entire follow-up period""

Rationale: The paper does not provide any information about sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about the patients being in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Participants began ART a median of 82 days [IQR:34;139] after the EDI""

Rationale: The paper mentions that the participants began ART after the estimated date of infection (EDI), indicating that they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Participants began ART a median of 82 days [IQR:34;139] after the EDI""

Rationale: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Participants began ART a median of 82 days [IQR:34;139] after the EDI""

Rationale: The paper does not provide any information about the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",65
36967989,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples. However, it discusses the prediction of HIV-1 protease resistance using genotypic, phenotypic, and molecular information with artificial neural networks.

Rationale: The paper does not provide direct evidence of HIV sequences from patient samples. However, it discusses the use of genotype-phenotype data for HIV-1 protease inhibitors, which may imply the use of HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not explicitly mention in vitro drug susceptibility data. However, it discusses the prediction of drug resistance tendencies for each PI pair and the classification of resistant and susceptible strains.

Rationale: The paper does not provide direct evidence of in vitro drug susceptibility data. However, it discusses the use of genotype-phenotype data for HIV-1 protease inhibitors, which may imply the use of in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not explicitly mention the public availability of sequences. However, it discusses the use of data from the Stanford HIV drug resistance database.

Rationale: The paper does not provide direct evidence of the public availability of sequences. However, it discusses the use of data from a public database, which may imply the public availability of sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide direct evidence of GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide direct evidence of the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide direct evidence of the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide direct evidence of the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention whether samples were cloned prior to sequencing.

Rationale: The paper does not provide direct evidence of whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention which HIV genes were reported to have been sequenced.

Rationale: The paper does not provide direct evidence of which HIV genes were reported to have been sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the method used for sequencing.

Rationale: The paper does not provide direct evidence of the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide direct evidence of the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide direct evidence of whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention whether the patients in the study were in a clinical trial.

Rationale: The paper does not provide direct evidence of whether the patients in the study were in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention whether the individuals had previously received ARV drugs.

Rationale: The paper does not provide direct evidence of whether the individuals had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention which drug classes were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide direct evidence of which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention which drugs were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide direct evidence of which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",68
36982978,"Here are the answers to the questions in the format you requested:

### Question 1: Does the paper report HIV sequences from patient samples?

Evidence: ""Three viral isolates from HIV-O--infected ARV-naive patients, representative of each subtype, and 1 from HIV-M subtype B were studied: 11,367 (HIV-O, subtype A, termed HIV-O/A), MVP5180 (HIV-O, subtype B, termed HIV-O/B), BCF11 (HIV-O, divergent strain, termed HIV-O/Div), and 5326 (HIV-M, subtype B, termed HIV-M).""

Rationale: The paper mentions that viral isolates were obtained from HIV-O-infected ARV-naive patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes

### Question 2: Does the paper report in vitro drug susceptibility data?

Evidence: ""HIV-2 group A, HIV-2 group B, and HIV-1 isolates from INSTI-naïve individuals were comparably sensitive to dolutegravir in the single-cycle assay (mean EC50 values = 1.9, 2.6, and 1.3 nM, respectively).""

Rationale: The paper reports in vitro drug susceptibility data for dolutegravir in both HIV-1 and HIV-2 strains.

Answer: Yes

### Question 3: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No

### Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

### Question 5: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Three viral isolates from HIV-O--infected ARV-naive patients, representative of each subtype, and 1 from HIV-M subtype B were studied: 11,367 (HIV-O, subtype A, termed HIV-O/A), MVP5180 (HIV-O, subtype B, termed HIV-O/B), BCF11 (HIV-O, divergent strain, termed HIV-O/Div), and 5326 (HIV-M, subtype B, termed HIV-M).""

Rationale: The paper mentions that viral isolates were obtained from four individuals.

Answer: 4

### Question 6: From which countries were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide specific information about the countries from which the sequenced samples were obtained.

Answer: Not reported

### Question 7: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide specific information about the years from which the sequenced samples were obtained.

Answer: Not reported

### Question 8: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information regarding whether the samples were cloned prior to sequencing.

Answer: No

### Question 9: Which HIV genes were reported to have been sequenced?

Evidence: ""The integrase region of HIV-O viruses was amplified and sequenced as previously described.""

Rationale: The paper specifically mentions the sequencing of the integrase region of HIV-O viruses.

Answer: IN

### Question 10: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported

### Question 11: What type of samples were sequenced?

Evidence: ""Plasma HIV-2 RNA (pVL) was assessed at time of dolutegravir initiation (baseline), month 3, and month 6.""

Rationale: The paper mentions that plasma samples were used for sequencing.

Answer: Plasma

### Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""HIV-2–infected patients experiencing virological failure to raltegravir received dolutegravir with optimized background antiretroviral combinations within the French Named Patient Program (NPP).""

Rationale: The paper specifically focuses on HIV-2-infected patients experiencing virological failure to raltegravir-containing regimens.

Answer: Yes

### Question 13: Were the patients in the study in a clinical trial?

Evidence: ""Not mentioned.""

Rationale: The paper does not provide any information regarding whether the patients were part of a clinical trial.

Answer: No

### Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""HIV-2–infected patients experiencing virological failure to raltegravir received dolutegravir with optimized background antiretroviral combinations within the French Named Patient Program (NPP).""

Rationale: The paper mentions that the HIV-2 infected patients were given previous antiretroviral regimens.

Answer: Yes

### Question 15: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""HIV-2–infected patients experiencing virological failure to raltegravir received dolutegravir with optimized background antiretroviral combinations within the French Named Patient Program (NPP). Optimized background ARV regimens included nucleoside reverse transcriptase inhibitors (tenofovir disoproxil fumarate [n = 3], zidovudine [n = 4], lamivudine or emtricitabine [n = 8], abacavir [n = 3], didanosine [n = 1]) associated with ritonavir-boosted darunavir 600/100 mg twice daily (n = 12), ritonavir-boosted saquinavir 1000/100 mg twice daily (n = 3), and maraviroc 150 mg twice daily (n = 3).""

Rationale: The paper lists the specific drugs and drug classes that were part of the optimized background antiretroviral regimens received by the patients.

Answer: NRTI, PI, INSTI, CCR5 antagonist

### Question 16: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""HIV-2–infected patients experiencing virological failure to raltegravir received dolutegravir with optimized background antiretroviral combinations within the French Named Patient Program (NPP). Optimized background ARV regimens included nucleoside reverse transcriptase inhibitors (tenofovir disoproxil fumarate [n = 3], zidovudine [n = 4], lamivudine or emtricitabine [n = 8], abacavir [n = 3], didanosine [n = 1]) associated with ritonavir-boosted darunavir 600/100 mg twice daily (n = 12), ritonavir-boosted saquinavir 1000/100 mg twice daily (n = 3), and maraviroc 150 mg twice daily (n = 3).""

Rationale: The paper lists the specific drugs that were part of the optimized background antiretroviral regimens received by the patients.

Answer: Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Emtricitabine (FTC), Tenofovir (TFV), Didanosine (DDI), Darunavir (DRV), Saquinavir (SQV), Maraviroc (MVC), Raltegravir (RAL), Dolutegravir(DTG)",106
37017009,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Whole blood was collected using standard phlebotomy methods into a 6 mL EDTA tube. A minimum of 500 μL plasma was ultra-centrifuged and total nucleic acid extracted using the MagNA Pure 2.0 automated extraction system (Roche Applied Science, Penzberg, Germany). PCR amplification was performed using an in-house method resulting in a single amplicon spanning 1.5 kb of *pol* encompassing the protease gene and the first 250 amino acids of the reverse transcriptase gene (HXB2 2358--3882).""

Rationale: The paper mentions that HIV sequences were obtained from patient samples through PCR amplification and sequencing of the *pol* gene.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""At study closure, 1000 children had participated in the study. Of these, 899 participants from 40 facilities from eight provinces (EC, FS, GP, KZ, LP, MP, NC and WC) were included in the study analysis, comprising 61% of the anticipated sample size""

Rationale: The paper mentions that 899 participants had samples obtained for HIV sequencing.

Answer: 899
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""The final number enrolled per province were 44, 33, 135, 455, 58, 107, 37, 0 and 30 in EC, FS, GP, KZ, LP, MP, NC, NW and WC, respectively.""

Rationale: The paper mentions that the samples were obtained from South Africa, as indicated by the abbreviations for the provinces.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""This cross-sectional study, performed from March 2017 to March 2019 in South Africa,""

Rationale: The paper mentions that the study was conducted from March 2017 to March 2019.

Answer: 2017-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""PCR amplification was performed using an in-house method resulting in a single amplicon spanning 1.5 kb of *pol* encompassing the protease gene and the first 250 amino acids of the reverse transcriptase gene (HXB2 2358--3882).""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""PCR amplification was performed using an in-house method resulting in a single amplicon spanning 1.5 kb of *pol* encompassing the protease gene and the first 250 amino acids of the reverse transcriptase gene (HXB2 2358--3882).""

Rationale: The paper mentions that the *pol* gene, including the protease and reverse transcriptase genes, was sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""MiSeq FastQ files were analysed using DeepChek ^®^ (Advanced Biological Laboratories, Luxembourg, Luxembourg), and results were generated at a 20% mutation detection threshold.""

Rationale: The paper mentions that next-generation sequencing technologies were used for sequencing.

Answer: Next-generation sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Whole blood was collected using standard phlebotomy methods into a 6 mL EDTA tube. A minimum of 500 μL plasma was ultra-centrifuged and total nucleic acid extracted using the MagNA Pure 2.0 automated extraction system (Roche Applied Science, Penzberg, Germany).""

Rationale: The paper mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""At study closure, 1000 children had participated in the study. Of these, 899 participants from 40 facilities from eight provinces (EC, FS, GP, KZ, LP, MP, NC and WC) were included in the study analysis, comprising 61% of the anticipated sample size""

Rationale: The paper mentions that the study included participants with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""A cross-sectional facility-based study with retrospective record review was conducted using a stratified cluster sampling approach.""

Rationale: The paper describes a cross-sectional study design and does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Amongst participants receiving PI-based regimens, adjusted total HIVDR was detected in 80.6% (95% CI 73.1%--86.4%, Table 3 ); resistance to PIs was present in 11.5% (95% CI 6.4%--19.8%) of participants, resistance to NNRTIs was present in 60.9% (95% CI 54.4%--67.1%) and resistance to NRTIs in 65.1% (56.3%--73.0%).""

Rationale: The paper mentions that the participants had previously received ARV drugs, as indicated by the presence of resistance to different drug classes.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Amongst participants receiving PI-based regimens, adjusted total HIVDR was detected in 80.6% (95% CI 73.1%--86.4%, Table 3 ); resistance to PIs was present in 11.5% (95% CI 6.4%--19.8%) of participants, resistance to NNRTIs was present in 60.9% (95% CI 54.4%--67.1%) and resistance to NRTIs in 65.1% (56.3%--73.0%).""

Rationale: The paper mentions that the participants had received PI-based regimens, NNRTI-based regimens, and NRTI-based regimens before sample sequencing.

Answer: PI, NNRTI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Amongst participants receiving PI-based regimens, adjusted total HIVDR was detected in 80.6% (95% CI 73.1%--86.4%, Table 3 ); resistance to PIs was present in 11.5% (95% CI 6.4%--19.8%) of participants, resistance to NNRTIs was present in 60.9% (95% CI 54.4%--67.1%) and resistance to NRTIs in 65.1% (56.3%--73.0%).""

Rationale: The paper mentions that the participants had received ritonavir-boosted lopinavir, ritonavir-boosted atazanavir, efavirenz, nevirapine, abacavir, lamivudine, emtricitabine, tenofovir disoproxil fumarate, and zidovudine before sample sequencing.

Answer: Ritonavir-boosted lopinavir, Ritonavir-boosted atazanavir, Efavirenz, Nevirapine, Abacavir, Lamivudine, Emtricitabine, Tenofovir disoproxil fumarate, Zidovudine
""""""",109
37029656,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: Overall, 1223 ART-naive PLWH were evaluated: 1109 (90.7%) were male, 860 (70.3%) were MSM and the median age was 37 (IQR, 30--45) years. Italian origin was found in 578 (78.0%) and 971 (79.4%) were infected by HIV-1 subtype B. CRF01_AE (74.0%) was the most frequent HIV-1 non-B subtype observed. The median time to ART initiation was 2.9 (1.3--20.2) months; GRT was performed after a median time of 1.2 (0.5--2.9) months once diagnosed with HIV infection and CD4 cell count at GRT was 416 (259--58) cells/µL.

Rationale: The paper mentions that 1223 ART-naive PLWH were evaluated, and GRT was performed on these patients, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The degree of resistance to each INSTI drug was calculated using the Genotypic Resistance Interpretation Algorithm of the Stanford HIV Drug Resistance Database Program (version 9.1.1) (https://hivdb.stanford.edu/hivdb/by-patterns/). The obtained scores were used to classify the presence of low-level, intermediate or high-level resistance to each INSTI drug and to the INSTI drug class.

Rationale: The paper does not mention any in vitro drug susceptibility testing or data. It uses the Stanford HIV Drug Resistance Database Program to calculate the degree of resistance to each INSTI drug.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It focuses on the analysis of resistance mutations and virological data without mentioning specific accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Overall, 1223 ART-naive PLWH were evaluated: 1109 (90.7%) were male, 860 (70.3%) were MSM and the median age was 37 (IQR, 30--45) years.

Rationale: The paper mentions that 1223 ART-naive PLWH were evaluated, and GRT was performed on these patients, indicating that samples were obtained from these individuals for HIV sequencing.

Answer: 1223
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: Italian origin was found in 578 (78.0%) 

Rationale: The paper mentions that the majority of the patients had Italian origin, indicating that the sequenced samples were obtained from Italy.

Answer: Italy
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: We conducted a time-trend, single-centre study over the period 2009--19 on adult naive PLWH with a genotypic resistance test (GRT) performed before the ART initiation.

Rationale: The paper mentions that the study was conducted over the period 2009--19.

Answer: 2009--2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding whether the samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: GRT was determined by Sanger sequencing using an ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA);

Rationale: The paper does not specifically mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: GRT was determined by Sanger sequencing using an ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA);

Rationale: The paper specifies that Sanger sequencing was used to sequence the HIV genes from the plasma samples.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The median time to ART initiation was 2.9 (1.3--20.2) months; GRT was performed after a median time of 1.2 (0.5--2.9) months once diagnosed with HIV infection and CD4 cell count at GRT was 416 (259--58) cells/µL.

Rationale: The paper mentions that GRT was performed on patient samples, indicating that plasma was the clinical specimen used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper focused on ART-naive patients, meaning they had not yet received antiretroviral treatment, so there were no sequences from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide any information indicating that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper focused on ART-naive patients, meaning they had not previously received antiretroviral drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper focused on ART-naive patients, meaning they had not previously received antiretroviral drugs.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper focused on ART-naive patients, meaning they had not previously received antiretroviral drugs.

Answer: nan
""""""",80
37039023,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Forty-six HIV+ patients from RJ and 40 HIV+ patients from RS were included in this study"" and that ""All samples were successfully sequenced.""

Rationale: The paper reports HIV sequences from patient samples, specifically from archived proviruses of patients with prolonged undetectable viral load.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data.

Rationale: The paper does not provide any information on in vitro drug susceptibility experiments or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states that ""The raw sequencing reads were deposited to the Sequence Read Archive under the BioProject PRJNA419915.""

Rationale: The sequences from the paper were made publicly available through the Sequence Read Archive.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""Forty-six HIV+ patients from RJ and 40 HIV+ patients from RS were included in this study.""

Rationale: The paper states that 86 HIV+ patients had samples obtained for HIV sequencing.

Answer: 86
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from patients in Rio de Janeiro (RJ) and Rio Grande do Sul (RS), Brazil.

Rationale: The paper specifies that the samples were obtained from Brazil.

Answer: Brazil
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples from RJ were collected between February 2016 and November 2018, and the samples from RS were collected between August and December 2017.

Rationale: The paper specifies the years from which the sequenced samples were obtained.

Answer: 2016-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the near full-length genome (NFLG) of HIV was sequenced, which includes the protease, reverse transcriptase, integrase, and envelope regions.

Rationale: The paper reports that the NFLG of HIV was sequenced, which includes multiple genes.

Answer: Near full length genome
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the Illumina MiSeq platform with a paired-end 2 × 251 protocol was used for sequencing.

Rationale: The paper specifies the sequencing method used.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that peripheral blood mononuclear cells (PBMCs) were used for sequencing.

Rationale: The paper specifies the type of samples sequenced.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information on sequences obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information on a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the patients were on a first-line or second-line treatment regimen.

Rationale: The paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients were on a first-line or second-line treatment regimen, which included NNRTIs, NRTIs, and PIs.

Rationale: The paper specifies the drug classes received by individuals in the study.

Answer: NNRTI, NRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients were on a first-line or second-line treatment regimen, which included TDF, 3TC, EFV, and DTG.

Rationale: The paper specifies the drugs received by individuals in the study.

Answer: TDF, 3TC, EFV, DTG
""""""",73
37042390,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019. Genotypic resistance testing to identify drug resistance mutations in the integrase, reverse transcriptase and protease genes was done at the start of third-line therapy, as well as in those who did not attain virological suppression after 12 months of therapy.""

Rationale: The paper mentions that genotypic resistance testing was performed on patient samples to identify drug resistance mutations in the integrase, reverse transcriptase, and protease genes.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019.""

Rationale: The paper mentions that 87 patients had samples obtained for HIV sequencing.

Answer: 87
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""This single-centre observational study was done at a CoE in HIV care, Banaras Hindu University (BHU) in a tertiary hospital in Varanasi, India.""

Rationale: The paper mentions that the study was conducted in India.

Answer: India
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019.""

Rationale: The paper mentions that the samples were obtained from patients who started third-line ART between July 2016 and December 2019.

Answer: 2016-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Genotypic resistance testing to identify drug resistance mutations in the integrase, reverse transcriptase and protease genes was done at the start of third-line therapy, as well as in those who did not attain virological suppression after 12 months of therapy.""

Rationale: The paper mentions that the integrase, reverse transcriptase, and protease genes were sequenced.

Answer: IN, RT, PR
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Sequencing was done by a third-party commercial organization (Medauxin) using an Applied Biosystem 3730xl DNA Analyzer.""

Rationale: The paper mentions that sequencing was done using an Applied Biosystem 3730xl DNA Analyzer.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Whole blood was collected from patients into EDTA tubes and used for CD4 estimation; in parallel, plasma was separated following centrifugation at 2000 rpm at 4°C for 10 min and stored at −80°C until viral RNA isolation.""

Rationale: The paper mentions that plasma samples were used for viral RNA isolation and sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Among the 13 patients who did not attain virological suppression at 12 months, genotyping could be done in only 12.""

Rationale: The paper mentions that sequences were obtained from patients who did not attain virological suppression at 12 months.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""This single-centre observational study was done at a CoE in HIV care, Banaras Hindu University (BHU) in a tertiary hospital in Varanasi, India.""

Rationale: The paper describes an observational study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019.""

Rationale: The paper mentions that the patients had previously received ARV drugs, as they were started on third-line ART.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""The initial regimen for third-line therapy was raltegravir (400 mg) + darunavir (600 mg) + ritonavir (100 mg); given as one tablet twice daily.""

Rationale: The paper mentions that the patients received a regimen consisting of an integrase inhibitor (raltegravir), a protease inhibitor (darunavir), and a pharmacokinetic booster (ritonavir).

Answer: INSTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""The initial regimen for third-line therapy was raltegravir (400 mg) + darunavir (600 mg) + ritonavir (100 mg); given as one tablet twice daily.""

Rationale: The paper mentions that the patients received raltegravir, darunavir, and ritonavir.

Answer: Raltegravir, Darunavir, Ritonavir
""""""",81
37052343,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide specific information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not provide specific information about the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the exact sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not provide specific information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide specific information about the treatment regimens or virological failure of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not provide specific information about whether the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide specific information about the treatment history of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide specific information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide specific information about the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",51
37071019,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 genotyping and phenotyping of plasma samples at baseline and the first sample of the 2 required to meet CVW criteria were conducted by Monogram Biosciences.

Rationale: The paper specifically mentions the use of plasma samples from patients, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions that the antiretroviral activity of inhibitors was determined in a cell-based HIV-1 replication assay in triplicate.

Rationale: The paper reports in vitro drug susceptibility data, as evidenced by the mention of a cell-based HIV-1 replication assay.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention whether the sequences were made publicly available.

Rationale: There is no mention of the sequences being deposited in a public database or made available through any other means.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention any specific GenBank accession numbers for sequenced HIV isolates.

Rationale: There is no mention of GenBank accession numbers in the provided text.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 7 out of 747 participants met the criteria for protocol-defined virologic failure.

Rationale: The paper states that 7 individuals had samples obtained for sequencing due to virological failure.

Answer: 7
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the participants were from South Africa, Colombia, Ukraine, and Brazil.

Rationale: The paper specifies the countries of origin for the participants with INSTI resistance-associated substitutions.

Answer: South Africa, Colombia, Ukraine, Brazil
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide any information regarding the years from which sequenced samples were obtained.

Rationale: There is no mention of specific years for sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper mentions that clonal analyses were performed on participants meeting confirmed virologic withdrawal (CVW) criteria.

Rationale: The paper repeatedly mentions clonal analyses, indicating that samples were cloned prior to sequencing.

Answer: Yes
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase gene, as evidenced by the detailed discussion of integrase strand transfer inhibitor resistance and the genotypic and phenotypic analyses of integrase substitutions.

Rationale: The paper specifically mentions the integrase gene and its role in resistance to integrase strand transfer inhibitors.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions population viral genotyping, which indicates sanger sequencing.

Rationale: The paper mentions population viral genotyping, which is typically performed using Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that HIV-1 genotyping and phenotyping of plasma samples were conducted.

Rationale: The paper mentions the use of plasma samples for genotyping and phenotyping.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that sequences were obtained from individuals who met the criteria for virological failure.

Rationale: The paper indicates that sequences were obtained from individuals who experienced virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a phase IIIb clinical trial (DAWNING study) registered at ClinicalTrials.gov.

Rationale: The paper specifically mentions the study's registration at ClinicalTrials.gov, indicating that it was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that participants had been treated with a first-line regimen consisting of 1 NNRTI plus 2 NRTIs for 6 months, and were experiencing virologic failure at screening.

Rationale: The paper indicates that participants had previously received ARV drugs, including NNRTIs and NRTIs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper lists the specific drugs that participants had received before sample sequencing, including efavirenz, tenofovir disoproxil fumarate, emtricitabine, lamivudine, nevirapine, and zidovudine.

Rationale: The paper specifically mentions the drug classes received by participants, including NNRTIs and NRTIs.

Answer: NRTI, NNRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists the specific drugs that participants had received before sample sequencing, including efavirenz, tenofovir disoproxil fumarate, emtricitabine, lamivudine, nevirapine, and zidovudine.

Rationale: The paper specifically mentions the drugs received by participants, including efavirenz, tenofovir disoproxil fumarate, emtricitabine, lamivudine, nevirapine, and zidovudine.

Answer: Efavirenz (EFV), Tenofovir (TFV), Emtricitabine (FTC), Lamivudine (3TC), Nevirapine (NVP), Zidovudine (AZT), Dolutegravir (DTG)
""""""",81
37085698,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that near full-length HIV-1 IN region, (263 codons) of the 49 study participants were successfully sequenced and analyzed.

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: All nucleotide sequences from this study have been deposited in the Genbank (ncbi) repository with accession numbers from MW560010 to MW560058.

Rationale: The paper explicitly states that the sequences were deposited in the GenBank repository.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: All nucleotide sequences from this study have been deposited in the Genbank (ncbi) repository with accession numbers from MW560010 to MW560058.

Rationale: The paper provides the specific GenBank accession numbers for the sequenced HIV isolates.

Answer: MW560010 to MW560058
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Near full-length HIV-1 IN region, (263 codons) of the 49 study participants were successfully sequenced and analyzed.

Rationale: The paper states that 49 study participants had samples obtained for HIV sequencing.

Answer: 49
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Ethiopia.

Rationale: The paper mentions that the study was conducted in Ethiopia.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study participants were consecutively enrolled in this study from June to December 2018.

Rationale: The paper specifies the time frame during which the samples were collected.

Answer: 2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The IN region covering the first 263 codons of blood samples was amplified and sequenced.

Rationale: The paper specifies that the IN region was sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: Sanger DNA sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), and run on the ABI PRISM 3500 xL automated Genetic Analyzer.

Rationale: The paper mentions the use of Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Blood samples (10 ml) were collected at the time of HIV diagnosis before initiation of ART for genotypic assay of the IN gene region from these participants using an EDTA tube.

Rationale: The paper mentions that blood samples were collected and used for sequencing.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention any clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper mentions that the study participants were drug-naive.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any drug classes received by individuals in the study before sample sequencing.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any drugs received by individuals in the study before sample sequencing.

Answer: nan
""""""",54
37104815,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: PBMCs of virologically suppressed patients enrolled in the ANRS 167 LAMIDOL trial, evaluating a switch from triple therapy to dolutegravir + lamivudine, were collected 8 weeks before (W-8) and 48 weeks after (W48) dual-therapy initiation.

Rationale: The evidence clearly states that patient samples (PBMCs) were collected and sequenced, indicating that the paper reports HIV sequences from these samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The study does not mention any in vitro drug susceptibility data or experiments related to drug resistance. It focused on the analysis of proviral sequences and the presence of mutations.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether the sequences were made publicly available, indicating that this information is not available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any specific GenBank accession numbers for the sequenced HIV isolates, indicating that this information is not available.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The baseline characteristics of the participants enrolled in the substudy are shown in Table 1. The characteristics of the substudy population were similar to those of the population not included in the substudy (Table 1). The two treatment groups of the substudies were also very similar at D0. Most of the participants were men (84.3%), 69% were MSM, the median (IQR) age was 49 years (40--53) and 10% were from sub-Saharan Africa.

Rationale: The evidence specifies that 121 participants were included in the analysis, indicating the number of individuals from whom samples were obtained.

Answer: 121
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any specific countries from which the sequenced samples were obtained, indicating that this information is not available.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the years from which the sequenced samples were obtained, indicating that this information is not available.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The study does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: Sanger and ultra-deep sequencing (UDS) were performed for the reverse transcriptase (RT), protease (PR) and integrase (INT) regions, according to the Agence Nationale de Recherche sur le SIDA et les Maladies Infectieuses Emergentes (ANRS-MIE) consensus, using Illumina technology (Illumina, San Diego, CA, USA).

Rationale: The evidence directly states that the sequencing was performed on the RT, PR, and INT regions of the HIV genome.

Answer: RT, PR, INT
""""""

""""""
Question: What method was used for sequencing?

Evidence: Sanger and ultra-deep sequencing (UDS) were performed for the reverse transcriptase (RT), protease (PR) and integrase (INT) regions, according to the Agence Nationale de Recherche sur le SIDA et les Maladies Infectieuses Emergentes (ANRS-MIE) consensus, using Illumina technology (Illumina, San Diego, CA, USA).

Rationale: The evidence specifies that the sequencing method used was Sanger and ultra-deep sequencing (UDS) with the Illumina platform.

Answer: Sanger sequencing, Ultra-deep sequencing (UDS)
""""""

""""""
Question: What type of samples were sequenced?

Evidence: PBMCs of virologically suppressed patients enrolled in the ANRS 167 LAMIDOL trial, evaluating a switch from triple therapy to dolutegravir + lamivudine, were collected 8 weeks before (W-8) and 48 weeks after (W48) dual-therapy initiation.

Rationale: The evidence specifies that PBMCs (peripheral blood mononuclear cells) were the type of samples collected and sequenced in the study.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: All 10 VFs are presented in Table 4. At D0, no DRMs were detected in the HIV DNA by Sanger sequencing. However, by UDS, 2/6 participants with VF in the 4/7 days group harboured a DRM, one T215S involved in resistance to tenofovir/tenofovir alafenamide and one Y188L associated with resistance to rilpivirine.

Rationale: The paper discusses sequences obtained from individuals who experienced virological failure (VF) while on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ANRS 170 QUATUOR was an open-label, randomized, multicentre, non-inferiority Phase III trial evaluating the efficacy and safety of a maintenance 4D/week therapy (4/7 days) versus daily intake (7/7 days) in those who are virally suppressed for 48 weeks.

Rationale: The evidence clearly states that the study was a clinical trial, indicating that the patients were part of a clinical research study.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: Among these patients, 55.8% were previously receiving an NNRTI-based regimen, 23.1% a PI-based regimen and 21.2% an INSTI-based regimen. PBMCs of virologically suppressed patients enrolled in the ANRS 167 LAMIDOL trial, evaluating a switch from triple therapy to dolutegravir + lamivudine, were collected 8 weeks before (W-8) and 48 weeks after (W48) dual-therapy initiation.

Rationale: The evidence indicates that a significant proportion of the patients had previously received antiretroviral (ARV) drugs, they were switched to dolutegravir + lamivudine. Their PBMC samples were sequenced.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: Among these patients, 55.8% were previously receiving an NNRTI-based regimen, 23.1% a PI-based regimen and 21.2% an INSTI-based regimen. PBMCs of virologically suppressed patients enrolled in the ANRS 167 LAMIDOL trial, evaluating a switch from triple therapy to dolutegravir + lamivudine, were collected 8 weeks before (W-8) and 48 weeks after (W48) dual-therapy initiation.

Rationale: The evidence specifies the drug classes that the patients were receiving NRTI, NNRTI, PI, INSTI prior to sample sequencing, indicating the types of ARV drugs used.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: Among these patients, 55.8% were previously receiving an NNRTI-based regimen, 23.1% a PI-based regimen and 21.2% an INSTI-based regimen. PBMCs of virologically suppressed patients enrolled in the ANRS 167 LAMIDOL trial, evaluating a switch from triple therapy to dolutegravir + lamivudine, were collected 8 weeks before (W-8) and 48 weeks after (W48) dual-therapy initiation.

Rationale: The evidence indicates that a significant proportion of the patients had previously received antiretroviral (ARV) drugs, they were switched to dolutegravir + lamivudine. So clearly they had received DTG and 3TC

Answer: DTG, 3TC
""""""",111
37112971,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: We analyzed 1071 HIV-1 pol-gene fragment sequences (2253–3369 bp) from patients who were initiating or reinitiating first-line ART in six EECA counties, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), between 2017 and 2019.

Rationale: The paper explicitly states that HIV-1 pol-gene fragment sequences were analyzed from patients, indicating that sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper focuses on the prevalence of HIV-1 drug resistance and the genetic analysis of HIV-1 sequences from patient samples. It does not mention any in vitro drug susceptibility testing.

Rationale: The paper does not provide any in vitro drug susceptibility data, focusing instead on the prevalence of drug resistance and genetic analysis.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The HIV-1 sequences generated from this study are available in the NCBI database with the GenBank accession numbers MH062016- MH062024, MH062026- MH062029, MH062125- MH062138, MK931539- MK931547, MK931784, MK931789- MK931801, MK931912- MK931931, MK931933, MK931934, MK931937, MK931939, MK931940, MK931942, MK931943, MK931945, MK931947- MK931964, MK931996, MK931997, MK931999- MK932016, and MW483846- MW484805.

Rationale: GenBank accession numbers listed in paper

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The HIV-1 sequences generated from this study are available in the NCBI database with the GenBank accession numbers MH062016- MH062024, MH062026- MH062029, MH062125- MH062138, MK931539- MK931547, MK931784, MK931789- MK931801, MK931912- MK931931, MK931933, MK931934, MK931937, MK931939, MK931940, MK931942, MK931943, MK931945, MK931947- MK931964, MK931996, MK931997, MK931999- MK932016, and MW483846- MW484805.

Rationale: GenBank accession numbers listed in paper

Answer: MH062016- MH062024, MH062026- MH062029, MH062125- MH062138, MK931539- MK931547, MK931784, MK931789- MK931801, MK931912- MK931931, MK931933, MK931934, MK931937, MK931939, MK931940, MK931942, MK931943, MK931945, MK931947- MK931964, MK931996, MK931997, MK931999- MK932016, and MW483846- MW484805.
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: We analyzed 1071 HIV-1 pol-gene fragment sequences (2253–3369 bp) from patients who were initiating or reinitiating first-line ART in six EECA counties, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), between 2017 and 2019.

Rationale: The paper states that 1071 HIV-1 pol-gene fragment sequences were analyzed from patients. Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178)

Answer: 1071
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: We analyzed 1071 HIV-1 pol-gene fragment sequences (2253–3369 bp) from patients who were initiating or reinitiating first-line ART in six EECA counties, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), between 2017 and 2019.

Rationale: The paper explicitly lists the countries from which the sequenced samples were obtained.

Answer: Armenia, Azerbaijan, Belarus, Russia, Tajikistan, Uzbekistan
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: We analyzed 1071 HIV-1 pol-gene fragment sequences (2253–3369 bp) from patients who were initiating or reinitiating first-line ART in six EECA counties, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), between 2017 and 2019.

Rationale: Paper mentioned the patients are ""between 2017 and 2019""

Answer: 2017-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: An AmpliSens1 HIV-Resist-Seq kit (Central Research Institute of Epidemiology, Russia) was used for RNA extraction from blood plasma samples, and for amplification and sequencing of the HIV pol-gene region encoding a protease and part of a reverse transcriptase

Rationale: The paper does not mention sample cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: An AmpliSens1 HIV-Resist-Seq kit (Central Research Institute of Epidemiology, Russia) was used for RNA extraction from blood plasma samples, and for amplification and sequencing of the HIV pol-gene region encoding a protease and part of a reverse transcriptase

Rationale: Paper mentioned ""pol-gene region encoding a protease and part of a reverse transcriptase""

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: An AmpliSens1 HIV-Resist-Seq kit (Central Research Institute of Epidemiology, Russia) was used for RNA extraction from blood plasma samples, and for amplification and sequencing of the HIV pol-gene region encoding a protease and part of a reverse transcriptase

Rationale: The paper mentions the use of an AmpliSens1 HIV-Resist-Seq kit for RNA extraction and sequencing, which does not fall under the common categories of Sanger or next-generation sequencing methods.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: An AmpliSens1 HIV-Resist-Seq kit (Central Research Institute of Epidemiology, Russia) was used for RNA extraction from blood plasma samples, and for amplification and sequencing of the HIV pol-gene region encoding a protease and part of a reverse transcriptase

Rationale: The paper mentions that RNA was extracted from blood plasma samples for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: To be included, patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.

Rationale: The paper mentions that  the study included patients who were initiating or reinitiating first-line ART, which doesn't mean that patients have experienced virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: Enrollment took place at AIDS clinics in six countries, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), as part of the cross-sectional, retrospective, surveillance study REZEDA-1 in EECA between January 2017 and February 2019.

Rationale: The paper describes  the study as a cross-sectional, retrospective, surveillance study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: To be included, patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.

Rationale: The paper includes patients who initiating or reinitiating first-line ART, which means some of the sequences were from individuals who had previously received ARV drugs

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: To be included, patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.

Rationale: The paper mentioned that patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.  The study didn't mention the specific drugs.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: To be included, patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.

Rationale: The paper mentioned that patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.  The study didn't mention the drugs.

Answer: Not reported
""""""",149
37147875,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""SBS of HIV-1 reverse transcriptase (RT), protease and integrase was performed before treatment initiation and revealed an S230R INSTI mutation.""

Rationale: The paper mentions that SBS of HIV-1 reverse transcriptase (RT), protease and integrase was performed before treatment initiation, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""Pham et al., using an infectious molecular clone with the insertion of S230R by site-directed mutagenesis, showed that this mutation conferred a 63% reduction in integrase enzyme efficiency and a fold change in mean IC ~50~ of 3.85, 3.72, 1.52 and 1.21 for dolutegravir, cabotegravir, raltegravir (RAL) and elvitegravir (EVG), respectively, compared with virus lacking S230R.""

Rationale: The paper includes data on the effects of specific mutations on drug susceptibility, as shown by the use of infectious molecular clones to study the impact of the S230R mutation on integrase enzyme efficiency.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether the sequences obtained were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A 22-year-old man presented in April 2022 to our infectious disease department as seropositive for HIV after a rapid test in a sexually transmitted infection clinic.""

Rationale: The paper describes a single case study of a 22-year-old man whose samples were obtained for sequencing.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not specify the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""A 22-year-old man presented in April 2022 to our infectious disease department as seropositive for HIV after a rapid test in a sexually transmitted infection clinic.""

Rationale: The paper mentions that the patient presented in April 2022, indicating that the samples were obtained in that year.

Answer: 2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""SBS of HIV-1 reverse transcriptase (RT), protease and integrase was performed before treatment initiation and revealed an S230R INSTI mutation.""

Rationale: The paper mentions that SBS of HIV-1 reverse transcriptase (RT), protease and integrase was performed.

Answer: RT, PR, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""SBS of HIV-1 reverse transcriptase (RT), protease and integrase was performed before treatment initiation and revealed an S230R INSTI mutation.""

Rationale: The paper mentions that Sanger-based sequencing (SBS) was used to detect all HIV-1 resistance mutations.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""SBS of HIV-1 reverse transcriptase (RT), protease and integrase was performed before treatment initiation and revealed an S230R INSTI mutation.""

Rationale: The paper mentions that SBS of HIV-1 reverse transcriptase (RT), protease and integrase was performed before treatment initiation, indicating that the samples were obtained from plasma.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patient was part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention any previous ARV treatment.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any previous ARV treatment.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any previous ARV treatment.

Answer: Not reported
""""""",70
37272233,"Here are the answers to the questions in the format you requested:


""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""A total of 336 patients were screened, and 248 were included in the analysis.""

Rationale: The paper mentions that 248 patients were included in the analysis, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""


""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""Results of HIV drug resistance mutation sequencing by PCR (AB 3500xL Dx genetic analyzer, Applied biosystem, Waltham, MA, USA) for each ARV class (nucleoside reverse transcriptase inhibitor [NRTI], non-nucleoside reverse transcriptase inhibitor [NNRTI], protease inhibitor [PI], and integrase strand transfer inhibitor [INSTI]) were reviewed, and data on gene mutation and actual resistance to each medication were collected and analyzed based on the HIV drug resistance database of Stanford University, Stanford, CA, USA [ 13 ].""

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""


""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the public availability of the sequences.

Answer: No
""""""


""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not available
""""""


""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 336 patients were screened, and 248 were included in the analysis.""

Rationale: The paper states that 248 patients were included in the analysis, indicating that samples were obtained from these individuals for HIV sequencing.

Answer: 248
""""""


""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the country of origin for the sequenced samples.

Answer: Not available
""""""


""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""All adults aged ≥19 years who were newly diagnosed with HIV infection between January 2010 and December 2020 at a 750-bed municipal hospital with two infectious disease specialists were included.""

Rationale: The paper specifies that the samples were collected from patients diagnosed between January 2010 and December 2020.

Answer: 2010-2020
""""""


""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing.

Answer: No
""""""


""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Results of HIV drug resistance mutation sequencing by PCR (AB 3500xL Dx genetic analyzer, Applied biosystem, Waltham, MA, USA) for each ARV class (nucleoside reverse transcriptase inhibitor [NRTI], non-nucleoside reverse transcriptase inhibitor [NNRTI], protease inhibitor [PI], and integrase strand transfer inhibitor [INSTI]) were reviewed, and data on gene mutation and actual resistance to each medication were collected and analyzed based on the HIV drug resistance database of Stanford University, Stanford, CA, USA [ 13 ].""

Rationale: The paper mentions that sequencing was performed for each ARV class, including NRTI, NNRTI, PI, and INSTI, indicating that these genes were reported to have been sequenced.

Answer: NRTI, NNRTI, PI, INSTI
""""""


""""""
Question: What method was used for sequencing?

Evidence: ""Results of HIV drug resistance mutation sequencing by PCR (AB 3500xL Dx genetic analyzer, Applied biosystem, Waltham, MA, USA) for each ARV class (nucleoside reverse transcriptase inhibitor [NRTI], non-nucleoside reverse transcriptase inhibitor [NNRTI], protease inhibitor [PI], and integrase strand transfer inhibitor [INSTI]) were reviewed, and data on gene mutation and actual resistance to each medication were collected and analyzed based on the HIV drug resistance database of Stanford University, Stanford, CA, USA [ 13 ].""

Rationale: The paper mentions that PCR sequencing was used for sequencing the HIV genes.

Answer: PCR sequencing
""""""


""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the type of samples sequenced.

Answer: Not available
""""""


""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""A total of 336 patients were screened, and 248 were included in the analysis.""

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""


""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the patients being part of a clinical trial.

Answer: No
""""""


""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""A total of 336 patients were screened, and 248 were included in the analysis.""

Rationale: The paper does not mention any HIV sequences from individuals who had previously received ARV drugs.

Answer: No
""""""


""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the drug classes received by individuals in the study before sample sequencing.

Answer: Not available
""""""


""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the specific drugs received by individuals in the study before sample sequencing.

Answer: Not available
""""""",84
37279764,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: A total of 12 320 participants with demographic data and partial pol sequences (GenBank accession no. MW947591–MW957968, OP058117–OP058658) were included in this study.

Rationale: The evidence clearly states that the study included HIV sequences from patient samples, specifically mentioning the number of participants and the GenBank accession numbers for the sequences.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data is provided in the paper.

Rationale: The paper focuses on the analysis of HIV-1 sequences and the prevalence of transmitted drug resistance mutations, but does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The GenBank accession numbers for the sequences reported in the study are provided (MW947591–MW957968, OP058117–OP058658).

Rationale: The paper explicitly states the GenBank accession numbers for the sequences, indicating that these sequences are publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The GenBank accession numbers for the sequences reported in the study are MW947591–MW957968 and OP058117–OP058658.

Rationale: The paper provides the specific GenBank accession numbers for the sequenced HIV isolates.

Answer: MW947591–MW957968, OP058117–OP058658
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 12 320 participants with demographic data and partial pol sequences were included in this study.

Rationale: The evidence clearly states the number of individuals from whom samples were obtained for sequencing.

Answer: 12,320
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Shenzhen, China.

Rationale: The paper specifically mentions the location where the study was conducted, indicating that the samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study included samples from newly diagnosed patients enrolled at Shenzhen from January 2011 to December 2019.

Rationale: The paper provides the specific years during which the samples were collected.

Answer: 2011-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence of cloning is provided in the paper.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The study analyzed the partial HIV-1 pol gene obtained from the newly reported HIV-1 positive cases.

Rationale: The paper specifically mentions the gene that was sequenced.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not explicitly state the sequencing method used.

Rationale: Although the paper does not explicitly state the sequencing method, it can be inferred that Sanger sequencing or NGS was used based on the context.

Answer: Sanger sequencing or NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The study analyzed blood samples from newly diagnosed patients.

Rationale: The paper mentions that blood samples were collected from patients and used for sequencing.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: All individuals were treatment naive at enrolment.

Rationale: The paper specifically mentions that all individuals were treatment naive, indicating that there were no sequences from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence of a clinical trial is provided in the paper.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: All individuals were treatment naive at enrolment.

Rationale: The paper specifically mentions that all individuals were treatment naive, indicating that there were no sequences from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence of drug classes received by individuals is provided in the paper.

Rationale: The paper does not mention any drug classes received by individuals in the study before sample sequencing.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence of drugs received by individuals is provided in the paper.

Rationale: The paper does not mention any drugs received by individuals in the study before sample sequencing.

Answer: nan
""""""",69
37327289,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""The *pol* gene was amplified and genotyped using sanger sequencing.""

Rationale: The paper mentions that the *pol* gene was amplified and genotyped using sanger sequencing, which indicates that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""The *pol* sequences have been archived in the DDBJ Nucleotide Database [LC723952-LC724015].""

Rationale: The paper explicitly states that the sequences have been archived in the DDBJ Nucleotide Database, indicating that they have been made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""The *pol* sequences have been archived in the DDBJ Nucleotide Database [LC723952-LC724015].""

Rationale: The paper provides the accession numbers for the sequenced HIV isolates, which are archived in the DDBJ Nucleotide Database.

Answer: LC723952-LC724015
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""This was a cross-sectional study that utilized 157 plasma samples obtained from HIV-1 seropositive and treatment-naïve FSWs between November 2020 and April 2021.""

Rationale: The paper mentions that 157 plasma samples were obtained from HIV-1 seropositive and treatment-naïve FSWs.

Answer: 157
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""The participants were recruited from 7 sex worker outreach program (SWOP) clinics in Nairobi County, specifically Nairobi City, Donholm, Kawangware, Korogocho, Langata, Majengo, and Thika Road.""

Rationale: The paper mentions that the participants were recruited from Nairobi County in Kenya.

Answer: Kenya
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""This was a cross-sectional study that utilized 157 plasma samples obtained from HIV-1 seropositive and treatment-naïve FSWs between November 2020 and April 2021.""

Rationale: The paper mentions that the samples were obtained between November 2020 and April 2021.

Answer: 2020-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The *pol* gene was amplified and genotyped using sanger sequencing.""

Rationale: The paper mentions that the *pol* gene was amplified and genotyped using sanger sequencing.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""The *pol* gene was amplified and genotyped using sanger sequencing.""

Rationale: The paper mentions that sanger sequencing was used for genotyping the *pol* gene.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""This was a cross-sectional study that utilized 157 plasma samples obtained from HIV-1 seropositive and treatment-naïve FSWs between November 2020 and April 2021.""

Rationale: The paper mentions that plasma samples were obtained from HIV-1 seropositive and treatment-naïve FSWs.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""No evidence""

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""This was a cross-sectional study that utilized 157 plasma samples obtained from HIV-1 seropositive and treatment-naïve FSWs between November 2020 and April 2021.""

Rationale: The paper describes a cross-sectional study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""No evidence""

Rationale: The paper does not mention any sequences obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any drug classes received by individuals in the study before sample sequencing.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any drugs received by individuals in the study before sample sequencing.

Answer: nan
""""""",75
37340869,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Pooled data from 1651 participants were used to explore dosing regimen (every 4 or every 8 weeks), demographic, viral, and pharmacokinetic covariates as potential predictors of CVF.""

Rationale: The paper discusses the use of pooled data from participants, which includes viral covariates, indicating that HIV sequences from patient samples were analyzed.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The presence of RPV RAMs, HIV-1 subtype A6/A1, and baseline BMI were significant in both the single-regimen and all-regimens models.""

Rationale: The paper discusses the presence of resistance-associated mutations (RAMs) and their impact on drug susceptibility, but it does not provide in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Across 3 studies, 1651 unique participants were included, 23/1651 (1.4%) of whom had CVF.""

Rationale: The paper mentions that 1651 unique participants were included in the study.

Answer: 1651
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Overall, 11 participants with CVF were from Russia, all of whom had HIV-1 subtype A6/A1 (Supplementary Table 7 A).""

Rationale: The paper mentions that 11 participants with CVF were from Russia.

Answer: Russia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The presence of RPV RAMs, HIV-1 subtype A6/A1, and baseline BMI were significant in both the single-regimen and all-regimens models.""

Rationale: The paper discusses the presence of resistance-associated mutations (RAMs) in the context of HIV-1 subtype classification, but it does not specify which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Pooled data from 1651 participants were used to explore dosing regimen (every 4 or every 8 weeks), demographic, viral, and pharmacokinetic covariates as potential predictors of CVF.""

Rationale: The paper discusses the use of pooled data from participants, which includes viral covariates, indicating that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Across 3 studies, 1651 unique participants were included, 23/1651 (1.4%) of whom had CVF.""

Rationale: The paper discusses the occurrence of confirmed virologic failure (CVF) in participants, indicating that sequences were obtained from individuals experiencing virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""FLAIR, ATLAS, and ATLAS-2M are randomized, multicenter, parallel-group, open-label, phase 3/3b studies.""

Rationale: The paper mentions that the study is a randomized, multicenter, parallel-group, open-label, phase 3/3b study, indicating that the patients were part of a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""All 8 participants were nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI) experienced, and 3 had prior nonnucleoside reverse transcriptase inhibitor (NNRTI) exposure.""

Rationale: The paper mentions that participants had prior exposure to NRTIs, PIs, and NNRTIs, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""All 8 participants were nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI) experienced, and 3 had prior nonnucleoside reverse transcriptase inhibitor (NNRTI) exposure.""

Rationale: The paper mentions that participants had prior exposure to NRTIs, PIs, and NNRTIs.

Answer: NRTI, PI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""All 8 participants were nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI) experienced, and 3 had prior nonnucleoside reverse transcriptase inhibitor (NNRTI) exposure. ABC, abacavir; ATV, atazanavir; DDI, didanosine; DRV, darunavir; DT, dispersible tablet; D4T, stavudine; EFV, efavirenz; FTC, emtricitabine; LPV, lopinavir; NFV, nelfinavir; NVP, nevirapine; RTV, ritonavir; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.""

Rationale: The paper lists the specific drugs that participants had been exposed to prior to the study.

Answer: Abacavir (ABC), atazanavir (ATV) Didanosine (DDI), darunavir (DRV), Stavudine (D4T), Efavirenz (EFV), Emtricitabine (FTC), Lopinavir (LPV), Nelfinavir (NFV), nevirapine (NVP) Lamivudine (3TC), Tenofovir (TFV), Zidovudine (ZDV)
""""""",95
37358226,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples. It focuses on clinical data and outcomes rather than detailed sequencing data.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any in vitro drug susceptibility testing. It focuses on clinical outcomes and resistance mutations from patient samples.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Among 14 242 eligible participants.

Rationale: The paper mentions that 14 242 eligible participants had samples obtained for HIV sequencing.

Answer: 14,242
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: Lesotho.

Rationale: The paper mentions that the study was conducted in Lesotho.

Answer: Lesotho
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Before 30 October 2021.

Rationale: The paper mentions that the study includes all VICONEL participants who transitioned from ART containing an NNRTI to ART containing DTG before 30 October 2021.

Answer: Before 2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: Yes, among 295 participants with a pretransition VL >999 copies/mL.

Rationale: The paper mentions that among 295 participants with a pretransition VL >999 copies/mL, 248 (84.1%) were suppressed to <50 copies/mL at 12 months and 244 (82.7%) at 24 months.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No.

Rationale: The paper mentions that this study is not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: Yes, among 14 242 eligible participants.

Rationale: The paper mentions that the study includes all VICONEL participants who transitioned from ART containing an NNRTI to ART containing DTG.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: NNRTI, NRTI, INSTI.

Rationale: The paper mentions that the study includes all VICONEL participants who transitioned from ART containing an NNRTI to ART containing DTG, and that the NRTI backbone was changed at transition for 2539 participants.

Answer: NNRTI, NRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: Efavirenz, Nevirapine, Abacavir, Zidovudine, Tenofovir disoproxil fumarate, Lamivudine, Dolutegravir.

Rationale: The paper mentions that the study includes all VICONEL participants who transitioned from ART containing an NNRTI (efavirenz or nevirapine) alongside 2 nucleoside reverse transcriptase inhibitors (NRTIs) (abacavir, zidovudine, or TDF together with 3TC) to ART containing DTG plus 2 NRTIs.

Answer: Efavirenz, Nevirapine, Abacavir, Zidovudine, Tenofovir disoproxil fumarate, Lamivudine, Dolutegravir
""""""",65
37376649,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention the sequencing of HIV from patient samples, but it discusses the analysis of resistance mutations and virological data.

Rationale: The paper focuses on the analysis of resistance mutations and virological data, but it does not explicitly mention the sequencing of HIV from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the clinical outcomes and resistance mutations in patients but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide specific information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific information about the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide specific information about the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the exact sequencing method used for the sequences.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide specific information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide specific information about whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The study was conducted in accordance with the Declaration of Helsinki and national and institutional standards.

Rationale: The paper mentions that the study was conducted in accordance with the Declaration of Helsinki and national and institutional standards, indicating that it was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses participants who were on long-acting cabotegravir and rilpivirine therapy, indicating they had previously received antiretroviral drugs.

Rationale: The paper discusses participants who were on long-acting cabotegravir and rilpivirine therapy, indicating they had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants had prior exposure to NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper mentions that participants had prior exposure to NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing: DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Answer: DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.
""""""",69
37381002,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Pol gene of HIV-1 viruses in blood samples of EDTA anticoagulants from 398 patients with failed antiviral treatment was successfully amplified by using an in-house assay.""

Rationale: The evidence clearly states that the paper reports HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on the genotyping of HIV-1 and the identification of drug resistance mutations but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information regarding the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information regarding the GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""Pol gene of HIV-1 viruses in blood samples of EDTA anticoagulants from 398 patients with failed antiviral treatment was successfully amplified by using an in-house assay.""

Rationale: The evidence clearly states that 398 individuals had samples obtained for HIV sequencing.

Answer: 398
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Suzhou City, China.

Rationale: The paper specifies that the samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2017 to 2020.

Rationale: The paper specifies that the samples were obtained from 2017 to 2020.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the partial *pol* gene fragment of HIV-1 virus was amplified.

Rationale: The evidence indicates that the *pol* gene was sequenced.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing method was used.

Rationale: The paper specifies that Sanger sequencing was the method used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that viral RNA was extracted from 200 µl plasma sample.

Rationale: The evidence clearly states that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study was conducted on patients with failed antiviral treatment.

Rationale: The paper specifies that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information regarding the patients being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study was conducted on patients with failed antiviral treatment.

Rationale: The paper specifies that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information regarding the specific drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information regarding the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",64
37439411,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""We retrieved HIV-1 RNA protease/reverse transcriptase sequences, demographic and clinical data of adult PLWH from the Antiviral Response Cohort Analysis (ARCA) database...""

Rationale: The paper explicitly mentions that HIV-1 RNA protease/reverse transcriptase sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database, which contains data from adult people living with HIV (PLWH).

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""In vitro susceptibility was assessed through a phenotypic assay measuring fold-change values with respect to the reference NL4-3 virus.""

Rationale: The paper does not report in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""We included 5982 naïves: 73.9% were males, median age was 39 years [interquartile range (IQR): 32--47] and 67.9% were Caucasian.""

Rationale: The paper states that 5982 naïve individuals were included in the study.

Answer: 5982
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""We retrieved HIV-1 RNA protease/reverse transcriptase sequences, demographic and clinical data of adult PLWH from the Antiviral Response Cohort Analysis (ARCA) database, a public observational database containing data from more than 100 Italian centres...""

Rationale: The paper mentions that the data were retrieved from the Antiviral Response Cohort Analysis (ARCA) database, which contains data from Italian centers.

Answer: Italy
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Transmitted drug resistance was found in 12.5% and declined from 17.3% in 2000--2003 to 10.9% in 2016--2020 (p = 0.003)""

Rationale: The paper states that the samples were obtained from 2000 to 2020.

Answer: 2000-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""We retrieved HIV-1 RNA protease/reverse transcriptase sequences...""

Rationale: The paper mentions that HIV-1 RNA protease/reverse transcriptase sequences were retrieved.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""We retrieved HIV-1 RNA protease/reverse transcriptase sequences...""

Rationale: The paper mentions that HIV-1 RNA protease/reverse transcriptase sequences were retrieved, indicating that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""At least one RAM for NNRTIs was detected in 33.2% and any PDR declined from 43.4% in 2000--2003 to 20.9% in 2016--2020 (p < 0.001)""

Rationale: The paper mentions that sequences were obtained from treatment-experienced individuals, including those with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not provide any information indicating that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""At least one RAM for NNRTIs was detected in 33.2% and any PDR declined from 43.4% in 2000--2003 to 20.9% in 2016--2020 (p < 0.001)""

Rationale: The paper mentions that sequences were obtained from treatment-experienced individuals, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information on the specific drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information on the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",73
37495103,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""HIV-1 RNA was isolated from 250 µL of plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) according to the kit's manual. Reverse transcription and PCR were performed using RealBest Master Mix RT (Vector-Best, Russia) and BioMaster HS-Taq PCR-Color (BioLabMix, Russia), respectively, to amplify the HIV-1 PR-RT fragment (1302 bp). DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser (Applied Biosystems, USA).""

Rationale: The paper describes the collection of plasma samples from patients and the extraction of viral RNA, which indicates that HIV sequences were obtained from these patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""The study cohort included 271 patients who were on first-line ART and visited Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.""

Rationale: The paper mentions that the study cohort included 271 patients.

Answer: 271
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""The study cohort included 271 patients who were on first-line ART and visited Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.""

Rationale: The paper does not explicitly mention the country of origin for the sequenced samples, but based on the hospital name, it can be inferred that the samples were obtained from Russia.

Answer: Russia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""The study cohort included 271 patients who were on first-line ART and visited Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.""

Rationale: The paper mentions that the samples were collected between March 2018 and August 2022.

Answer: 2018-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser (Applied Biosystems, USA).""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Reverse transcription and PCR were performed using RealBest Master Mix RT (Vector-Best, Russia) and BioMaster HS-Taq PCR-Color (BioLabMix, Russia), respectively, to amplify the HIV-1 PR-RT fragment (1302 bp).""

Rationale: The paper mentions that the HIV-1 PR-RT fragment was amplified, which includes the protease (PR) and reverse transcriptase (RT) genes.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser (Applied Biosystems, USA).""

Rationale: The paper mentions that Sanger sequencing was performed using an ABI PRISM 3130xl DNA Analyser.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""HIV-1 RNA was isolated from 250 µL of plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) according to the kit's manual.""

Rationale: The paper describes the collection of plasma samples from patients.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""All patients had undetectable viral load (VL) levels for 3--6 months while taking ART with further virological failure.""

Rationale: The paper mentions that all patients had virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""All patients received first-line ART prior to virological failure.""

Rationale: The paper mentions that all patients received first-line ART prior to virological failure, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Most of the patients with high-level adherence were identified among those who were on TDF+3TC+DTG.""

Rationale: The paper mentions that some patients received TDF+3TC+DTG, which includes NRTIs and INSTIs.

Answer: NRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Most of the patients with high-level adherence were identified among those who were on TDF+3TC+DTG.""

Rationale: The paper mentions that some patients received TDF+3TC+DTG.

Answer: TDF, 3TC, DTG
""""""",73
37498738,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 proviral sequences from patient samples, including the use of near full-length proviral sequencing and next-generation sequencing.

Rationale: The paper explicitly states that HIV-1 sequences were obtained from patient samples, including PBMCs, and were analyzed using various sequencing methods.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 proviral sequences and the presence of mutations, but does not report any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention whether the sequences were made publicly available.

Rationale: The paper does not provide any information regarding the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any specific GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 101 individuals participated in the study, but only 43 had successful consensus sequences for all three time points.

Rationale: The paper specifies that 43 individuals had samples obtained for HIV sequencing, but the total number of participants was 101.

Answer: 43
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention any specific countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information regarding the countries of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years during which the samples were obtained.

Rationale: The paper mentions a longitudinal study over 48 weeks but does not specify the exact years.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the use of near full-length proviral sequencing and next-generation sequencing, but does not mention any cloning steps.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that near full-length HIV-1 proviral sequences were obtained, which includes the gag, pol, and env genes.

Rationale: The paper specifies that near full-length HIV-1 proviral sequences were obtained, which includes the gag, pol, and env genes.

Answer: Near full length genome
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of near full-length proviral sequencing and next-generation sequencing.

Rationale: The paper specifies that near full-length proviral sequencing and next-generation sequencing were used to obtain the HIV-1 sequences.

Answer: NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that PBMCs were used for sequencing.

Rationale: The paper specifies that PBMCs were used for sequencing.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that no virological failure was observed in the study participants.

Rationale: The paper specifies that no virological failure was observed in the study participants.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a randomized clinical trial (RCT).

Rationale: The paper specifies that the study was a randomized clinical trial (RCT), indicating that the patients were part of a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study participants had previously received antiretroviral therapy (ART).

Rationale: The paper specifies that the study participants had previously received ART, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study participants had previously received ART, which includes various drug classes.

Rationale: The paper specifies that the study participants had previously received ART, which includes various drug classes, but does not provide specific details.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study participants had previously received dolutegravir (DTG) and other antiretroviral drugs.

Rationale: The paper specifies that the study participants had previously received DTG and other antiretroviral drugs, but does not provide a comprehensive list of all drugs received.

Answer: DTG
""""""",68
37515095,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper analyzed 968 partial HIV-1 pol gene sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The evidence clearly states that the study involved analyzing HIV-1 sequences obtained from patient samples, indicating that the paper does report HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The evidence indicates that the study focused on the analysis of HIV-1 sequences and drug resistance mutations, but it does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The evidence does not provide any information about the public availability of the sequences, indicating that they were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The evidence does not provide any GenBank accession numbers, indicating that the sequences were not deposited in a public database.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper analyzed 968 partial HIV-1 pol gene sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The evidence clearly states that 968 samples were obtained for HIV sequencing, providing the exact number of individuals involved.

Answer: 968
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper analyzed 968 partial HIV-1 pol gene sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The evidence specifies that the samples were obtained from Kazakhstan, indicating the country of origin for the sequenced samples.

Answer: Kazakhstan
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper analyzed 968 partial HIV-1 pol gene sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The evidence provides a clear range of years during which the samples were collected, specifically mentioning 2017 to 2020.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The evidence does not provide any information about cloning, indicating that samples were not cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper analyzed 968 partial HIV-1 pol gene sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The evidence indicates that the pol gene was sequenced, confirming the specific gene analyzed.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the sequences were generated using AmpliSens HIV-Resist-Seq and Applied Biosystems Genetic Analyzer 3130.

Rationale: The evidence does not explicitly state the sequencing method, but it mentions the use of AmpliSens HIV-Resist-Seq and Applied Biosystems Genetic Analyzer 3130, which are associated with Sanger sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that the mRNA from blood samples was purified using the Ribo-zol-C Kit.

Rationale: The evidence indicates that blood samples were collected for sequencing, which is a common clinical specimen type for such studies.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that 311 sequences exhibited high-level drug resistance, indicating that some patients had experienced virological failure.

Rationale: The evidence indicates that some patients had high-level drug resistance, which suggests that they had experienced virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The evidence does not provide any information about a clinical trial, indicating that the patients were not part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some patients had previously received ARV drugs.

Rationale: The evidence indicates that some patients had previously received ARV drugs, confirming that the paper reports HIV sequences from such individuals.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some patients had previously received ARV drugs, including NRTIs and NNRTIs.

Rationale: The evidence indicates that patients had received drugs from the NRTI and NNRTI classes, confirming the drug classes involved.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Rationale: The evidence does not provide any information about the specific drugs received, indicating that this information is not reported.

Answer: Not reported
""""""",74
37515146,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the collection of plasma samples from HIV-positive patients and the extraction of viral RNA, which indicates that HIV sequences were obtained from these patient samples.

Rationale: The paper explicitly states that sequencing of HIV-1 protease and reverse transcriptase was performed, and HIVDR was interpreted using Stanford HIVdb.v.9.4.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper discusses the identification of drug resistance mutations and their correlation with treatment regimens, but it does not provide specific in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: Sequence data are available on GenBank under the accession numbers GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.

Rationale: The paper explicitly states that the sequences were submitted to GenBank, indicating that they were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: Sequence data are available on GenBank under the accession numbers GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates, confirming their availability.

Answer: MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 391 participants were recruited, with sequencing successfully carried out in 379 individual participant samples.

Rationale: The paper provides the total number of individuals from whom samples were obtained for sequencing.

Answer: 379
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Cameroon.

Rationale: The paper indicates that the samples were obtained from patients in Cameroon.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study was conducted from December 2014 to June 2019.

Rationale: The paper provides the specific time frame for when the samples were collected.

Answer: 2014-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: Sequencing of HIV-1 protease and reverse transcriptase was performed.

Rationale: The paper explicitly states that the protease and reverse transcriptase genes were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The products of the sequencing reaction obtained were purified by exclusion chromatography on SEPHADEX G50 resin and then sequenced using a genetic analyzer (ABI 3500 ^®^ ).

Rationale: The paper mentions using ABI 3500 genetic analyzer which related to Sanger sequencing method.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma samples were collected, and viral RNA was extracted.

Rationale: The paper describes the collection of plasma samples from patients, which were then used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The study included patients who were ART-naive or had interrupted ART before restarting first-line ART without reported virological failure.

Rationale: The paper indicates that the study included individuals who were naïve or had interrupted ART but did not report any cases of virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The study was a cross-sectional and analytical study.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The study included patients who were ART-naive or had interrupted ART before restarting first-line ART without reported virological failure.

Rationale: The paper indicates that the study included individuals who had interrupted ART, which indicates these people had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drug classes received by individuals in the study before sample sequencing.

Rationale: The paper indicates that the study included individuals who had interrupted ART, but it does not provide information on the specific drug classes received.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper indicates that the study included individuals who had interrupted ART, but it does not provide information on the specific drugs received.

Answer: Not reported
""""""",70
37520425,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention any HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention any publicly available sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not report any individuals from whom samples were obtained for HIV sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any sequenced samples or their countries of origin.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the years of sequenced samples.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not discuss any cloning of samples, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not report any sequencing of HIV genes.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequencing methods, as it does not report on any sequencing of HIV samples.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of samples, as it does not involve sequencing.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper discusses virological non-suppression but does not mention obtaining sequences from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""",49
37537871,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: A total of 77 plasma samples, collected from 70 male and 7 female patients ages 18 to 68, were obtained from the Queen Mary Hospital in Hong Kong between 2002 and 2014.

Rationale: The paper mentions that plasma samples were collected from patients, which indicates that HIV sequences were obtained from these patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any information regarding whether the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 77 plasma samples, collected from 70 male and 7 female patients ages 18 to 68, were obtained from the Queen Mary Hospital in Hong Kong between 2002 and 2014.

Rationale: The paper states that 77 plasma samples were collected from patients, which indicates the number of individuals from whom samples were obtained for sequencing.

Answer: 77
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The samples were obtained from the Queen Mary Hospital in Hong Kong.

Rationale: The paper mentions that the samples were obtained from Hong Kong, which indicates the country from which the sequenced samples were obtained.

Answer: Hong Kong
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The samples were obtained from the Queen Mary Hospital in Hong Kong between 2002 and 2014.

Rationale: The paper states that the samples were obtained between 2002 and 2014, which indicates the years from which the sequenced samples were obtained.

Answer: 2002-2014
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The long genomic region (NC_001802.1: 1413--7363, amplicon length: 5951 base pairs) was targeted for amplification.

Rationale: The paper mentions that the long genomic region was targeted for amplification, which includes multiple genes across the genome.

Answer: Near full length genome
""""""

""""""
Question: What method was used for sequencing?

Evidence: The sequencing was performed with the Applied Biosystems 3730xl DNA Analyzer (Life Technologies, CA, USA) for Sanger sequencing, and the ONT GridION for nanopore sequencing.

Rationale: The paper describes the use of Sanger sequencing and nanopore sequencing methods.

Answer: Sanger sequencing, Nanopore sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma samples were used for sequencing.

Rationale: The paper describes the collection of plasma samples from patients, which were then used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: Four cases were found to have quasispecies with DRMs, in which 2 harbored quasispecies with more than one class of DRMs.

Rationale: The paper indicates that sequences were obtained from individuals with virological failure, as evidenced by the presence of DRMs.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: All patients were previously diagnosed with HIV-1 using the national testing algorithm, which included two rapid assays, and were all ART-experienced.

Rationale: The paper clearly states that all patients included in the study were ART-experienced, indicating that they had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The majority of patients (47.1%) were on first-line regimen AZT + 3TC + NVP or EFV, and only 17.6% of the patients received a DTG-containing regimen, an integrase strand transfer inhibitor (INSTI).

Rationale: The paper provides information on the treatment regimens of the patients, indicating that they received NRTIs (AZT, 3TC), NNRTIs (NVP, EFV), and INSTIs prior to sample sequencing.

Answer: NRTI, NNRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The majority of patients (47.1%) were on first-line regimen AZT + 3TC + NVP or EFV, and only 17.6% of the patients received a DTG-containing regimen, an integrase strand transfer inhibitor (INSTI).

Rationale: The paper lists specific drugs included in the treatment regimens of the patients, indicating that they were received prior to sample sequencing.

Answer: AZT, 3TC, NVP, EFV, DTG
""""""",77
37540331,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention whether sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention which HIV genes were reported to have been sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention sequences obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: This study was registered at the Iranian Registry of Clinical Trials (IRCT20191005044984N1, registered at 2019--12-21) and conducted as an open-label randomized non-inferiority trial.

Rationale: The paper mentions that the study was conducted as an open-label randomized non-inferiority trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",48
37541705,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples, but it does discuss the use of antiretroviral therapy (ART) and the monitoring of HIV-1 RNA levels in children with HIV.

Rationale: The paper focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination (FDC) of abacavir, dolutegravir, and lamivudine in children with HIV, but it does not explicitly mention the sequencing of HIV from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination (FDC) of abacavir, dolutegravir, and lamivudine in children with HIV, but it does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention the public availability of sequences.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that GenBank accession numbers were reported.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that the number of individuals who had samples obtained for HIV sequencing was reported.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which sequenced samples were obtained.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that the countries from which sequenced samples were obtained were reported.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which sequenced samples were obtained.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that the years from which sequenced samples were obtained were reported.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that cloning of samples prior to sequencing was reported.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention the sequencing of specific HIV genes.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that specific HIV genes were reported to have been sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that the sequencing method used was reported.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that the type of samples sequenced was reported.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a phase I/II, multi-site, open-label, non-comparative dose confirmation study.

Rationale: The paper explicitly mentions that the study was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that sequences were reported from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that drug classes received by individuals in the study before sample sequencing were reported.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention the sequencing of HIV from patient samples, so it is unlikely that drugs received by individuals in the study before sample sequencing were reported.

Answer: Not reported
""""""",78
37546367,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.

Rationale: The paper reports that HIV-1 sequences were obtained from patient samples. Specifically, it mentions that plasma samples were collected from patients and that a significant number of those samples were successfully sequenced, indicating that the paper does report HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The Stanford HIV dbprogram 9.4 (last updated on 7th Dec. 2022, https://hivdb.stanford.edu/hivdb/by-sequences/) was used to identify DRMs and infer resistance to antiretroviral drugs, including protease inhibitors (PI), nucleoside reverse-transcriptase inhibitors (NRTI) and non-nucleoside reverse-transcriptase inhibitors (NNRTI).

Rationale: The paper does not mention any in vitro drug susceptibility testing. It focuses on genotypic drug resistance analysis using sequences obtained from patient samples.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The partial *pol* nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates, indicating that these sequences are publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The partial *pol* nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.

Rationale: The paper provides a specific range of GenBank accession numbers associated with the sequenced HIV isolates, indicating that these numbers are available for reference.

Answer: OQ886077 - OQ888150
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 3274 patients were enrolled and 2074 HIV-1 partial *pol* sequences were obtained and subsequently used to establish the dataset.

Rationale: The paper states that 3274 patients were enrolled in the study and had their HIV-1 partial *pol* sequences obtained.

Answer: 3274
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.

Rationale: The paper specifies that the plasma samples were obtained from patients in Guangdong Province, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.

Rationale: The paper states that the plasma samples were obtained from patients between January 2011 and December 2022.

Answer: 2011-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing, indicating that this detail is not addressed.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The partial HIV-1 *pol* gene (HXB2 nt 2253--3252) was amplified by one-step RT-PCR and nested PCR as previously described.

Rationale: The paper reports the sequencing of the partial HIV-1 *pol* gene.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The patient-derived PR-RT PCR products were directly sequenced with Sanger sequencing method.

Rationale: The paper specifies that Sanger sequencing was the method used for sequencing the HIV-1 samples.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.

Rationale: The paper specifies that plasma samples were the clinical specimens collected and sequenced in the study.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: HIV-1 infected individuals were eligible for inclusion in this study if they have received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL.

Rationale: The paper mentions that the study included HIV-1 infected individuals who had received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL, indicating virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide any information indicating that the patients were part of a clinical trial, suggesting that this detail is not addressed.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: HIV-1 infected individuals were eligible for inclusion in this study if they have received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL.

Rationale: The paper mentions that the study included HIV-1 infected individuals who had received ART for at least 6 months, indicating that they had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The Stanford HIV dbprogram 9.4 (last updated on 7th Dec. 2022, https://hivdb.stanford.edu/hivdb/by-sequences/) was used to identify DRMs and infer resistance to antiretroviral drugs, including protease inhibitors (PI), nucleoside reverse-transcriptase inhibitors (NRTI) and non-nucleoside reverse-transcriptase inhibitors (NNRTI).

Rationale: The paper mentions that the study included HIV-1 infected individuals who had received ART for at least 6 months, but the specific drug classes received by individuals in the study before sample sequencing were not mentioned.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the specific drugs received by individuals in the study before sample sequencing, indicating that this detail is not addressed.

Answer: Not reported
""""""",92
37554471,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the use of long-acting cabotegravir/rilpivirine (CAB/RPV) in an AIDS patient and mentions the patient's HIV viral load and CD4 count, but does not explicitly report HIV sequences from patient samples.

Rationale: The paper focuses on the clinical case and the treatment outcomes, but does not provide detailed information about HIV sequencing.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not provide any information regarding in vitro drug susceptibility data.

Rationale: The paper focuses on the clinical case and the treatment outcomes, but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention whether the sequences were made publicly available.

Rationale: The paper does not provide any information about the availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any specific accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes a single patient case throughout the study.

Rationale: The focus of the paper is on one individual, indicating that only one person had samples obtained for sequencing.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information about the countries from which the sequenced samples were obtained.

Rationale: The paper does not mention any specific countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the sequenced samples were obtained.

Rationale: The paper does not mention any specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention whether samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning procedures.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not specify individual HIV genes sequenced.

Rationale: The paper discusses the patient's HIV viral load and CD4 count, but does not provide detailed information about HIV sequencing.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that plasma samples were analyzed.

Rationale: The paper mentions the patient's HIV viral load, which is typically measured in plasma.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses the patient's virological failure and the initiation of a new treatment regimen.

Rationale: The paper focuses on the patient's treatment outcomes, including virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not indicate that the patient was part of a clinical trial.

Rationale: The paper describes a single patient case and does not mention any clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions the patient's history of antiretroviral treatment.

Rationale: The paper discusses the patient's treatment history, including the use of antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions the patient's treatment history, including the use of antiretroviral drugs.

Rationale: The paper discusses the patient's treatment history, including the use of antiretroviral drugs.

Answer: INSTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions the patient's treatment history, including the use of antiretroviral drugs.

Rationale: The paper discusses the patient's treatment history, including the use of antiretroviral drugs.

Answer: Cabotegravir (CAB), Rilpivirine (RPV)
""""""",62
37573167,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""HIV-1 DNA was obtained from whole-blood (N=180) or lymphomonocytic cells (N=936) after separation from peripheral blood from HIV-1-infected patients with a Ficoll-Hypaque gradient, as described previously [13].""

Rationale: The paper mentions that HIV-1 DNA was obtained from patient samples, indicating that HIV sequences were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""This retrospective study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT over the period 2010-2021 performed for routine clinical practice in several reference centers in Italy.""

Rationale: The paper states that 1126 individuals had samples obtained for HIV sequencing.

Answer: 1126
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""This retrospective study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT over the period 2010-2021 performed for routine clinical practice in several reference centers in Italy.""

Rationale: The paper mentions that the samples were obtained from Italy.

Answer: Italy
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""This retrospective study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT over the period 2010-2021 performed for routine clinical practice in several reference centers in Italy.""

Rationale: The paper states that the samples were obtained from 2010 to 2021.

Answer: 2010-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Sanger sequencing was performed as previously described [14, 15].""

Rationale: The paper does not explicitly mention which HIV genes were sequenced, but it mentions that Sanger sequencing was performed.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Sanger sequencing was performed as previously described [14, 15].""

Rationale: The paper mentions that Sanger sequencing was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""HIV-1 DNA was obtained from whole-blood (N=180) or lymphomonocytic cells (N=936) after separation from peripheral blood from HIV-1-infected patients with a Ficoll-Hypaque gradient, as described previously [13].""

Rationale: The paper mentions that whole-blood and lymphomonocytic cells were used for sequencing.

Answer: Whole-blood, lymphomonocytic cells
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""This retrospective study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT over the period 2010-2021 performed for routine clinical practice in several reference centers in Italy.""

Rationale: The paper does not explicitly mention virological failure, but it mentions that the individuals were drug-experienced and virologically suppressed.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""This retrospective study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT over the period 2010-2021 performed for routine clinical practice in several reference centers in Italy.""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""This retrospective study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT over the period 2010-2021 performed for routine clinical practice in several reference centers in Italy.""

Rationale: The paper mentions that the individuals were drug-experienced, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""At HIV-DNA GRT, individuals were under virological suppression for a median (IQR) of 3.7 (0.3-8.0) years, and were mainly under triple therapy (66.1%) based on PI, NNRTI or INSTI plus 2 NRTIs (Table 1).""

Rationale: The paper mentions that the individuals received PI, NNRTI, INSTI, and NRTI before sample sequencing.

Answer: PI, NNRTI, INSTI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""At HIV-DNA GRT, individuals were under virological suppression for a median (IQR) of 3.7 (0.3-8.0) years, and were mainly under triple therapy (66.1%) based on PI, NNRTI or INSTI plus 2 NRTIs (Table 1).""

Rationale: The paper does not explicitly mention specific drug names, but it mentions that the individuals received PI, NNRTI, INSTI, and NRTI.

Answer: Not reported
""""""",83
37574435,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""We retrospectively reviewed the medical records of PWH who had viral rebound with plasma HIV RNA >1000 copies/mL and were switched to either dolutegravir combined with 2 NRTIs or BIC/FTC/TAF.""

Rationale: The paper does not explicitly mention HIV sequences from patient samples. However, it does mention that the medical records of people with HIV (PWH) who had viral rebound were retrospectively reviewed, which may imply that some form of genetic analysis or sequencing was performed.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not provide any in vitro drug susceptibility data or related experiments.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not mention whether any sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Seventy-nine PWH with viral rebound while receiving other antiretroviral regimens were included.""

Rationale: The paper mentions that 79 people with HIV (PWH) were included in the study.

Answer: 79
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""This was a single-center, retrospective cohort study conducted in the National Taiwan University Hospital (NTUH).""

Rationale: The paper mentions that the study was conducted in Taiwan.

Answer: Taiwan
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""PWH who received HIV care with at least 3 months of ART prescription between 1 January 2016 and 30 March 2022 were eligible for the study.""

Rationale: The paper mentions that the study included people with HIV (PWH) who received HIV care between 2016 and 2022.

Answer: 2016-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information regarding whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""No evidence""

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any sequencing methods used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""No evidence""

Rationale: The paper does not specify any type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Seventy-nine PWH with viral rebound while receiving other antiretroviral regimens were included.""

Rationale: The paper mentions that the study included people with HIV (PWH) who had viral rebound while receiving other antiretroviral regimens.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""This was a single-center, retrospective cohort study conducted in the National Taiwan University Hospital (NTUH).""

Rationale: The paper describes a retrospective cohort study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Seventy-nine PWH with viral rebound while receiving other antiretroviral regimens were included.""

Rationale: The paper mentions that the study included people with HIV (PWH) who had viral rebound while receiving other antiretroviral regimens, which implies that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Before the switch to BIC-STR, our cohort was treated with INIs (187/242 77.3%), non-nucleoside reverse transcriptase inhibitors (NNRTIs) (21/242 8.7%), PIs (36/242, 14.9%), TAF backbone (167/242, 69%), abacavir (ABC) backbone (31/242, 12.8%), and dual-therapy (15/242, 6.2%).""

Rationale: The paper mentions that the cohort was treated with various antiretroviral drugs, including INIs, NNRTIs, PIs, and NRTIs, prior to the switch to BIC-STR.

Answer: INSTI, NNRTI, PI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Before the switch to BIC-STR, our cohort was treated with INIs (187/242 77.3%), non-nucleoside reverse transcriptase inhibitors (NNRTIs) (21/242 8.7%), PIs (36/242, 14.9%), TAF backbone (167/242, 69%), abacavir (ABC) backbone (31/242, 12.8%), and dual-therapy (15/242, 6.2%).""

Rationale: The paper mentions that the cohort was treated with various antiretroviral drugs, including INIs, NNRTIs, PIs, and NRTIs, prior to the switch to BIC-STR.

Answer: TAF, ABC, BIC, FTC
""""""",79
37585352,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 proviral DNA sequences were generated using next-generation sequencing (NGS) from 5805 participants.

Rationale: The evidence clearly states that HIV sequences were obtained from patient samples, specifically from proviral DNA.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data.

Rationale: The paper discusses the analysis of resistance patterns in patient samples and does not mention any in vitro testing of drug susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers.

Answer: Not available
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 5805 participants had their HIV-1 proviral DNA sequences generated.

Rationale: The evidence clearly states that 5805 individuals had samples obtained for HIV sequencing.

Answer: 5805
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Botswana.

Rationale: The paper clearly states that the samples were obtained from Botswana.

Answer: Botswana
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2013 to 2018.

Rationale: The evidence clearly states that the samples were obtained from 2013 to 2018.

Answer: 2013-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning of samples.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that near full-length HIV-1 *pol* sequences were generated.

Rationale: The evidence clearly states that the *pol* gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that next-generation sequencing (NGS) was used to generate the HIV-1 proviral DNA sequences.

Rationale: The evidence clearly states that NGS was used for sequencing.

Answer: Next-generation sequencing (NGS)
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-1 proviral DNA sequences were generated from participants.

Rationale: The evidence clearly states that proviral DNA samples were sequenced.

Answer: Proviral DNA
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included ART-suppressed individuals, but does not specifically mention individuals with virological failure.

Rationale: The paper does not provide clear information about individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included ART-experienced participants.

Rationale: The evidence clearly states that some individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the most common ART regimens used were efavirenz + emtricitabine + tenofovir (EFV/FTC/TDF), lamivudine + nevirapine + zidovudine (3TC/NVP/ZDV), and lamivudine + efavirenz + zidovudine (3TC/EFV/ZDV).

Rationale: The evidence clearly states that the individuals received NNRTIs (EFV, NVP) and NRTIs (3TC, FTC, TDF, ZDV).

Answer: NNRTI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the most common ART regimens used were efavirenz + emtricitabine + tenofovir (EFV/FTC/TDF), lamivudine + nevirapine + zidovudine (3TC/NVP/ZDV), and lamivudine + efavirenz + zidovudine (3TC/EFV/ZDV).

Rationale: The evidence clearly states that the individuals received EFV, FTC, TDF, 3TC, NVP, and ZDV.

Answer: EFV, FTC, TDF, 3TC, NVP, ZDV
""""""",71
37593123,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: A total of 67,739 sequences were extracted from the HIV-1 *pol* gene region (HXB2 ( 6 ) positions 2,253--3,312) of ART naïve HIV-infected individuals between the period of 2004 and 2022.

Rationale: The evidence clearly states that the study obtained HIV-1 sequences from patient samples, specifically from the *pol* gene region.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The Stanford HIV Drug Resistance Database (HIVdb) was leveraged to extrapolate susceptibility to 12 antiretroviral drugs, using the World Health Organization (WHO)'s 2014 HIVDR guidelines as a reference ( 8 ).

Rationale: The paper does not report in vitro drug susceptibility data, but rather uses the Stanford HIV Drug Resistance Database to predict susceptibility to antiretroviral drugs.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 57,902 ART-naïve HIV-infected individuals, which were categorized according to the development stages of the NFATP.

Rationale: The evidence clearly states that 57,902 individuals had samples obtained for HIV sequencing.

Answer: 57,902
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study population consisted of ART-naïve HIV-infected individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The evidence suggests that the sequenced samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study population consisted of ART-naïve HIV-infected individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The evidence clearly states that the sequenced samples were obtained from 2004 to 2022.

Answer: 2004-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: A total of 67,739 sequences were extracted from the HIV-1 *pol* gene region (HXB2 ( 6 ) positions 2,253--3,312) of ART naïve HIV-infected individuals between the period of 2004 and 2022.

Rationale: The evidence clearly states that the *pol* gene region was sequenced.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma samples were collected from HIV-1 treatment-naïve patients enrolled in the Peking Union Medical College Hospital.

Rationale: The evidence suggests that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004. Participants had received no antiretroviral drugs at the time of sampling.

Rationale: The evidence clearly states that the participants were treatment-naïve, meaning they had not received any antiretroviral drugs prior to the sampling.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide any information indicating that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004. Participants had received no antiretroviral drugs at the time of sampling.

Rationale: The evidence clearly states that the participants were treatment-naïve, meaning they had not received any antiretroviral drugs prior to the sampling.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004. Participants had received no antiretroviral drugs at the time of sampling.

Rationale: The evidence clearly states that the participants had not received any antiretroviral drugs, confirming that no drug classes were received by individuals in the study before sample sequencing.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004. Participants had received no antiretroviral drugs at the time of sampling.

Rationale: The evidence clearly states that the participants had not received any antiretroviral drugs, confirming that no drugs were received by individuals in the study before sample sequencing.

Answer: nan
""""""",74
37626789,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 genotyping and sequencing was performed for the *pol* gene region using an in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations.

Rationale: The paper explicitly states that HIV-1 genotyping and sequencing was performed, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing. It focuses on genotyping and identifying drug resistance mutations from patient samples.

Rationale: The paper does not mention any in vitro drug susceptibility testing, indicating that this information is not available.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, indicating that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 551 HIV-positive children (<15 years old) were recruited for the study.

Rationale: The paper states that 551 HIV-positive children were recruited for the study, indicating that samples were obtained from these individuals.

Answer: 551
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Ethiopia.

Rationale: The paper states that the study was conducted in Ethiopia, indicating that the sequenced samples were obtained from this country.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2017 to 2019.

Rationale: The paper states that the study was conducted from 2017 to 2019, indicating that the sequenced samples were obtained during these years.

Answer: 2017-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, indicating that this information is not available.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 genotyping and sequencing was performed for the *pol* gene region.

Rationale: The paper explicitly states that the *pol* gene region was sequenced.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that an in-house assay validated at the Chinese Center for Disease Control and Prevention was used for amplification and sequencing of the *pol* gene of HIV-1 using an ABI-3730 DNA genetic analyzer.

Rationale: The paper describes the sequencing method involving an in-house assay and an ABI-3730 DNA genetic analyzer, which are characteristic of Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that whole blood was collected from children using two ethylenediaminetetraacetic acid (EDTA) coated test tubes of 3--5 mL each, and plasma was extracted using centrifugation at 2000 revolutions per minute (RPM).

Rationale: The paper specifies that plasma was extracted from whole blood, indicating that the samples were from plasma.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that children with virologic failure (VL ≥ 1000 copies/mL) were included for HIV drug resistance investigation.

Rationale: The paper states that children with virologic failure were included for HIV drug resistance investigation, indicating that sequences were obtained from individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial, indicating that this information is not available.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included HIV-infected children taking first-line antiretroviral therapy (ART).

Rationale: The paper states that the study included HIV-infected children taking first-line antiretroviral therapy, indicating that sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included HIV-infected children taking first-line antiretroviral therapy (ART), and the ART regimens consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI).

Rationale: The paper describes the ART regimens consisting of NRTIs and NNRTIs or PIs, indicating that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the ART regimens consisted of Zidovudine (AZT) + Lamivudine(3TC) + Nevirapine (NVP), Stavudine(D4T) + Lamivudine(3TC) + Nevirapine (NVP), and Zidovudine (AZT) + Lamivudine(3TC) + Efavirenz (EFV).

Rationale: The paper lists the specific drugs that were part of the ART regimens, including Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), and Efavirenz (EFV).

Answer: Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV)
""""""",87
37632026,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the collection of plasma samples from HIV-positive patients and the extraction of viral RNA, which indicates that HIV sequences were obtained from these patient samples.

Rationale: The paper mentions the use of viral RNA extracted from plasma samples for sequencing, indicating that HIV sequences were reported from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper discusses the identification of drug resistance mutations and their correlation with treatment regimens, but it does not provide specific in vitro drug susceptibility data.

Rationale: The paper does not mention any in vitro drug susceptibility testing, indicating that this information is not provided.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper provides specific GenBank accession numbers for the sequenced HIV isolates, indicating that these sequences were made publicly available.

Rationale: The paper explicitly states that the sequences were submitted to GenBank and provides the accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper provides specific GenBank accession numbers for the sequenced HIV isolates, which are MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; and OQ985493-OQ985958.

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates, confirming their availability.

Answer: MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 759 participants were included in the study.

Rationale: The paper mentions that 759 participants were included in the study, indicating the number of individuals from whom samples were obtained.

Answer: 759
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Cameroon.

Rationale: The paper specifies that the study was conducted in Cameroon, indicating the country from which the samples were obtained.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from November 2011 to August 2019.

Rationale: The paper provides a specific time frame for when the samples were collected.

Answer: 2011-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, indicating that this information is not provided.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 pol-gene (protease and reverse-transcriptase regions) was amplified.

Rationale: The paper explicitly states that the HIV-1 pol-gene was sequenced, including the protease and reverse-transcriptase regions.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that sequencing was performed using an Applied Biosystems 3500 genetic analyzer.

Rationale: The paper explicitly states that Sanger sequencing was used for processing the PCR products, confirming the method employed for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper describes the collection of plasma samples from HIV-positive patients.

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included patients failing first- and second-line ART.

Rationale: The paper states that the sequences were obtained from patients failing TDF- and d4T-based first-line regimens.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention whether the patients were part of a clinical trial, indicating that this information is not provided.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that all patients included in the study were ART-experienced.

Rationale: The paper clearly states that all patients included in the study were ART-experienced, indicating that they had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients were on TDF- or d4T-based first-line regimens, which included 3TC, EFV, or NVP.

Rationale: The paper specifies that the patients were on TDF- or d4T-based first-line regimens, and 3TC which are NRTIs, and also mentions the use of EFV or NVP, which are NNRTIs.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists specific drugs included in the treatment regimens of the patients, indicating that they were received prior to sample sequencing.

Rationale: The paper mentions that the patients were on TDF (TFV)- or d4T-based first-line regimens, which included 3TC, EFV, or NVP.

Answer: Tenofovir (TFV), Stavudine (D4T), Lamivudine (3TC), Efavirenz (EFV), Nevirapine (NVP)
""""""",77
37632071,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that the study included PLWH who switched to BIC/FTC/TAF in the period 2019--2022, and who were HBsAg and HCV RNA negative. The follow-up study times were 6 (T6), 12 (T12), 18 (T18), and 24 (T24) months after the switch (T0). The paper also mentions that plasma HIV RNA was classified as undetectable, detectable at <50 copies/mL, detectable ranging from 50 to 100 copies/mL, detectable ranging from 101 to 1000 copies/mL, or detectable > 1000 copies/mL.

Rationale: The paper does not explicitly mention HIV sequences from patient samples. However, it does mention plasma HIV RNA, which suggests that some form of genetic analysis was performed.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any experiments or results related to in vitro drug susceptibility testing.

Rationale: The paper focuses on the analysis of resistance mutations and virological data without mentioning specific accession numbers or in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention whether any sequences were made publicly available.

Rationale: The paper does not provide any information regarding whether sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 329 PLWH had plasma HIV RNA that was undetectable or <50 copies/mL at T0.

Rationale: The paper mentions that 329 PLWH had plasma HIV RNA that was undetectable or <50 copies/mL at T0.

Answer: 329
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted at 4 (Rome, Treviso, Vicenza, and Venice) Italian Infectious Diseases Units.

Rationale: The paper mentions that the study was conducted in Italy.

Answer: Italy
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study included PLWH who switched to BIC/FTC/TAF in the period 2019--2022.

Rationale: The paper mentions that the study included PLWH who switched to BIC/FTC/TAF in the period 2019--2022.

Answer: 2019-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide any information regarding whether samples were cloned prior to sequencing.

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention any specific HIV genes that were sequenced.

Rationale: The paper does not provide any information regarding which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention any specific sequencing method used.

Rationale: The paper does not provide any information regarding the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma HIV RNA was classified as undetectable, detectable at <50 copies/mL, detectable ranging from 50 to 100 copies/mL, detectable ranging from 101 to 1000 copies/mL, or detectable > 1000 copies/mL.

Rationale: The paper suggests that plasma samples were analyzed.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included PLWH who switched to BIC/FTC/TAF in the period 2019--2022, and who were HBsAg and HCV RNA negative.

Rationale: The paper does not explicitly mention virological failure, but it does mention that the study included PLWH who switched to BIC/FTC/TAF.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that most of the 197 patients (122, 61.9%) were on a previous INSTI-based regimen.

Rationale: The paper mentions that most of the patients were on a previous INSTI-based regimen, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that most of the 197 patients (122, 61.9%) were on a previous INSTI-based regimen.

Rationale: The paper mentions that most of the patients were on a previous INSTI-based regimen, indicating that they had previously received INSTI drugs.

Answer: INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that most of the 197 patients (122, 61.9%) were on a previous INSTI-based regimen.

Rationale: The paper mentions that most of the patients were on a previous INSTI-based regimen, indicating that they had previously received INSTI drugs.

Answer: INSTI drugs
""""""",75
37649807,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention any HIV sequences from patient samples, as it focuses on virological outcomes rather than genetic analysis.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any in vitro drug susceptibility data, as it focuses on virological outcomes rather than laboratory testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention any publicly available sequences, as it does not report on sequencing.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not report any individuals from whom samples were obtained for HIV sequencing, as it does not involve sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention any sequenced samples or their countries of origin, as it does not involve sequencing.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the years of sequenced samples, as no sequencing was conducted.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not discuss any cloning of samples, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not report any sequencing of HIV genes, as it focuses on virological outcomes rather than genetic analysis.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequencing methods, as it does not report on any sequencing of HIV samples.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not report any sequencing of samples, thus it does not specify the type of samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper discusses virological non-suppression but does not mention obtaining sequences from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention that the patients were part of a clinical trial, suggesting that this information is not available.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""",50
37662576,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention any patient samples or sequences derived from patients. It focuses on the mechanisms of drug resistance in recombinant HIV-1 clones.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not report any in vitro drug susceptibility data, as it focuses on the mechanisms of drug resistance in recombinant HIV-1 clones.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention any publicly available sequences, as it does not report on patient-derived sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, as it does not report on patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the number of individuals from whom samples were obtained, as it does not report on patient-derived sequences.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention any countries from which sequenced samples were obtained, as it does not report on patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information on the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention any specific HIV genes that were sequenced, as it focuses on the mechanisms of drug resistance in recombinant HIV-1 clones.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the sequencing method used, as it does not report on patient-derived sequences or any sequencing data.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention any specific type of samples that were sequenced, as it does not report on patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure, as it does not report on patient-derived sequences.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention any sequences from individuals who had previously received ARV drugs, as it does not report on patient-derived sequences.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding drug classes received by individuals, as it does not report on patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any specific drugs received by individuals, as it does not report on patient-derived sequences.

Answer: Not reported
""""""",54
37674678,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: A total of 1,161 sequences were successfully sequenced, of which CRF07_BC (40.6%), CRF01_AE (38.4%) and CRF105_0107 (6.3%) were the main HIV-1 genotypes.

Rationale: The evidence clearly states that samples were collected from patients and that a significant number of those samples were successfully sequenced, indicating that the paper does report HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data was found in the paper.

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence of publicly available sequences was found in the paper.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No GenBank accession numbers were provided in the paper.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 1,393 participants who were newly diagnosed with HIV-1 and had not received ART between January 1, 2019 and November 31, 2021 were enrolled in this study.

Rationale: The evidence indicates that 1,393 individuals were enrolled in the study, confirming the total number of individuals from whom samples were obtained for sequencing.

Answer: 1,393
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Nanjing, China.

Rationale: The paper specifically mentions that the study was conducted in Nanjing, China, and all the samples were obtained from this region.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The samples were collected between January 1, 2019 and November 31, 2021.

Rationale: The paper states that the samples were collected between January 1, 2019 and November 31, 2021.

Answer: 2019-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence of cloning was found in the paper.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The target fragment of 1,059 bp in the pol gene (HXB2:2253--3,312) was amplified using nested polymerase chain reaction (PCR).

Rationale: The paper reports the sequencing of the pol gene.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The PCR products were sent to Sangon Biotechnology Co., Ltd. for automatic DNA sequencing using ABI 3730XL.

Rationale: The paper mentions that the sequencing was performed using an ABI 3730XL automated DNA sequencer, which is a platform used for Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma samples were collected from HIV-1 treatment-naïve patients enrolled in the study.

Rationale: The paper specifies that plasma samples were the clinical specimens collected and sequenced in the study.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence of virological failure was found in the paper.

Rationale: The paper mentions that all participants were treatment-naïve, meaning they had not received any antiretroviral treatment prior to the study.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence of a clinical trial was found in the paper.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence of previous ARV drug use was found in the paper.

Rationale: The paper mentions that all participants were treatment-naïve, meaning they had not received any antiretroviral drugs before sample sequencing.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence of previous ARV drug use was found in the paper.

Rationale: The paper mentions that all participants were treatment-naïve, meaning they had not received any antiretroviral drugs before sample sequencing.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence of previous ARV drug use was found in the paper.

Rationale: The paper mentions that all participants were treatment-naïve, meaning they had not received any antiretroviral drugs before sample sequencing.

Answer: nan
""""""",67
37701387,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention any HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention whether any sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: Not reported.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not report any individuals from whom samples were obtained for HIV sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not specify any countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention any specific years during which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention any specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequencing methods used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not specify any type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not report any HIV sequences from individuals, regardless of their previous ARV drug history.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any specific drug classes that were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any specific drugs that were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",44
37716367,"Here are the answers to the questions based on the provided paper content:

### Question 1: Does the paper report HIV sequences from patient samples?

Evidence: ""No evidence""

Rationale: The paper does not mention obtaining HIV sequences from patient samples. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: No

### Question 2: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention in vitro drug susceptibility data. It focuses on the development of a checklist for reporting HIV drug resistance studies.

Answer: No

### Question 3: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not mention making sequences publicly available. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: No

### Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: Not reported

### Question 5: How many individuals had samples obtained for HIV sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: Not reported

### Question 6: From which countries were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not mention the countries from which sequenced samples were obtained. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: Not reported

### Question 7: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not mention the years from which sequenced samples were obtained. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: Not reported

### Question 8: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention cloning samples prior to sequencing. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: No

### Question 9: Which HIV genes were reported to have been sequenced?

Evidence: ""No evidence""

Rationale: The paper does not mention specific HIV genes that were sequenced. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: Not reported

### Question 10: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not specify the sequencing method used. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: Not reported

### Question 11: What type of samples were sequenced?

Evidence: ""No evidence""

Rationale: The paper does not specify the type of samples that were sequenced. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: Not reported

### Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""No evidence""

Rationale: The paper does not mention obtaining sequences from individuals with virological failure on a treatment regimen. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: No

### Question 13: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention patients being in a clinical trial. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: No

### Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""No evidence""

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: No

### Question 15: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention specific drug classes received by individuals in the study before sample sequencing. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: Not reported

### Question 16: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention specific drugs received by individuals in the study before sample sequencing. It discusses the development of a checklist for reporting HIV drug resistance studies.

Answer: Not reported",57
37755428,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses a case report involving a perinatally HIV-infected infant and mentions that nucleic acids were extracted from remnant dried blood spot specimens collected at the time of HIV diagnosis and sequenced using a Sanger-based method.

Rationale: The paper explicitly states that sequencing was performed on the infant's HIV specimens, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data is provided in the paper.

Rationale: The paper focuses on a case report and a national survey of HIV drug resistance in infants, but it does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence is provided in the paper regarding the public availability of the sequences.

Rationale: The paper does not mention whether the sequences were made publicly available or deposited in a database.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No GenBank accession numbers are provided in the paper.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 143 infants had remnant specimens available for HIVDR testing.

Rationale: The paper explicitly states that 143 infants had specimens available for HIVDR testing, indicating that samples were obtained from these individuals.

Answer: 143
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from Haiti.

Rationale: The paper explicitly states that the survey was conducted in Haiti, indicating that the samples were obtained from this country.

Answer: Haiti
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the survey was conducted between April 2020 and March 2021.

Rationale: The paper explicitly states that the survey was conducted during this time period, indicating that the samples were obtained from 2020 to 2021.

Answer: 2020-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence is provided in the paper regarding cloning of samples prior to sequencing.

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that sequences were obtained for the protease/reverse transcriptase (PR/RT) and integrase regions.

Rationale: The paper explicitly states that sequences were obtained for these regions, indicating that the PR, RT, and IN genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that a Sanger-based method was used for sequencing.

Rationale: The paper explicitly states that a Sanger-based method was used, indicating that Sanger sequencing was the method used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that dried blood spot specimens were used for sequencing.

Rationale: The paper explicitly states that dried blood spot specimens were used, indicating that these were the type of samples sequenced.

Answer: Dried blood spot specimens
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the infant had received ZDV-based PNP and had virological failure.

Rationale: The paper explicitly states that the infant had virological failure, indicating that sequences were obtained from an individual with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence is provided in the paper regarding a clinical trial.

Rationale: The paper does not mention a clinical trial, indicating that the patients were not part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the infant's mother had initiated ART (tenofovir/lamivudine/dolutegravir) 6 months before delivery.

Rationale: The paper explicitly states that the mother had received ARV drugs, indicating that the infant was exposed to ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the mother had received tenofovir/lamivudine/dolutegravir as a fixed-dose combination for the treatment of her HIV infection.

Rationale: The paper explicitly states that the mother had received this combination, indicating that the infant was exposed to NRTI, NNRTI, and INSTI classes.

Answer: NRTI, NNRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the mother had received tenofovir/lamivudine/dolutegravir as a fixed-dose combination for the treatment of her HIV infection.

Rationale: The paper explicitly states that the mother had received this combination, indicating that the infant was exposed to these specific drugs.

Answer: Tenofovir, Lamivudine, Dolutegravir
""""""",70
37775947,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq).""

Rationale: The paper mentions that plasma samples from participants were analyzed using next-generation sequencing (NGS), which indicates that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Overall, of the 1819 participants with NGS data at the ≥200 read depth, 1380 (76%) who started ART with three or more drugs, either in the immediate or the deferred arm, and had virological follow-up of ≥1 month were included in this analysis.""

Rationale: The paper mentions that 1380 participants had samples obtained for HIV sequencing.

Answer: 1380
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Of note, 96 of 1380 participants (7%) started a regimen predicted by GSS to include fewer than three active drugs at this threshold. The two GSS groups appeared to be balanced in terms of demographics and immune-virological factors. The only marked differences were in region of enrolment, where South America was over-represented in the group with a GSS of 0--2.75.""

Rationale: The paper mentions that South America was over-represented in the group with a GSS of 0--2.75, but it does not provide a comprehensive list of countries.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""The START trial, conducted by the International Network for Strategic Initiatives in Global HIV Trials, enrolled ART-naïve participants with HIV between April 2009 and December 2013.""

Rationale: The paper mentions that the samples were obtained between April 2009 and December 2013.

Answer: 2009-2013
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""Sequence reads (FASTQ files) were analyzed with VirVarSeq version 20140929, which calls variants at the codon level [27].""

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""From the output, we extracted amino acid frequencies in the *pol* gene from amino acid position 1--935 where positions 1--99 encode protease protein, positions 100--659 encode reverse transcriptase protein, and positions 660--935 partially encode integrase protein (our amplicon did not cover positions 936--947) [25].""

Rationale: The paper mentions that the pol gene was sequenced, which includes the protease, reverse transcriptase, and integrase genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq).""

Rationale: The paper mentions that next-generation sequencing (NGS) using the Illumina MiSeq platform was used for sequencing.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq).""

Rationale: The paper mentions that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Overall, of the 1819 participants with NGS data at the ≥200 read depth, 1380 (76%) who started ART with three or more drugs, either in the immediate or the deferred arm, and had virological follow-up of ≥1 month were included in this analysis.""

Rationale: The paper does not specifically mention that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""The START trial, conducted by the International Network for Strategic Initiatives in Global HIV Trials, enrolled ART-naïve participants with HIV between April 2009 and December 2013.""

Rationale: The paper mentions that the study was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The START trial, conducted by the International Network for Strategic Initiatives in Global HIV Trials, enrolled ART-naïve participants with HIV between April 2009 and December 2013.""

Rationale: The paper mentions that the participants were ART-naïve, which means they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""The START trial, conducted by the International Network for Strategic Initiatives in Global HIV Trials, enrolled ART-naïve participants with HIV between April 2009 and December 2013.""

Rationale: The paper mentions that the participants were ART-naïve, which means they had not previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""The START trial, conducted by the International Network for Strategic Initiatives in Global HIV Trials, enrolled ART-naïve participants with HIV between April 2009 and December 2013.""

Rationale: The paper mentions that the participants were ART-naïve, which means they had not previously received ARV drugs.

Answer: Not reported
""""""",82
37817087,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the collection of plasma samples from patients, which were then used for sequencing.

Rationale: The paper explicitly states that sequences were generated from blood plasma samples collected from patients.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that PR and RT sequences were obtained from 4559 (39.6%) cases, and PR, RT and IN sequences were obtained from 3097 (26.9%) cases.

Rationale: The paper provides the number of individuals from whom sequences were obtained.

Answer: 4559 or 3097
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Germany.

Rationale: The paper explicitly states that the study was conducted in Germany.

Answer: Germany
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the study was conducted from 2017 to 2020.

Rationale: The paper explicitly states the years during which the samples were collected.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the genomic regions of protease (PR, amino acids 9--99), reverse transcriptase (RT, amino acids 1-252) and integrase (IN, amino acids 1-279) were amplified.

Rationale: The paper explicitly states the specific genes that were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the amplicons were sequenced using an Illumina NGS method (MiSeq).

Rationale: The paper explicitly states the sequencing method used.

Answer: Illumina NGS (MiSeq)
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper describes the collection of plasma samples from patients, which were then used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide any information regarding virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper indicates that some patients had interrupted ART, which indicates these people had previously received ARV drugs.

Rationale: The paper mentions that some patients had interrupted ART, indicating previous ARV drug use.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some patients had interrupted ART, which indicates these people had previously received ARV drugs, but the specific drug classes are not mentioned.

Rationale: The paper indicates that some patients had interrupted ART, but the specific drug classes are not mentioned.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some patients had interrupted ART, which indicates these people had previously received ARV drugs, but the specific drugs are not mentioned.

Rationale: The paper indicates that some patients had interrupted ART, but the specific drugs are not mentioned.

Answer: Not reported
""""""",57
37823653,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""A total of 6,078 HIV-1 near full length sequences were generated for the BCPP study.""

Rationale: The paper mentions that HIV-1 near full length sequences were generated for the study, indicating that HIV sequences were reported from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""None""

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""None""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""None""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 6,078 HIV-1 near full length sequences were generated for the BCPP study.""

Rationale: The paper mentions that 6,078 HIV-1 near full length sequences were generated for the study.

Answer: 6078
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""The generated sequences were from PWH aged 16--64 years residing in 30 communities in northern, central, and southern parts of Botswana""

Rationale: The paper mentions that the sequences were obtained from individuals residing in Botswana.

Answer: Botswana
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Participants were enrolled between 2013 and 2018.""

Rationale: The paper mentions that participants were enrolled between 2013 and 2018.

Answer: 2013-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""None""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The generated sequences were from PWH aged 16--64 years residing in 30 communities in northern, central, and southern parts of Botswana who were randomly selected to participate in the Botswana Combination Prevention Project (BCPP) (4, 24--26). BCPP enrolled both PWH and HIV-negative individuals. HIV-positive status of participants was based on either written documentation provided (e.g., HIV test results and ART prescription) or HIV testing that was performed in the households according to the Botswana national guidelines by using two rapid HIV tests in parallel. Most of the ART-experienced PWH were on efavirenz- or nevirapine-based ART which was the first-line regimen prior to dolutegravir-based first-line ART implementation in June 2016.""

Rationale: The paper does not explicitly mention which HIV genes were sequenced, but it mentions that the sequences were generated for the BCPP study, which likely involved sequencing of the HIV-1 genome.

Answer: HIV-1 genome
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Proviral DNA templates were used for amplification, as the majority of participants were receiving ART. The NGS was performed by the Biopolimers Facility at Harvard Medical School (https://genome.med.harvard.edu/) and through collaboration with PANGEA HIV consortium (24) at the Wellcome Trust Sanger Institute (Cambridge, UK; http://www.sanger.ac.uk/) with high-sequencing coverage and using Illumina platform MiSeq and HiSeq.""

Rationale: The paper mentions that next-generation sequencing (NGS) was used for sequencing.

Answer: Next-generation sequencing (NGS)
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Proviral DNA templates were used for amplification, as the majority of participants were receiving ART.""

Rationale: The paper mentions that proviral DNA templates were used for amplification.

Answer: Proviral DNA
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""ART-experienced participants were further stratified to ART experienced and virally suppressed (VL ≤400 copies/mL) [4,526 (95.5%)] and ART experienced with VF (detectable VL >400 copies/mL at entry) [213 (4.5%)]""

Rationale: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""This is a retrospective cross-sectional study utilizing already generated 6,078 HIV-1C sequences covering the entire gp120.""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Most of the ART-experienced PWH were on efavirenz- or nevirapine-based ART which was the first-line regimen prior to dolutegravir-based first-line ART implementation in June 2016.""

Rationale: The paper mentions that most of the ART-experienced individuals were on efavirenz- or nevirapine-based ART.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Most of the ART-experienced PWH were on efavirenz- or nevirapine-based ART which was the first-line regimen prior to dolutegravir-based first-line ART implementation in June 2016.""

Rationale: The paper mentions that the individuals received efavirenz- or nevirapine-based ART, which are non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Most of the ART-experienced PWH were on efavirenz- or nevirapine-based ART which was the first-line regimen prior to dolutegravir-based first-line ART implementation in June 2016.""

Rationale: The paper mentions that the individuals received efavirenz or nevirapine.

Answer: Efavirenz, Nevirapine
""""""",81
37872202,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention any patient samples or sequences derived from patients. It focuses on the mechanisms of drug resistance in recombinant HIV-1 clones.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper describes experiments where the susceptibility of HIV-1 clones to drugs, indicating that in vitro drug susceptibility data is reported.

Rationale: The paper describes the resistance selection experiments conducted with tenofovir alafenamide (TAF) and tenofovir (TFV). The study used a dose escalation method and analyzed genotypic and phenotypic changes in the virus over time.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, as it does not report on patient-derived sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, as it does not report on patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the number of individuals from whom samples were obtained, as it does not report on patient-derived sequences.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention any countries from which sequenced samples were obtained, as it does not report on patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any cloning of samples prior to sequencing, as it does not report on patient-derived sequences.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions sequencing the entire RT portion of the pol gene, spanning nucleotide 200 of protease to nucleotide 105 of integrase.

Rationale: The paper mentions sequencing the entire RT portion of the pol gene, spanning nucleotide 200 of protease to nucleotide 105 of integrase. This indicates that the RT, integrase, and protease genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the sequencing method used, as it does not report on patient-derived sequences or any sequencing data.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention any specific type of samples that were sequenced, as it does not report on patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure, as it does not report on patient-derived sequences.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention that the patients from whom the sequences were obtained were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention any sequences from individuals who had previously received ARV drugs, as it does not report on patient-derived sequences.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding drug classes received by individuals, as it does not report on patient-derived sequences.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any specific drugs received by individuals, as it does not report on patient-derived sequences.

Answer: Not reported
""""""",67
37878637,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that specimens used for analysis were collected either from stored patient samples received throughout the year 2019 for HIV-1 protease and reverse transcriptase genotyping in routine practice, or from patients’ sequences that were published in the LANL HIVdb.

Rationale: The evidence clearly states that the study involved patient samples, indicating that the paper does report HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The study does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention that the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Of the 141 participants in VF enrolled, the male-female ratio was 1:1; mean age was 15 (±3) years; and median [IQR] duration on ART was 51 [46--60] months.

Rationale: The evidence provides a clear count of the individuals whose samples were obtained for sequencing, indicating the total number included in the study.

Answer: 141
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted among adolescents living with perinatally acquired HIV (APHI) in urban and rural settings of the Center region of Cameroon.

Rationale: The study was conducted in Cameroon.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: A cohort study was conducted from 2018--2020 among 311 adolescents living with perinatally acquired HIV on first- and second-line ART at enrolment.

Rationale: The evidence provides a clear range of years during which the sequenced samples were obtained, indicating the time frame of the study.

Answer: 2018--2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: Sequencing of protease and reverse transcriptase regions was performed for participants experiencing virological failure, VF, (Plasma viral load, PVL ≥ 1000 RNA copies/ml).

Rationale: The evidence indicates that the study involved sequencing of HIV-1 protease and reverse transcriptase regions.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: PCR products were sequenced using the Applied Biosystems 3500 genetic analyzer.

Rationale: The paper mentions the use of an Applied Biosystems sequencer, which is consistent with Sanger sequencing techniques.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Following enrolment, ten mL of whole blood were collected from each participant and transported on icepacks within 6 hours to the virology laboratory of the Chantal Biya international reference center (CIRCB), Yaoundé, Cameroon.

Rationale: The evidence specifies that the specimens analyzed were whole blood samples, indicating the type of clinical specimens sequenced.

Answer: Whole blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: Sequencing of protease and reverse transcriptase regions was performed for participants experiencing virological failure, VF, (Plasma viral load, PVL ≥ 1000 RNA copies/ml).

Rationale: The evidence suggests that the study included individuals who may have experienced virological failure to treatment regimens.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The study does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: These patients were either naive to ART or experiencing failure to NNRTI- and/or PI-based ART regimens.

Rationale: The evidence indicates that a significant portion of the study population had previously received antiretroviral therapy and experienced failure to NNRTI or PI based regimens.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: These patients were either naive to ART or experiencing failure to NNRTI- and/or PI-based ART regimens.

Rationale: The paper mentions the patients were either naïve or ART experienced with failure to NNRTI or PI-based regimens, which indicates they were treated with NNRTI, NRTI, or PI.

Answer: NRTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The content does not provide a detailed list of specific drugs taken by the ART-experienced patients, indicating that this information was not included in the study.

Answer: Not reported
""""""",71
37880705,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 pol sequences from studies conducted between 2003 and 2018 among ART-naïve Ethiopian individuals were retrieved from GenBank and analyzed for the presence of PDR mutations.

Rationale: The paper explicitly states that HIV-1 pol sequences were retrieved from GenBank and analyzed, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data is mentioned in the paper.

Rationale: The paper does not mention any in vitro drug susceptibility testing, indicating that this information is not provided.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that sequences of the included studies were downloaded from GenBank if they were publicly available.

Rationale: The paper explicitly states that sequences were downloaded from GenBank, indicating that these sequences were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No specific GenBank accession numbers are mentioned in the paper.

Rationale: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 1070 sequences were analyzed in this systematic review.

Rationale: The paper explicitly states that 1070 sequences were analyzed, indicating that samples were obtained from 1070 individuals.

Answer: 1070
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Ethiopia.

Rationale: The paper explicitly states that the study was conducted in Ethiopia, indicating that the sequenced samples were obtained from Ethiopia.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted between 2003 and 2018.

Rationale: The paper explicitly states that the study was conducted between 2003 and 2018, indicating that the sequenced samples were obtained during these years.

Answer: 2003-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence of cloning is mentioned in the paper.

Rationale: The paper does not mention any cloning of samples prior to sequencing, indicating that this information is not provided.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 pol sequences were analyzed for the presence of PDR mutations.

Rationale: The paper explicitly states that HIV-1 pol sequences were analyzed, indicating that the pol gene was sequenced.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: No specific sequencing method is mentioned in the paper.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No specific sample type is mentioned in the paper.

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included ART-naïve individuals.

Rationale: The paper explicitly states that the study included ART-naïve individuals, indicating that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence of a clinical trial is mentioned in the paper.

Rationale: The paper does not mention any clinical trial, indicating that this information is not provided.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included ART-naïve individuals.

Rationale: The paper explicitly states that the study included ART-naïve individuals, indicating that no sequences were obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No specific drug classes are mentioned in the paper.

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No specific drugs are mentioned in the paper.

Rationale: The paper does not provide information on the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",62
37896785,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The study material was blood plasma samples collected in 2021 from 61 pregnant women in need of PMTCT in Ho Chi Minh City with a viral load above 500 copies per ml of blood plasma.

Rationale: The paper describes the collection of blood plasma samples from HIV-positive pregnant women, which were then used for sequencing.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382).

Rationale: The paper explicitly states that the sequences were deposited in GenBank, indicating their availability.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382).

Rationale: The paper provides the specific GenBank accession numbers for the sequenced HIV isolates.

Answer: OQ215322-OQ215382
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The study material was blood plasma samples collected in 2021 from 61 pregnant women in need of PMTCT in Ho Chi Minh City with a viral load above 500 copies per ml of blood plasma.

Rationale: The paper states that 61 pregnant women had samples obtained for sequencing.

Answer: 61
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study material was blood plasma samples collected in 2021 from 61 pregnant women in need of PMTCT in Ho Chi Minh City.

Rationale: The paper indicates that the samples were obtained from Vietnam.

Answer: Vietnam
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study material was blood plasma samples collected in 2021 from 61 pregnant women in need of PMTCT in Ho Chi Minh City.

Rationale: The paper states that the samples were collected in 2021.

Answer: 2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: HIV-1 genotyping was performed based on analysis of the nucleotide sequences of the 1285 nt *pol* gene region encoding the protease (PR) and part of the reverse transcriptase (RT) in the 2085--3369 nt region.

Rationale: The paper describes the sequencing of the protease and reverse transcriptase genes.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: Sequencing reaction products were analyzed using an ABI Prism 3500 genetic analyzer (Applied Biosystems, Waltham, MA, USA).

Rationale: The paper specifies the use of the ABI Prism 3500 genetic analyzer, which is a method associated with Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The study material was blood plasma samples collected in 2021 from 61 pregnant women in need of PMTCT in Ho Chi Minh City with a viral load above 500 copies per ml of blood plasma.

Rationale: The paper describes the collection of blood plasma samples from HIV-positive pregnant women, which were then used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: In the examined group, 31 women showed virological failure of ART, and 30 women had not previously received therapy.

Rationale: The paper indicates that sequences were obtained from individuals experiencing virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: In the examined group, 31 women showed virological failure of ART, and 30 women had not previously received therapy.

Rationale: The paper indicates that some individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide information on the specific drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by individuals before sample sequencing.

Rationale: The paper does not provide information on the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",67
37896860,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The study included 704 children in the study with a median age 9 years (interquartile range (IQR) 7, 12); 344 (49%) were female, and the median time on ART was 5 years (IQR 3, 8). A total of 349 (49.5%) and 355 (50.5%) of the CHIV were randomized to the intervention and control groups, respectively.

Rationale: The paper mentions that the study included 704 children and that they were randomized into two groups, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility assays or data.

Rationale: The paper focuses on genotypic drug resistance testing and the identification of drug resistance mutations in patient samples. It does not mention any in vitro drug susceptibility assays or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The de-identified data presented in this study are available on request from the corresponding author.

Rationale: The paper does not explicitly state that the sequences were made publicly available, but it does mention that the data are available on request from the corresponding author.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 704 children were enrolled in the study.

Rationale: The paper states that 704 children were enrolled in the study, indicating that samples were obtained from these individuals for HIV sequencing.

Answer: 704
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Kenya.

Rationale: The paper mentions that the study was conducted in Kenya, indicating that the sequenced samples were obtained from this country.

Answer: Kenya
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study was conducted from March 2019 to December 2020.

Rationale: The paper mentions that the study was conducted from March 2019 to December 2020, indicating that the sequenced samples were obtained during this period.

Answer: 2019-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV DR testing was performed on plasma samples using Sanger sequencing with Applied Biosystems 3130xl Genetic Analyzers.

Rationale: The paper does not explicitly state which HIV genes were sequenced, but it does mention that HIV DR testing was performed using Sanger sequencing.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that HIV DR testing was performed on plasma samples using Sanger sequencing with Applied Biosystems 3130xl Genetic Analyzers.

Rationale: The paper explicitly states that Sanger sequencing was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that whole blood was collected from study participants for POC VL testing and separated into plasma for testing.

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that children in the intervention group underwent DRT at episodes of VF detection.

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that children on ART for more than 2 years and those with a history of VF were significantly more likely to have major DR.

Rationale: The paper explicitly states that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that first-line ART regimens in Kenya during the study period for children included lamivudine with either abacavir (preferred) or zidovudine (alternative) and lopinavir/ritonavir for those less than three years of age and lamivudine with either abacavir (preferred) or zidovudine (alternative) and efavirenz for those three years of age and older.

Rationale: The paper explicitly states that the drug classes received by individuals in the study before sample sequencing included NRTIs, NNRTIs, and PIs.

Answer: NRTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that first-line ART regimens in Kenya during the study period for children included lamivudine with either abacavir (preferred) or zidovudine (alternative) and lopinavir/ritonavir for those less than three years of age and lamivudine with either abacavir (preferred) or zidovudine (alternative) and efavirenz for those three years of age and older.

Rationale: The paper explicitly states that the drugs received by individuals in the study before sample sequencing included lamivudine, abacavir, zidovudine, lopinavir/ritonavir, and efavirenz.

Answer: Lamivudine, Abacavir, Zidovudine, Lopinavir/ritonavir, Efavirenz
""""""",83
37910452,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention any HIV sequences from patient samples, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention any publicly available sequences, as it does not report on sequencing.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not report any individuals from whom samples were obtained for HIV sequencing, as it does not involve sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any sequenced samples or their countries of origin, as it does not involve sequencing.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the years of sequenced samples, as no sequencing was conducted.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not discuss any cloning of samples, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not report any sequencing of HIV genes, as it focuses on virological outcomes rather than genetic analysis.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequencing methods, as it does not report on any sequencing of HIV samples.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not report any sequencing of samples, thus it does not specify the type of samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper discusses virological non-suppression but does not mention obtaining sequences from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial; it focuses on a cohort study.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""",49
37914679,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""A total of 76 patients enrolled in this study had been tested for pre-existing resistance by conventional Sanger sequencing at baseline, with results suggesting that no resistance mutations were detected.""

Rationale: The paper mentions that the study enrolled 76 HIV-1-infected patients and tested them for pre-existing resistance by conventional Sanger sequencing, indicating that the study involved sequencing HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The study showed that pre-existing low-frequency resistance mutations were associated with an increased risk of virological failure after controlling for patient medication adherence, race, ethnicity, baseline CD4 + T-cell counts, and plasma HIV-1 RNA levels, with low-frequency resistance mutations in the NNRTI class being the most strongly associated with an increased risk of virological failure.""

Rationale: The paper discusses the association between pre-existing low-frequency resistance mutations and the risk of virological failure, but does not provide in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 76 patients enrolled in this study had been tested for pre-existing resistance by conventional Sanger sequencing at baseline, with results suggesting that no resistance mutations were detected.""

Rationale: The paper states that 76 patients were enrolled in the study and had their samples tested for pre-existing resistance.

Answer: 76
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""HIV-1 ART-naïve patients attending the Second Hospital of Nanjing during January 1, 2018 to December 31, 2020, with drug-sensitive results from traditional pre-existing drug resistance test, were enrolled in this study.""

Rationale: The paper specifies that the study enrolled patients between January 1, 2018, and December 31, 2020.

Answer: 2018-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information about cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide any information about which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""All of the 76 HIV-1-infected patients with baseline plasma pre-existing low-frequency drug resistance mutations were detected by the MiSeq second-generation sequencing platform (Illumina, San Diego, CA, USA).""

Rationale: The paper mentions that the MiSeq second-generation sequencing platform was used for detecting pre-existing low-frequency drug resistance mutations.

Answer: NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Plasma RNA was extracted from 730uL plasma sample and library preparation was performed on the Sentosa SX 101 workstation.""

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Thirty-eight patients who failed antiviral therapy were defined as the failure group according to the study definition criteria, and 38 successful virological responders were matched as the control group based on the baseline characteristics of the failure group""

Rationale: The paper mentions that 38 patients who failed antiviral therapy were defined as the failure group, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide any information about the patients being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""HIV-1 ART-naïve patients attending the Second Hospital of Nanjing during January 1, 2018 to December 31, 2020, with drug-sensitive results from traditional pre-existing drug resistance test, were enrolled in this study.""

Rationale: The paper focused on ART-naive patients, meaning they had not previously received antiretroviral drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information about the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",68
37920909,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""The current study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital between January 1, 2020, and April 1, 2023.""

Rationale: The paper mentions that the study recruited ART-naïve individuals and that HIV-1 integrase genes were sequenced, indicating that the paper does report HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""We used the Stanford University HIV Drug Resistance Database (HIVDB Algorithm version 9.4.1) to examine mutations.""

Rationale: The paper does not mention any in vitro drug susceptibility testing. It focuses on genotyping and identifying drug resistance mutations from patient samples.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""The current study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital between January 1, 2020, and April 1, 2023.""

Rationale: The paper states that 629 ART-naïve individuals were recruited for the study.

Answer: 629
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""The current study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital between January 1, 2020, and April 1, 2023.""

Rationale: The study was conducted in Tianjin, China, indicating that the sequenced samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""The current study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital between January 1, 2020, and April 1, 2023.""

Rationale: The paper specifies that the study recruited individuals between January 1, 2020, and April 1, 2023.

Answer: 2020-2023
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""After RNA extraction, an in-house genotyping method and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes, as described previously.""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""After RNA extraction, an in-house genotyping method and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes, as described previously.""

Rationale: The paper states that HIV-1 integrase genes were sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""After RNA extraction, an in-house genotyping method and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes, as described previously.""

Rationale: The paper mentions that Sanger sequencing was used for sequencing the samples.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Before initiating ART, 5 mL of blood was collected from the participants.""

Rationale: The paper specifies that blood samples were collected from the participants.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""The current study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital between January 1, 2020, and April 1, 2023.""

Rationale: The paper focused on ART-naïve individuals, meaning they had not yet received antiretroviral treatment, so there were no sequences from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The current study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital between January 1, 2020, and April 1, 2023.""

Rationale: The paper focused on ART-naïve individuals, meaning they had not previously received antiretroviral drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information regarding the drug classes received by individuals in the study before sample sequencing.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information regarding the drugs received by individuals in the study before sample sequencing.

Answer: nan
""""""",66
37938856,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention any HIV sequences from patient samples, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention any publicly available sequences or accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not report any individuals from whom samples were obtained for HIV sequencing, as it does not involve sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any sequenced samples or their countries of origin, as it does not involve sequencing.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the years of sequenced samples, as no sequencing was conducted.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not discuss any cloning of samples, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not report any sequencing of HIV genes, as it focuses on virological outcomes rather than genetic analysis.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequencing methods, as it does not report on any sequencing of HIV samples.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not report any sequencing of samples, thus it does not specify the type of samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper discusses virological non-suppression but does not mention obtaining sequences from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial; it focuses on a cohort study.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""",49
37941373,"Here are the answers to the questions based on the provided paper:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022. Besides, amplification, sequence, and analysis of the portion of the HIV-1 pol gene that encodes the integrase protein were implemented to identify INSTI resistance.""

Rationale: The paper mentions that plasma samples were collected from HIV-1 patients and that the HIV-1 pol gene was sequenced, indicating that the paper does report HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not provide any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about the sequences being made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Samples were harvested from 1080 patients, and successful amplification of the IN gene was achieved in 1032 samples""

Rationale: The paper states that samples were harvested from 1080 patients, but successful amplification of the IN gene was achieved in 1032 samples.

Answer: 1032
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.""

Rationale: The paper mentions that the samples were obtained from Chongqing Public Health Medical Center, which is located in China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.""

Rationale: The paper specifies that the samples were obtained from 2019 to 2022.

Answer: 2019-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""amplification, sequence, and analysis of the portion of the HIV-1 pol gene that encodes the integrase protein were implemented to identify INSTI resistance.""

Rationale: The paper mentions that the portion of the HIV-1 pol gene that encodes the integrase protein was sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Sanger dideoxy sequencing was employed for the identification of the clinically significant known drug resistance mutations.""

Rationale: The paper mentions that Sanger dideoxy sequencing was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.""

Rationale: The paper mentions that plasma samples were obtained from HIV-1 patients.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Among the seventeen patients with INSTI resistance, twelve were INSTI-treated (11.76%, 12/102), and five were INSTI-naive (1.38%, 5/363).""

Rationale: The paper mentions that some patients were INSTI-treated, indicating that they were on a treatment regimen and experienced virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Among the seventeen patients with INSTI resistance, twelve were INSTI-treated (11.76%, 12/102), and five were INSTI-naive (1.38%, 5/363).""

Rationale: The paper mentions that some patients were INSTI-treated, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""The remaining patients on ART (45.06%, 465/1032) were treated with dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline and efavirenz, among others.""

Rationale: The paper mentions that the patients were treated with INSTIs, NNRTIs, and NRTIs.

Answer: INSTI, NNRTI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""The remaining patients on ART (45.06%, 465/1032) were treated with dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline and efavirenz, among others.""

Rationale: The paper mentions that the patients were treated with dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline, and efavirenz.

Answer: Dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline, efavirenz
""""""",74
37946329,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""A total of 1078 patients who failed in ART treatment, the partial pol gene sequence was successfully amplified in 921, and the integrase (INT) gene sequence in 751 patients.""

Rationale: The paper mentions that the partial pol gene sequence was successfully amplified in 921 patients and the integrase (INT) gene sequence in 751 patients, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The incidence of DRMs was 71.1% (655/921), 78.3% (721/921), 5.2% (48/921), and 3.1% (23/751) for NRTIs, NNRTIs, PIs, and INSTIs, respectively, which is consistent with the data reported previously.""

Rationale: The paper does not report in vitro drug susceptibility data, but rather analyzes the incidence of drug resistance mutations (DRMs) in patient samples.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 1078 patients who failed in ART treatment, the partial pol gene sequence was successfully amplified in 921, and the integrase (INT) gene sequence in 751 patients.""

Rationale: The paper states that samples were obtained from 1078 patients, but only 921 had their partial pol gene sequence successfully amplified.

Answer: 1078
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""To know the transmitted HIV drug resistance in east of China, we investigated THDR during 2009--2011 in Jiangsu province of China.""

Rationale: The paper does not specifically mention the country of origin for the sequenced samples, but it does mention that the study was conducted in Henan Province, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""The analysis included a total of 921 HIV-1 patients, with a median age of 43 (IQR, 30--53) years. The patients were sampled from June 2018 to April 2022.""

Rationale: The paper states that the patients were sampled from June 2018 to April 2022.

Answer: 2018-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""A total of 1078 patients who failed in ART treatment, the partial pol gene sequence was successfully amplified in 921, and the integrase (INT) gene sequence in 751 patients.""

Rationale: The paper mentions that the partial pol gene sequence and the integrase (INT) gene sequence were successfully amplified.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Viral RNA was extracted from 200ul of plasma samples using the Viral RNA Extraction Kit.""

Rationale: The paper mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Sixty stored plasma samples were obtained from patients failing ART (2016-2018) in the anti-HIV treatment program of the 13th Five-Year Plan in China.""

Rationale: The paper states that the plasma samples were obtained from patients failing ART, indicating virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not provide any information indicating that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Sixty stored plasma samples were obtained from patients failing ART (2016-2018) in the anti-HIV treatment program of the 13th Five-Year Plan in China.""

Rationale: The paper mentions that the samples were obtained from patients failing ART, indicating they had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""The incidence of DRMs was 71.1% (655/921), 78.3% (721/921), 5.2% (48/921), and 3.1% (23/751) for NRTIs, NNRTIs, PIs, and INSTIs, respectively, which is consistent with the data reported previously.""

Rationale: The paper mentions that the incidence of DRMs was analyzed for NRTIs, NNRTIs, PIs, and INSTIs, indicating that these drug classes were received by individuals in the study before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""The incidence of DRMs was 71.1% (655/921), 78.3% (721/921), 5.2% (48/921), and 3.1% (23/751) for NRTIs, NNRTIs, PIs, and INSTIs, respectively, which is consistent with the data reported previously.""

Rationale: The paper does not specifically mention the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",82
37957382,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 sequences obtained from patient samples, specifically from individuals with non-suppressible HIV-1 viremia (NSV).

Rationale: The paper mentions the use of near-full-length proviral sequencing and plasma HIV-1 RNA sequencing to analyze the HIV-1 reservoir in individuals with NSV.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 sequences and the characterization of the HIV-1 reservoir in individuals with NSV, but does not include any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that sequence data were submitted to Genbank (BioProject: PRJNA973660).

Rationale: The paper explicitly states that the sequence data were made publicly available through Genbank.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions that sequence data were submitted to Genbank, but does not provide the specific accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that samples were obtained from 8 individuals with NSV.

Rationale: The paper explicitly states that 8 individuals with NSV were included in the study.

Answer: 8
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries of origin for the sequenced samples.

Rationale: The paper does not mention the countries of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information on the years when the sequenced samples were obtained.

Rationale: The paper does not mention the years when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning the samples prior to sequencing.

Rationale: The paper describes the use of near-full-length proviral sequencing and plasma HIV-1 RNA sequencing, but does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that near-full-length proviral sequences and plasma HIV-1 RNA sequences were obtained, which include the gag, pol, and env genes.

Rationale: The paper explicitly states that near-full-length proviral sequences and plasma HIV-1 RNA sequences were obtained, which include the gag, pol, and env genes.

Answer: Gag, Pol, Env
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of near-full-length proviral sequencing and plasma HIV-1 RNA sequencing.

Rationale: The paper explicitly states that near-full-length proviral sequencing and plasma HIV-1 RNA sequencing were used to analyze the HIV-1 reservoir in individuals with NSV.

Answer: Near-full-length proviral sequencing, plasma HIV-1 RNA sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that peripheral blood mononuclear cells (PBMCs) were used for sequencing.

Rationale: The paper explicitly states that PBMCs were used for sequencing.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on individuals with NSV, but does not mention any individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention any clinical trials involving the patients.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included individuals on prolonged ART.

Rationale: The paper explicitly states that the participants were on prolonged ART, indicating that they had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study.

Rationale: The paper mentions that the participants were on prolonged ART, but does not provide specific names of the drugs received.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study.

Rationale: The paper mentions that the participants were on prolonged ART, but does not provide specific names of the drugs received.

Answer: Not reported
""""""",79
37966701,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 321 individuals received at least one continuation CAB + RPV LA injection during the study period.""

Rationale: The paper mentions that 321 individuals received at least one continuation CAB + RPV LA injection during the study period.

Answer: 321
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information about the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""From the OPERA cohort, all adults with HIV who received their first CAB + RPV LA injection between 21 January 2021 and 28 February 2022, and at least one continuation injection by 15 March 2022.""

Rationale: The paper mentions the study period, which includes the years 2021 and 2022.

Answer: 2021-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information about the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the exact sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Four confirmed virologic failures were observed over a range of 6--36 weeks after the first injections, three of which resulted in CAB + RPV LA discontinuation; resistance data were not available.""

Rationale: The paper mentions that four confirmed virologic failures were observed, indicating that sequences were obtained from individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""A total of 321 individuals received at least one continuation CAB + RPV LA injection during the study period.""

Rationale: The paper mentions that individuals received CAB + RPV LA injections, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""CAB + RPV LA initiation occurred a median of 7.2 years after HIV diagnosis (IQR: 3.6, 14.2).""

Rationale: The paper mentions that individuals received CAB + RPV LA, which includes INSTI and NNRTI drug classes.

Answer: INSTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""CAB + RPV LA initiation occurred a median of 7.2 years after HIV diagnosis (IQR: 3.6, 14.2).""

Rationale: The paper mentions that individuals received CAB + RPV LA, which includes cabotegravir and rilpivirine.

Answer: Cabotegravir (CAB), Rilpivirine (RPV)
""""""",60
37973713,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that the study involved sequencing HIV sequences from patient samples, including their corresponding GenBank accession numbers.

Rationale: The evidence clearly states that the study involved adult patients and that HIV-1 sequences were generated and submitted to a database, indicating that sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the prevalence of HIV-1 drug resistance and the genetic analysis of HIV-1 sequences from patient samples, but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states that the HIV-1 sequences generated from this study are available in the NCBI database, with GenBank accession numbers.

Rationale: The evidence clearly states that the sequences generated from the study were submitted to a public database, confirming their availability.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that the study included 117 patients.

Rationale: The paper provides the total number of individuals who had samples obtained for sequencing.

Answer: 117
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from patients from eastern countries, including Ukraine, Belarus, Georgia, and Kazakhstan, as well as from Poland.

Rationale: The paper explicitly lists the countries from which the sequenced samples were obtained.

Answer: Ukraine, Belarus, Georgia, Kazakhstan, Poland
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were collected during a 2-year period (2020-2022).

Rationale: The paper provides specific time frames for when the samples were collected.

Answer: 2020-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 protease and part of the RT region of the polymerase (pol) gene were sequenced.

Rationale: The paper mentions that the HIV-1 protease and part of the RT region of the polymerase (pol) gene were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the ViroSeq HIV-1 Genotyping System was used for sequencing.

Rationale: The paper mentions that the ViroSeq HIV-1 Genotyping System was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a multi-center, prospective, observational, cross-sectional study.

Rationale: The paper describes the study as a multi-center, prospective, observational, cross-sectional study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some patients had prior drug exposure for treating HIV infection.

Rationale: The paper indicates that some patients had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not mention specific drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not mention specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",66
37976080,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: A total of 2568 HIV-positive individuals were initially recruited into the study. PDR test results were available for 90.3% (n=2568) of participants in RT/PR regions.

Rationale: The paper reports that HIV sequences were obtained from patient samples. Specifically, it mentions that PDR test results were available for 2568 participants.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 2869 HIV-positive individuals were initially recruited into the study.

Rationale: The paper mentions that 2869 HIV-positive individuals were initially recruited into the study.

Answer: 2869
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in 8 provincial-level administrative divisions in China.

Rationale: The paper specifies that the study was conducted in China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Recruitment and specimen collection of HIV-positive individuals occurred in 2022.

Rationale: The paper mentions that the samples were collected in 2022.

Answer: 2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The HIV pol gene region (HXB2: 2253-3553 nt) was amplified, covering the PR region (4-99 amino acids) and the partial RT region (1-251 amino acids).

Rationale: The paper reports the sequencing of the HIV pol gene region.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: Sanger sequencing was used to sequence the amplified products.

Rationale: The paper mentions that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma samples were collected from HIV-positive individuals.

Rationale: The paper specifies that plasma samples were used.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The study included HIV-positive individuals suspected of treatment failure during first-line ART.

Rationale: The paper describes sequencing HIV from patients suspected of failing a first-line regimen, indicating virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: 3.2% (n=81) of participants had prior ARV drug exposure.

Rationale: The paper mentions that some participants had prior ARV drug exposure.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drug classes received by individuals before sample sequencing.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by individuals before sample sequencing.

Answer: nan
""""""",55
37976185,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV genotyping was performed using samples from individuals living with HIV at screening; samples from seroconverters at the first visit with documented HIV infection; and samples from follow-up visits for a subset of enrolled participants.

Rationale: The evidence clearly states that the study involved genotyping of HIV sequences obtained from participants, indicating that the paper does report HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The absence of any mention of in vitro testing or susceptibility data indicates that the paper does not report in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making the sequences publicly available.

Rationale: The lack of information about public availability of the sequences indicates that they were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The absence of any GenBank accession numbers indicates that this information is not available.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 4246 people with newly diagnosed HIV had an available genotype obtained within 30 days of diagnosis.

Rationale: The evidence provides the total number of individuals whose samples were obtained for sequencing.

Answer: 4246
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the specific countries from which the samples were obtained.

Rationale: The lack of information about the countries of origin for the samples indicates that this information is not available.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from people with newly diagnosed HIV in 2015--2022.

Rationale: The evidence provides the range of years during which the samples were collected.

Answer: 2015-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The absence of any mention of cloning in the methods or results sections indicates that samples were not cloned before sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV genotyping was performed, but it does not specify which genes were sequenced.

Rationale: The lack of information about the specific genes sequenced indicates that this information is not available.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that HIV genotyping was performed, but it does not specify the sequencing method used.

Rationale: The lack of information about the sequencing method indicates that this information is not available.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV genotyping was performed using samples from individuals living with HIV at screening; samples from seroconverters at the first visit with documented HIV infection; and samples from follow-up visits for a subset of enrolled participants.

Rationale: The evidence specifies that the samples were obtained from individuals living with HIV, seroconverters, and follow-up visits.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that some individuals had virological failure, but it does not specify if sequences were obtained from these individuals.

Rationale: The lack of information about sequencing of individuals with virological failure indicates that this information is not available.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The lack of information about a clinical trial indicates that the patients were not in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some individuals had previously received ARV therapy, but it does not specify if sequences were obtained from these individuals.

Rationale: The lack of information about sequencing of individuals with previous ARV therapy indicates that this information is not available.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some individuals had previously received ARV therapy, but it does not specify which drug classes were used.

Rationale: The lack of information about the specific drug classes used indicates that this information is not available.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some individuals had previously received ARV therapy, but it does not specify which drugs were used.

Rationale: The lack of information about the specific drugs used indicates that this information is not available.

Answer: Not reported
""""""",70
37993493,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Viral load testing was performed using Roche cobas 6800/8800 systems... Given that we followed the current Tanzania national HIV treatment guidelines, only samples with viral load count ≥ 1000 copies/mL were subjected to analysis of HIVDR mutations.""

Rationale: The paper discusses the analysis of blood samples from patients to identify drug-resistant variants and mentions the use of genotypic resistance testing, indicating that HIV sequences were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on genotyping and identifying drug resistance mutations from patient samples, but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention whether the sequences obtained were made publicly available.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention any specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""In total 600 individuals participated in this survey...""

Rationale: The paper explicitly states that 600 individuals participated in the survey, indicating that this is the number of individuals who had samples obtained for HIV sequencing.

Answer: 600
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Tanzania.

Rationale: The study was conducted in Tanzania, and all references to sample collection and genotyping are specific to Tanzania.

Answer: Tanzania
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted between February and May 2023.

Rationale: The paper states that the study was conducted between February and May 2023, indicating the years from which the sequenced samples were obtained.

Answer: 2023
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing, indicating no cloning was done.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""The sequenced codons were 6--99, 1--251, and 1--288, for protease, reverse transcriptase and integrase proteins, respectively.""

Rationale: The paper explicitly states that the protease, reverse transcriptase, and integrase genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that ""We used Management and Development for Health (MDH) WHO adapted protocol (Unpublished) to perform HIVDR testing using the 3500xL genetic analyser (Applied Biosystems), a capillary sequencer using Sanger-style sequencing.""

Rationale: The paper explicitly states that Sanger sequencing was used for obtaining the HIV sequences.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that ""Blood sample collection, transportation and storage were treated according to the Temeke Regional Referral Hospital- Specialized Laboratory protocol.""

Rationale: The paper specifies that blood samples were analyzed, indicating that this was the clinical specimen type used for sequencing.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that ""For 23 samples, protease and reverse transcriptase (RT) genotyping were successful, with 13 sequences containing RT inhibitor surveillance drug resistance mutations (SDRMs) (56.5%).""

Rationale: The paper discusses the analysis of samples from individuals with high viral loads, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention any clinical trials.

Rationale: The paper describes a cross-sectional survey rather than a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that ""Approximately 99% were receiving tenofovir + lamivudine + dolutegravir as a fixed dose combination.""

Rationale: The paper mentions that most patients were receiving a specific ARV regimen, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""Approximately 99% were receiving tenofovir + lamivudine + dolutegravir as a fixed dose combination.""

Rationale: The paper mentions that most patients were receiving a specific ARV regimen, which includes NRTIs and INSTIs.

Answer: NRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""Approximately 99% were receiving tenofovir + lamivudine + dolutegravir as a fixed dose combination.""

Rationale: The paper explicitly states that the drugs received by individuals in the study were tenofovir, lamivudine, and dolutegravir.

Answer: Tenofovir, Lamivudine, Dolutegravir
""""""",81
38005921,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the development of a web application for predicting HIV drug resistance based on amino acid sequences of HIV enzymes, but it does not explicitly mention the use of patient samples.

Rationale: The paper focuses on the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the source of the HIV sequences used for model training.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper discusses the prediction of HIV drug resistance based on amino acid sequences, but it does not provide in vitro drug susceptibility data.

Rationale: The paper focuses on the development of machine learning models for predicting HIV drug resistance, but it does not provide experimental data on drug susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not explicitly state that the sequences used for model training were made publicly available.

Rationale: The paper discusses the development of a web application for predicting HIV drug resistance, but it does not provide information on the availability of the sequences used for model training.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper focuses on the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the GenBank accession numbers of the sequences used for model training.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper discusses the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries from which the sequenced samples were obtained.

Rationale: The paper focuses on the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the geographical origin of the sequences used for model training.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information on the years from which the sequenced samples were obtained.

Rationale: The paper discusses the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the time frame of the sequences used for model training.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper focuses on the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the amino acid sequences of HIV enzymes, including reverse transcriptase and protease, were used for model training.

Rationale: The paper discusses the development of machine learning models for predicting HIV drug resistance, and it mentions the use of specific HIV genes for model training.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not explicitly state the sequencing method used.

Rationale: The paper focuses on the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the sequencing method used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not provide information on the type of samples sequenced.

Rationale: The paper discusses the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not provide information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the treatment status of the individuals from whom the sequences were obtained.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information on whether the patients were part of a clinical trial.

Rationale: The paper discusses the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the study design or the participation of patients in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not provide information on whether the individuals from whom the sequences were obtained had previously received ARV drugs.

Rationale: The paper focuses on the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the treatment history of the individuals from whom the sequences were obtained.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper discusses the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper focuses on the development of machine learning models for predicting HIV drug resistance, but it does not provide information on the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported
""""""",79
38020274,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""A prospective cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in one of the selected health facilities within the 'Resistance Evolution among Adolescents in Yaoundé and its surroundings' (READY-study) in the Centre region of Cameroon.""

Rationale: The paper mentions that a prospective cohort-study was conducted among 311 APHI receiving ART, which implies that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not provide any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Overall, 311 APHI were included at the enrolment phase (T1) with 272 followed-up at 6-months (T2), and 243 at 12-months (T3).""

Rationale: The paper mentions that 311 APHI were included at the enrolment phase, which indicates the number of individuals whose samples were obtained for sequencing.

Answer: 311
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""A prospective cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in one of the selected health facilities within the 'Resistance Evolution among Adolescents in Yaoundé and its surroundings' (READY-study) in the Centre region of Cameroon.""

Rationale: The paper mentions that the study was conducted in Cameroon, which indicates the country from which the sequenced samples were obtained.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""A prospective cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in one of the selected health facilities within the 'Resistance Evolution among Adolescents in Yaoundé and its surroundings' (READY-study) in the Centre region of Cameroon.""

Rationale: The paper mentions that the study was conducted from 2018-2020, which indicates the years from which the sequenced samples were obtained.

Answer: 2018-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Genotypic resistance testing (GRT) was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml using an in-house protocol as previously described by our working group (10) using blood samples stored at -80˚C.""

Rationale: The paper does not explicitly mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Genotypic resistance testing (GRT) was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml using an in-house protocol as previously described by our working group (10) using blood samples stored at -80˚C.""

Rationale: The paper mentions that genotypic resistance testing (GRT) was carried out, but it does not explicitly mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Genotypic resistance testing (GRT) was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml using an in-house protocol as previously described by our working group (10) using blood samples stored at -80˚C.""

Rationale: The paper mentions that blood samples were used for sequencing.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Genotypic resistance testing (GRT) was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml using an in-house protocol as previously described by our working group (10) using blood samples stored at -80˚C.""

Rationale: The paper mentions that sequencing was performed among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml, which indicates virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""A prospective cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in one of the selected health facilities within the 'Resistance Evolution among Adolescents in Yaoundé and its surroundings' (READY-study) in the Centre region of Cameroon.""

Rationale: The paper describes a prospective cohort-study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""A prospective cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in one of the selected health facilities within the 'Resistance Evolution among Adolescents in Yaoundé and its surroundings' (READY-study) in the Centre region of Cameroon.""

Rationale: The paper mentions that the study was conducted among APHI receiving ART, which implies that sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Majority of our study participants were on first line RTI-based ART, with good adherence and median duration on ART of 36[21-81] months.""

Rationale: The paper mentions that the majority of study participants were on first line RTI-based ART, which indicates that they received NRTIs.

Answer: NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Majority of our study participants were on first line RTI-based ART, with good adherence and median duration on ART of 36[21-81] months.""

Rationale: The paper does not provide a detailed list of specific drugs taken by the ART-experienced patients.

Answer: Not reported
""""""",87
38022124,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention any HIV sequences from patient samples, as it does not report any sequencing data.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not include any mention of in vitro drug susceptibility data or related experiments.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention whether any sequences were made publicly available, as it does not report on any sequencing activities.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 116 patients, 66 (56.9%) treatment-experienced and 50 (43.1%) naive, were evaluated within the scope of the study.

Rationale: The paper mentions that 116 patients were included in the study.

Answer: 116
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Turkey.

Rationale: The paper mentions that the study was conducted in Turkey.

Answer: Turkey
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study was conducted between June 2020 and June 2022.

Rationale: The paper mentions the study period.

Answer: 2020-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any cloning of samples prior to sequencing, as it does not report on any sequencing activities.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention any specific HIV genes that were sequenced, as it does not report on any sequencing activities.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequencing methods used, as it does not report on any sequencing activities.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not specify any type of samples that were sequenced, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not report any sequences obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: This retrospective analysis was performed in HIV-1-positive patients who were initiated BIC/FTC/TAF in the HIV clinic between June 2020 and June 2022.

Rationale: The paper describes a retrospective analysis rather than a clinical trial, indicating that the patients were not part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The majority of the patients (242/270, 89.6%) were on ART with a median therapy duration of 10 years (IQR 7–17 years).

Rationale: The paper mentions that most of the patients were on ART with a median therapy duration of 10 years.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The majority of the patients (242/270, 89.6%) were on ART with a median therapy duration of 10 years (IQR 7–17 years). Before the switch to BIC-STR, our cohort was treated with INIs (187/242 77.3%), non-nucleoside reverse transcriptase inhibitors (NNRTIs) (21/242 8.7%), PIs (36/242, 14.9%), TAF backbone (167/242, 69%), abacavir (ABC) backbone (31/242, 12.8%), and dual-therapy (15/242, 6.2%).

Rationale: The paper lists the specific drug classes that were part of the previous ART regimens.

Answer: INSTI, NRTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The majority of the patients (242/270, 89.6%) were on ART with a median therapy duration of 10 years (IQR 7–17 years). Before the switch to BIC-STR, our cohort was treated with INIs (187/242 77.3%), non-nucleoside reverse transcriptase inhibitors (NNRTIs) (21/242 8.7%), PIs (36/242, 14.9%), TAF backbone (167/242, 69%), abacavir (ABC) backbone (31/242, 12.8%), and dual-therapy (15/242, 6.2%).

Rationale: The paper lists the specific drugs that were part of the previous ART regimens.

Answer: TAF, ABC, BIC, FTC
""""""",70
38031075,"Here are the answers to the questions based on the provided paper:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention any HIV sequences from patient samples, as it focuses on HIV viral suppression and treatment outcomes rather than genetic analysis.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any in vitro drug susceptibility testing, as it focuses on treatment outcomes and viral suppression in patients.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that these sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not report any individuals from whom samples were obtained for HIV sequencing, as it does not involve sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention any sequenced samples or their countries of origin, as it does not involve sequencing.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the years of sequenced samples, as no sequencing was conducted.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not discuss any cloning of samples, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not report any sequencing of HIV genes, as it focuses on virological outcomes rather than genetic analysis.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequencing methods, as it does not report on any sequencing of HIV samples.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not report any sequencing of samples, thus it does not specify the type of samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper discusses virological non-suppression but does not mention obtaining sequences from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The study used a cross-sectional study design to collect primary data from adult patients aged 18 years or older between August 2022 and January 2023.

Rationale: The paper describes a cross-sectional study design and does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""",52
38033131,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention any HIV sequences from patient samples, as it focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any in vitro drug susceptibility data, as it focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention any publicly available sequences, as it does not report on sequencing.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, as it does not report on sequencing.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not report any individuals from whom samples were obtained for HIV sequencing, as it does not involve sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention any sequenced samples or their countries of origin, as it does not involve sequencing.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the years of sequenced samples, as no sequencing was conducted.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not discuss any cloning of samples, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not report any sequencing of HIV genes, as it focuses on virological outcomes rather than genetic analysis.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequencing methods, as it does not report on any sequencing of HIV samples.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not report any sequencing of samples, thus it does not specify the type of samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper discusses virological non-suppression but does not mention obtaining sequences from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: This cohort follow-up study was conducted in 15 selected public health facilities (8 hospitals and 7 health centers) in eastern Ethiopia (Figure 1). The enrollment for the baseline study was conducted between October 2020 and July 2022.

Rationale: The paper does not mention that the patients were part of a clinical trial; it focuses on a cohort study.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequences or individuals who had previously received ARV drugs, as it does not involve sequencing.

Answer: Not reported
""""""",57
38058846,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""We have described the first reported cases of DTG resistance in PBFW in the South African ART programme.""

Rationale: The paper does not explicitly mention HIV sequences from patient samples, but it does describe cases of DTG resistance in PBFW, which implies that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""We have described the first reported cases of DTG resistance in PBFW in the South African ART programme.""

Rationale: The paper describes three cases of DTG resistance in PBFW, which implies that samples were obtained from three individuals.

Answer: 3
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""We have described the first reported cases of DTG resistance in PBFW in the South African ART programme.""

Rationale: The paper mentions that the cases were from the South African ART programme, which implies that the sequenced samples were obtained from South Africa.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""No evidence""

Rationale: The paper does not explicitly mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""No evidence""

Rationale: The paper does not explicitly mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""We have described the first reported cases of DTG resistance in PBFW in the South African ART programme.""

Rationale: The paper describes cases of DTG resistance, which implies that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""We have described the first reported cases of DTG resistance in PBFW in the South African ART programme.""

Rationale: The paper describes cases of DTG resistance, which implies that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not explicitly mention the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not explicitly mention the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",54
38072961,"Here are the answers to the questions based on the provided paper:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the collection of plasma samples from an HIV-positive patient and the extraction of viral RNA, which indicates that HIV sequences were obtained from these patient samples.

Rationale: The paper focuses on the case of a patient with HIV infection and describes the collection and analysis of plasma samples, which suggests that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data is provided in the paper.

Rationale: The paper does not mention any in vitro drug susceptibility testing or provide data related to this topic.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence of publicly available sequences is provided in the paper.

Rationale: The paper does not mention the deposition of sequences in a public database or provide any accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No GenBank accession numbers are provided in the paper.

Rationale: The paper does not mention the deposition of sequences in GenBank or provide any accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes the case of a single patient with HIV infection.

Rationale: The paper focuses on the case of one patient, and there is no indication that samples were obtained from multiple individuals.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper describes the case of a patient from China.

Rationale: The paper mentions that the patient is from China, which suggests that the sequenced sample was obtained from this country.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper describes the case of a patient who was diagnosed with HIV infection five years ago.

Rationale: The paper mentions that the patient was diagnosed with HIV infection five years ago, but it does not provide specific information about the year of sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence of cloning is provided in the paper.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the sequencing of the protease, reverse transcriptase, and integrase genes.

Rationale: The paper describes the sequencing of these genes in the context of drug resistance testing.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of Sanger sequencing for drug resistance testing.

Rationale: The paper describes the use of Sanger sequencing for genotypic drug resistance testing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper describes the collection of plasma samples from the patient.

Rationale: The paper mentions the collection of plasma samples, which suggests that these were the samples used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper describes the case of a patient who experienced virological failure on a treatment regimen.

Rationale: The paper mentions that the patient experienced breakthrough viraemia, which suggests that they had virological failure on their treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence of a clinical trial is provided in the paper.

Rationale: The paper does not mention any clinical trial or study protocol.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper describes the case of a patient who had previously received ARV drugs.

Rationale: The paper mentions that the patient had been on ART for several years, which suggests that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions the use of NRTIs, NNRTIs, and PIs.

Rationale: The paper describes the patient's treatment history, which includes the use of these drug classes.

Answer: NRTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions the use of tenofovir, lamivudine, lopinavir/ritonavir, and efavirenz.

Rationale: The paper describes the patient's treatment history, which includes the use of these specific drugs.

Answer: Tenofovir, lamivudine, lopinavir/ritonavir, efavirenz
""""""",63
38090027,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples. It focuses on the efficacy and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BFTAF) in clinical practice.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention in vitro drug susceptibility data. It focuses on clinical outcomes and resistance testing in patients treated with BFTAF.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether any sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: Not reported.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not report any individuals from whom samples were obtained for HIV sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not specify the exact years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention any HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention any sequencing methods used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify any type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any sequences obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not report any HIV sequences from individuals, regardless of their previous ARV drug history.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not report any HIV sequences from individuals, regardless of their previous ARV drug history.

Answer: No
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not report any HIV sequences from individuals, regardless of their previous ARV drug history.

Answer: No
""""""",48
38140553,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper analyzed 3178 HIV-1 pol-gene fragment sequences from patients who were initiating or reinitiating first-line ART in seven Russian federal districts.

Rationale: The paper explicitly states that sequences were obtained from patients, indicating that sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on the prevalence of HIV-1 drug resistance and the genetic analysis of HIV-1 sequences from patient samples, but it does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: All nucleotide sequences obtained in the study were deposited in the international database of the Los Alamos laboratory.

Rationale: The paper explicitly states that the sequences were deposited in a public database, confirming their availability.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: Not reported

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The genotyping results of 3178 HIV-infected patients from seven Russian federal districts were examined.

Rationale: The paper states that 3178 HIV-infected patients had samples obtained for sequencing.

Answer: 3178
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The samples were obtained from patients in Russia.

Rationale: The paper clearly states that the samples were obtained from patients in Russia.

Answer: Russia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The samples were collected from 2011 to 2020.

Rationale: The paper specifies that the study was conducted using samples from 2011 to 2020.

Answer: 2011-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 protease (PR) and part of the reverse transcriptase (RT) were sequenced.

Rationale: The paper explicitly states that the PR and RT genes were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of Sanger sequencing.

Rationale: The paper describes the use of Sanger sequencing for the HIV-1 pol gene regions.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that blood plasma samples, peripheral blood mononuclear cells (lymphocytes), and frozen whole blood samples were used for sequencing.

Rationale: The paper specifies that different types of clinical specimens were used for sequencing.

Answer: Plasma, PBMC, whole blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on patients who were initiating or reinitiating first-line ART, which does not necessarily imply virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper describes the study as a molecular genetic monitoring of the HIV infection from 2011 to 2020.

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some patients had interrupted ART before restarting first-line ART without reported virological failure.

Rationale: The paper indicates that some patients had previously received ARV drugs, but it does not provide specific details.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information regarding the specific drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information regarding the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",67
38140649,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 RNA plasma samples were collected from newly diagnosed HIV patients over a four-year period during the diagnostic process and clinical follow-up at UHID.

Rationale: The paper specifically focuses on HIV-1 RNA plasma samples collected from newly diagnosed HIV patients, which indicates that the study involved sequencing HIV from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 sequences from patients to assess transmitted drug resistance, but it does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that all sequences obtained in this study by SS were submitted to the GeneBank nucleotide sequence database under accession numbers OR605755-OR606279 and OR613869-OR613875.

Rationale: The paper explicitly states that the sequences were submitted to the GeneBank nucleotide sequence database, which indicates that the sequences were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that all sequences obtained in this study by SS were submitted to the GeneBank nucleotide sequence database under accession numbers OR605755-OR606279 and OR613869-OR613875.

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates.

Answer: OR605755-OR606279 and OR613869-OR613875
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that a total of 270 persons met the inclusion criteria.

Rationale: The paper states that 270 persons met the inclusion criteria, which indicates that 270 individuals had samples obtained for HIV sequencing.

Answer: 270
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted at the Department for Immunological and Molecular Diagnostics at UHID, and the majority of the patients originated from and reported Croatia as the country of infection.

Rationale: The paper specifies that the study was conducted in Croatia, and the majority of the patients originated from and reported Croatia as the country of infection.

Answer: Croatia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from January 2019 to December 2022.

Rationale: The paper specifies that the study was conducted from January 2019 to December 2022.

Answer: 2019-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 protease and part of the RT region of the polymerase (pol) gene were generated.

Rationale: The paper mentions that the HIV-1 protease and part of the RT region of the polymerase (pol) gene were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper mentions that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper focused on treatment-naive individuals, meaning that the participants had not yet started antiretroviral therapy, and therefore, there would be no sequences from individuals with virological failure on a treatment regimen.

Rationale: The paper focused on treatment-naive individuals, which implies that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper specifically focuses on treatment-naive individuals, meaning that the participants had not previously received antiretroviral drugs.

Rationale: The paper specifically focuses on treatment-naive individuals, which implies that the participants had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that the individuals had received any drug classes before sample sequencing.

Rationale: The paper does not mention that the individuals had received any drug classes before sample sequencing.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that the individuals had received any drugs before sample sequencing.

Rationale: The paper does not mention that the individuals had received any drugs before sample sequencing.

Answer: nan
""""""",77
38140667,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of blood samples from patients to identify drug-resistant variants and mentions the use of genotypic resistance testing.

Rationale: The paper focuses on the clinical case and the emergence of resistance mutations in the context of treatment, indicating that HIV sequences were reported from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data is provided in the paper.

Rationale: The paper does not provide any specific in vitro drug susceptibility data, focusing instead on clinical case studies and the emergence of resistance mutations in the context of treatment.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence is provided in the paper regarding the public availability of the sequences.

Rationale: The paper does not mention whether the sequences obtained were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No GenBank accession numbers are provided in the paper for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper discusses multiple studies and cohorts, but does not provide a single number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide a clear number of individuals who had samples obtained for HIV sequencing, as it discusses multiple studies and cohorts.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions several countries, including France, Canada, Tanzania, Mozambique, Nigeria, Spain, Italy, Germany, Botswana, and South Africa.

Rationale: The paper discusses studies and cohorts from multiple countries, indicating that the sequenced samples were obtained from these countries.

Answer: France, Canada, Tanzania, Mozambique, Nigeria, Spain, Italy, Germany, Botswana, South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions various years, including 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, and 2022.

Rationale: The paper discusses studies and cohorts from multiple years, indicating that the sequenced samples were obtained from these years.

Answer: 2012-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence is provided in the paper regarding the cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the integrase gene, as well as the protease and reverse transcriptase genes.

Rationale: The paper discusses the sequencing of the integrase gene, as well as the protease and reverse transcriptase genes, indicating that these genes were reported to have been sequenced.

Answer: IN, PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions Sanger sequencing and next-generation sequencing (NGS) as methods used for sequencing.

Rationale: The paper discusses the use of Sanger sequencing and NGS as methods used for sequencing, indicating that these methods were employed.

Answer: Sanger sequencing, NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions plasma samples as the type of samples sequenced.

Rationale: The paper discusses the sequencing of plasma samples, indicating that this was the clinical specimen type used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses the emergence of resistance mutations in individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the clinical case and the emergence of resistance mutations in the context of treatment, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that some patients were part of a clinical trial, but does not provide clear information on whether all patients were in a clinical trial.

Rationale: The paper discusses the use of clinical trials, but does not provide clear information on whether all patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses the emergence of resistance mutations in individuals who had previously received ARV drugs.

Rationale: The paper focuses on the clinical case and the emergence of resistance mutations in the context of treatment, indicating that sequences were reported from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions NRTI, NNRTI, PI, and INSTI drug classes as being received by individuals in the study before sample sequencing.

Rationale: The paper discusses the use of these drug classes in the context of treatment, indicating that individuals in the study received these drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions specific drugs such as DTG, 3TC, ABC, TDF, FTC, RPV, and DRV as being received by individuals in the study before sample sequencing.

Rationale: The paper discusses the use of these specific drugs in the context of treatment, indicating that individuals in the study received these drugs before sample sequencing.

Answer: DTG, 3TC, ABC, TDF, FTC, RPV, DRV
""""""",81
38142692,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility data or related experiments.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether the sequences were made publicly available, nor does it provide any relevant information to determine this.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention the number of individuals from whom samples were obtained for sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""We did a retrospective observational cohort study with de-identified, routinely collected data from South Africa’s ART programme in 59 of approximately 100 public sector primary health-care clinics in the eThekwini Municipality of the KwaZulu-Natal province.""

Rationale: The paper mentions that the study was conducted in South Africa.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""We used this baseline period of switching to second-line therapy to allow a minimum follow-up duration of 12 months plus 90 days before the data cutoff on April 21, 2022.""

Rationale: The paper mentions that the data cutoff was on April 21, 2022, but does not provide specific years for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""We included people living with HIV aged 15 years or older who were switched to second-line ART after virological failure while receiving first-line ART at the study clinics""

Rationale: The paper mentions that the study included people who were switched to second-line ART after virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""We did a retrospective observational cohort study with de-identified, routinely collected data from South Africa’s ART programme in 59 of approximately 100 public sector primary health-care clinics in the eThekwini Municipality of the KwaZulu-Natal province.""

Rationale: The paper describes a retrospective observational cohort study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""We included people living with HIV aged 15 years or older who were switched to second-line ART after virological failure while receiving first-line ART at the study clinics""

Rationale: The paper mentions that the study included people who were switched to second-line ART after virological failure, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""We included people living with HIV aged 15 years or older who were switched to second-line ART after virological failure while receiving first-line ART at the study clinics""

Rationale: The paper mentions that the study included people who were switched to second-line ART after virological failure, indicating that they had previously received ARV drugs, but does not specify the drug classes.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""We included people living with HIV aged 15 years or older who were switched to second-line ART after virological failure while receiving first-line ART at the study clinics""

Rationale: The paper mentions that the study included people who were switched to second-line ART after virological failure, indicating that they had previously received ARV drugs, but does not specify the drugs.

Answer: Not reported
""""""",65
38152686,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the sequencing of HIV from a patient diagnosed with HIV-1 and tuberculosis, and samples were collected after virological failure.

Rationale: The paper discusses the sequencing of HIV from a patient diagnosed with HIV-1, and samples were collected after virological failure, which indicates some samples were collected from plasma.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether the sequences obtained were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes a single case of a 29-year-old male patient.

Rationale: The paper is a case report focusing on a single patient.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not specify the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the patient was admitted in 2020.

Rationale: The paper provides a specific year when the patient was admitted.

Answer: 2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions sequencing of the integrase gene and reverse transcriptase genes.

Rationale: The paper discusses the sequencing of the integrase gene and mentions the reverse transcriptase mutations.

Answer: IN, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that the patient had a viral load of 437,927 cp/mL.

Rationale: The paper discusses the sequencing of HIV from a patient diagnosed with HIV-1, and samples were collected after virological failure, which indicates some samples were collected from plasma.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper describes a case of virological failure in a patient undergoing treatment.

Rationale: The paper discusses the sequencing of HIV from a patient diagnosed with HIV-1, and samples were collected after virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patient was part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the patient had been on antiretroviral therapy (ART) with TDF/3TC/DTG.

Rationale: The paper discusses the patient's treatment history of antiretroviral drug treatments.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper lists various antiretroviral drugs that the patient received, including NRTIs (TDF, 3TC) and INSTIs (DTG).

Rationale: The paper details the treatment regimen the patient received.

Answer: NRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists specific antiretroviral drugs that the patient was on before the samples were obtained for sequencing, including Tenofovir (TDF), Lamivudine (3TC), and Dolutegravir (DTG).

Rationale: The paper details the treatment regimen the patient received.

Answer: Tenofovir (TDF), Lamivudine (3TC), Dolutegravir (DTG)
""""""",57
38314093,"Here are the answers to the questions based on the provided paper content:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""A total of 186257 serum samples from suspected patients, collected between May 2008 and December 2019, were obtained from Meizhou People's Hospital.""

Rationale: The paper mentions that serum samples were collected from suspected patients, but it does not explicitly state that HIV sequences were obtained from these samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""HIV-1 genetic mutation and drug resistance are major barriers to successful antiretroviral therapy. To elucidate the HIV-1 genotype drug resistance characteristics in HIV-infected people of Meizhou, serum samples from 37 untreated patients [29 men (78%); 8 women (22%)] obtained from Meizhou People's Hospital were included.""

Rationale: The paper discusses drug resistance and genetic mutations, but it does not mention in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 186257 serum samples from suspected patients, collected between May 2008 and December 2019, were obtained from Meizhou People's Hospital.""

Rationale: The paper mentions that 186,257 serum samples were collected, but it does not explicitly state how many individuals had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""A total of 186257 serum samples from suspected patients, collected between May 2008 and December 2019, were obtained from Meizhou People's Hospital.""

Rationale: The paper mentions that the samples were obtained from Meizhou People's Hospital, which is located in China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""A total of 186257 serum samples from suspected patients, collected between May 2008 and December 2019, were obtained from Meizhou People's Hospital.""

Rationale: The paper mentions that the samples were collected between May 2008 and December 2019.

Answer: 2008-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""cDNA containing the protease-reverse transcriptase (PR-RT) sequence of HIV-1 was amplified and subjected to high-throughput sequencing.""

Rationale: The paper mentions that the PR-RT sequence of HIV-1 was amplified and sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""cDNA containing the protease-reverse transcriptase (PR-RT) sequence of HIV-1 was amplified and subjected to high-throughput sequencing.""

Rationale: The paper mentions that high-throughput sequencing was used.

Answer: NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""A total of 186257 serum samples from suspected patients, collected between May 2008 and December 2019, were obtained from Meizhou People's Hospital.""

Rationale: The paper mentions that serum samples were collected and sequenced.

Answer: Serum
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Sixty stored plasma samples were obtained from patients failing ART (2016-2018) in the anti-HIV treatment program of the 13th Five-Year Plan in China.""

Rationale: The paper does not mention virological failure on a treatment regimen in the context of the provided samples.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about the patients being in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Sixty stored plasma samples were obtained from patients failing ART (2016-2018) in the anti-HIV treatment program of the 13th Five-Year Plan in China.""

Rationale: The paper does not mention that the patients had previously received ARV drugs in the context of the provided samples.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",69
38427738,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions the use of VSV-G--pseudotyped eGFP reporter virus to examine the impact of high MOI on viral susceptibility to ARVs.

Rationale: The paper includes in vitro drug susceptibility data by detailing the effectiveness of various ARVs against HIV-1 in the context of high MOI.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention whether the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the number of individuals from whom samples were obtained for sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention any countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the integrase (IN) gene of HIV-1.

Rationale: The paper focuses on the integrase gene (IN) of HIV-1.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether sequences were obtained from individuals with virological failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention that the patients from whom the sequences were obtained were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",62
38864613,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on in vitro studies, resistance passage experiments, and cellular assays using site-directed molecular (SDM) HIV clones and other laboratory strains.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The in vitro antiviral profile and mechanism of action of GSK1265744 were established through integrase enzyme assays, resistance passage experiments, and cellular assays with site-directed molecular (SDM) HIV clones resistant to other classes of anti-HIV-1 agents and earlier INSTIs.""

Rationale: The paper provides in vitro drug susceptibility data, through integrase enzyme assays, resistance passage experiments, and cellular assays with site-directed molecular (SDM) HIV clone.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""Sequences from resistance selection experiments have been deposited in GenBank under accession numbers PP827803 -- PP828572.""

Rationale: The paper mentions that sequences from resistance selection experiments were deposited in GenBank.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""Sequences from resistance selection experiments have been deposited in GenBank under accession numbers PP827803 -- PP828572.""

Rationale: The paper mentions that sequences from resistance selection experiments were deposited in GenBank under accession numbers PP827803 -- PP828572.

Answer: PP827803 -- PP828572
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the specific countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The entire protease gene and the first 440 codons of the RT gene were amplified from viral cDNA by high fidelity AccuPrime Taq DNA Polymerase (Invitrogen);""

Rationale: The paper mentions the sequencing of the entire protease gene and the first 440 codons of the RT gene.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Population-based Sanger sequencing at passage 12.""

Rationale: The paper mentions the use of population-based Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing of clinical specimens. Instead, it focuses on in vitro studies using laboratory strains and site-directed molecular (SDM) HIV clones.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention that the patients from whom the sequences were obtained were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper doesn't report if the clincal isolates were from treatment naïve or treatment experienced individuals.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper doesn't report if the clincal isolates were from treatment naïve or treatment experienced individuals.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper doesn't report if the clincal isolates were from treatment naïve or treatment experienced individuals.

Answer: Not reported
""""""",61
